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Abstract 
This thesis investigates molecular and cellular mechanisms involved in lgA secretion 
in the bovine mammary gland. Our previous research showed that multi-site 
immunisation during late-pregnancy, involving priming by intra-peritoneal and intra-
muscular routes followed by intra-mammary immunisation, enhanced lgA secretion in 
milk and this effect was localised to immunised glands. This thesis addresses the 
hypothesis that increased lgA is produced by localised lgA plasma cells of mucosa! 
origin that are recruited to the mammary gland by changes induced by intra-
mammary immunisation. 
Recruitment mechanisms for lymphocytes were studied by examining expression of 
adhesion molecules MAdCAM-1, VCAM-1 and PNAd in mammary tissues of 
untreated animals, using immunohistochemical and molecular techniques. No 
immunoreactive MAdCAM-1 protein was found in venules and very low levels of 
MAdCAM-1 mRNA were found in tissues. By contrast, VCAM-1 protein was 
observed on larger venules. PNAd protein was only detected in supramammary 
lymph nodes, suggestive of a role for recruiting na"ive lymphocytes. 
Cows were immunised with only one udder-half receiving intra-mammary 
immunisation to investigate effects on immunised glands. Animals with increased 
levels of lgA in milk had significantly more lgA plasma cells and T cells in immunised 
glands compared with non-immunised glands. Again no detectable MAdCAM-1 
protein and only very low levels of MAdCAM-1 mRNA were found. No differences 
were observed in VCAM-1 protein expression between immunised and non-
immunised mammary tissues. Together these studies suggest that MAdCAM-1 and 
VCAM-1 are not involved in lymphocyte recruitment to the bovine mammary gland, 
which contrasts to mice. 
In another study, cows categorised as either high- or low-responders to the multi-site 
immunisation were re-immunised to compare responses. Changes to lymphocytes in 
mammary secretions collected at intervals following two intra-mammary 
immunisations were monitored by flow cytometry. The percentage of T cells was 
found to decrease in both groups, although CD4 cells increased relative to CD8. The 
percentage of lgA-positive cells increased in a biphasic manner with high-responding 
animals showing an earlier and more sustained increase in lgA-positive cells 
compared with low-responders. The strong correlation observed between 
percentages of lgA-positive cells and lgA antibody in secretions suggests high levels 
of lgA require greater numbers of lgA-producing cells. 
Molecular analysis of known key cytokines found higher levels of IL-8 and IFN-y 
mRNA in immunised mammary tissues compared with non-immunised glands. In 
cells from mammary secretions, IL-8 mRNA increased shortly after immunisation 
while IFN-y and TGF-J3 mRNA increased at a later stage. However, no discernible 
differences were observed between high- and low-responding animals. TNF-a, IL-2, 
IL-6 and IL-10 mRNA were found to be low in both mammary tissues and secretion 
cells. lgA mRNA was increased in immunised tissues although no correlation was 
observed between lgA mRNA and mRNA levels of the polyimmunoglobulin receptor. 
These analyses indicate that innate and cell-mediated responses were induced along 
with an antibody response to immunisation. 
Together these results support the hypothesis and indicate that intra-mammary 
immunisation increases lgA-producing cells in the mammary gland accompanied by 
changes in expression profiles of a range of cytokine genes. However, in contrast to 
mice, the data suggest little involvement of known adhesion molecules in recruiting 
lymphocytes to the gland. 
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Chapter 1 
Introduction and literature review 
1.1 General introduction 
This thesis investigates the induction of local immunoglobulin A (lgA) secretion in the 
bovine mammary gland. Prior to this study, our group at AgResearch had developed 
a successful immunisation protocol for production of lgA in ruminant milk 
(Hodgkinson and Hodgkinson, 2003). The concept being that milk antibodies 
directed against human gut pathogens would provide valuable protection as a human 
therapeutic agent or bioactive food ingredient. The immunisation development 
programme specifically targeted lgA antibodies, rather than other immunoglobulin 
classes, based on the knowledge that lgA is the natural immunoglobulin of mucosal 
surfaces. For example, lgA is the antibody class normally secreted at the mucosal 
surface of the gastrointestinal tract. Consequently lgA is structurally designed to 
resist enzymatic attack in these environments and has a major role in preventing 
colonization of pathogens at mucosal surfaces and eliminating these 
microorganisms. Therefore, lgA would logically qualify as an effective and efficient 
human therapeutic/ prophylactic antibody for providing protection of mucosal 
surfaces. 
Although milk is a rich source of naturally occurring antibodies, in the ruminant the 
predominant lacteal immunoglobulin is lgG1, in contrast to humans where lgA is the 
major immunoglobulin of both colostrum and milk (Butler, 1969). In the human, the 
origin of lgA in mammary secretions is well defined by the concept of the gut-
mammary axis, where precursors of antibody-producing cells traffic between the two 
mucosal sites (Brandtzaeg, 1983). By contrast, this axis does not appear to be 
particularly well developed in the ruminant (Watson, 1981 ). 
To induce an lgA response in cows' milk our own empirical experiments have shown 
that the most successful regimen is to treat pregnant non-lactating animals with 
injections of antigen by combined intra-peritoneal, intra-muscular and intra-mammary 
routes, with booster doses of antigen to all three sites given subsequently. The 
method was successful in raising high levels of antigen-specific and total lgA 
antibodies but the underlying immunology was not well understood. Additionally, 
there was a large variation in response to the immunisation regimen. Whereas some 
animals responded with high-titre lgA antibodies, other individual animals did not 
respond at all. To ensure the immunisation protocol was economically viable a good 
response from each animal was important. The fundamental molecular and cellular 
mechanisms underlying our immunisation regimen required investigation to provide 
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essential knowledge for further development and optimisation of the immunisation 
procedure. Development of this understanding is the objective of this thesis. 
Chapter One reviews the current literature for the mucosal immune system. This is 
not an exhaustive review but concentrates on those aspects that pertain to our 
immunisation regimen. The review focuses on the induction of a 8-cell immune 
response in the gut and follows through the process of homing the cell to the effector 
site and its terminal differentiation into an antibody-secreting plasma cell. The 
structure of lgA is described along with its unique characteristics and functions. 
Essential literature on the immunology of the ruminant mammary gland is reviewed 
together with the literature backgrounding current know-how on inducing an antibody 
response in mammary secretions in the cow. 
While ruminant immunology has contributed novel findings to the field of immunology 
as a whole, most research to date has been in rodent and human systems; therefore, 
the general information reviewed in this chapter is largely based on research in these 
species. Specific data on the ruminant immune systems is centred on knowledge of 
the cow (Bos taurus) and the sheep (Ovis aries) as these domesticated bovidae have 
been the most extensively studied of the ruminants. 
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1.2 The mucosal immune system 
The immune system acts to protect the body from the invasion of pathogens by two 
main systems; the innate and the adaptive systems, which share many common 
mechanisms. The innate system is the first line of defence and acts to clear the 
infection or contain it until the adaptive response develops. Adaptive immunity 
specifically recognises pathogens and provides protection against re-infection by 
producing an immunological memory of the antigen. The adaptive immune response 
can be artificially induced by vaccination, for example, by introducing antigen to the 
body by injection. The key cells for the adaptive immune response are the 
lymphocytes, derived from hematopoietic stem cells in the bone marrow. B 
lymphocytes (B cells) differentiate into plasma cells that secrete antibody. T 
lymphocytes (T cells) are involved in the activation of B cells and can be further 
defined into subsets, dependent on their effector role. 
In contrast to other leukocytes, lymphocytes continuously recirculate from peripheral 
blood to efferent lymph through secondary lymphoid tissues. This recirculation 
increases the chance that a na"fve lymphocyte will encounter its specific antigen and 
is also important for the dissemination of activated cells to their effector sites. 
Anatomically the adaptive immune system consists of organised lymphoid tissue that 
can be separated into primary lymphoid organs, where lymphocytes are generated, 
and secondary lymphoid organs, where adaptive immune responses are initiated and 
lymphocytes are maintained. The adaptive system can be divided into two major 
systems, which in many ways are independent with respect to regulation and 
function. The first is the systemic lymphoid system which utilises the spleen and 
peripheral lymph nodes and responds to antigen that has entered the body through 
tissues or blood. A systemic immune response is characterised by production of 
serum antibodies of the lgG, lgM and lgE classes. The second major system, the 
mucosal immune system, consists of mucosal lymphoid tissue, mucosal-associated 
lymph nodes and secretory epithelium. The response tends to be local and is typified 
by the lgA class of antibody, produced in external secretions such as saliva, tears, 
milk and mucus. One exception of note is that of the ruminant mammary gland, 
where lgG predominates in the mammary secretions. 
The mucosal immune system provides protection from foreign antigens and 
pathogens encountered at mucosal surfaces including the oral and nasal cavities and 
the respiratory, gastrointestinal, and urogential tracts. Organised lymphoid tissues 
4 
throughout the body facilitate the uptake of these potential threats to the host. In the 
gastrointestinal tract these comprise of the gut-associated lymphoid tissues (GALT). 
In the respiratory tract and the nasal/oral cavity the organised lymphoid tissues are 
termed the bronchial-associated lymphoid tissues and the nasal-associated lymphoid 
tissues, respectively. Collectively, the lymphoid tissues protecting the mucosa are 
known as the mucosal-associated lymphoid tissues. The GALT region is the largest 
of the mucosal immune system and at least 80% of all immunoglobulin-producing 
plasma cells in the body are found in the GALT effector site, the lamina propria of the 
gut (Conley and Delacroix, 1987). 
1.2.1 The common mucosa/ immune system 
The mucosal immune system provides an integrated network of lymphoid organs that 
operate, to a large extent, independently of the systemic immune system. The 
concept of the 'common mucosal immune system' was proposed by researchers as 
early as the 1970's (McDermott and Bienenstock, 1979; McDermott et al., 1980). 
Adoptive transfer studies showed that lymphocytes from the GALT populate many 
mucosal effector sites including intestine, urogenital tract, mammary glands, salivary 
glands and respiratory tract (Husband and Gowans, 1978; Rudzik et al., 1975; 
Weisz-Carrington et al., 1979). The concept is that the antigenic experience at one 
mucosal surface can be mirrored in immune effector responses at a distant mucosal 
tissue. This rationale has been used as a basis for the design of mucosal vaccines 
(lijima et al., 2001; Mestecky, 1987; Staats and McGhee, 1996). We used this 
principle to develop our immunisation protocol for inducing lgA in ruminant milk 
(Hodgkinson and Hodgkinson, 2003). More recent studies have indicated that the 
common mucosal immune system may be more compartmentalised than originally 
thought (Butcher et al., 1999; Csencsits et al., 2001) and that there may be 
preferential homing to some locations dependent on the site of induction (Quiding-
Jarbrink et al., 1997). 
In the remainder of Section 1.2, the course of events that occur in the common 
mucosal response is described in detail. In the mucosal response, T cells and B 
cells circulating between inductive and distant effector sites are responsible for the 
lgA production in external secretions. Figure 1.1 shows the integration of mucosal 
and effector sites in the common mucosal immune system. Antigen or pathogen is 
sampled from the external mucosal surface by specialised antigen-presenting cells 
and transported to inductive sites in lymphoid tissue enriched with T cells and B cells 
(for example, Peyer's patches in the GALT). 
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Figure 1.1 A schematic representation of the network of inductive and effector 
sites in the common mucosa! immune system 
The immune cells have been colour coded: B cells and plasma cells are green, T cells 
are purple, and antigen-presenting cells are pink. (Diagram adapted from Brandzaeg 
et al, 1999b) 
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Antigen presentation induces lymphocyte activation and migration. Effector 
lymphocytes enter the lymphatic system and are transported into the blood from 
where they may repopulate the site of initial activation or distant sites in the common 
mucosal immune system. Preferential migration and extravasation at the effector site 
is directed by differential expression of adhesion molecule and chemokine receptors 
on the cell surface of lymphocytes. At the effector sites, local antigen-driven signals 
are thought to provide stimulus for retention, expansion and terminal differentiation of 
B cells into plasma cells. 
1.2.2 Induction of the mucosa/ response 
1.2.2.1 Antigen uptake across epithelial barriers 
To initiate an immune response it is essential to first have capture of antigens and 
pathogens and then presentation to and recognition by the appropriate immune cells. 
On mucosal surfaces the pathogens and immune cells are separated from one 
another by epithelial barriers. Epithelium differs structurally at different mucosal sites 
in the body and the strategy for antigen sampling varies according to the nature of 
this epithelium (Neutra et al., 1996b). In the stratified epithelium of the tonsils and 
vagina, motile intra-epithelial dendritic cells, similar to Langerhans cells in the skin, 
act as surveillance cells (Miller et al., 1992; Okato et al., 1989). These cells capture 
antigens and then migrate to local or distant lymphoid tissues. 
The gastrointestinal tract and airways have a simple epithelium sealed by tight 
junctions. Antigen is sampled by two distinct methods. One mechanism involves a 
network of intra-epithelial dendritic cells (Holt et al., 1990; Marie et al., 1996). In the 
gut, in vitro and in vivo studies have shown that dendritic cells are able to sample the 
luminal space via tight junctions in the epithelium. Dendritic cells open the tight 
junction, extend dendrites outside the epithelium and directly sample bacteria 
(Rescigno et al., 2001 ). The integrity of the epithelial layer is preserved because 
dendritic cells have the ability to express tight junction proteins such as occludin, 
claudin 1 and zona occludens 1. Dendritic cells then present antigen locally to 
organised lymphoid tissue or migrate to regional lymph nodes. 
An alternative sampling method involves a specialised area in the epithelium, termed 
the follicle-associated epithelium which overlies mucosal lymphoid follicles. The 
structure of these follicles differs in different sites in the body. Aggregates of 
lymphoid follicles, termed Peyer's patches, are found only in the small intestine while 
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isolated lymphoid follicles are more widespread and occur in the large and small 
intestine (Hamada et al., 2002) as well as the nasal cavities and the bronchi 
(Bienenstock and Clancy, 1994 ). The specialised follicle-associated epithelium 
contains microfold cells, a sub-epithelial-dome rich in dendritic cells, and B-cell 
follicles that include germinal centres (Kato and Owen, 1999). In Peyer's patches, 
there are specific inter-follicular areas containing T-cell-rich areas and specialised 
post-capillary venules, termed high endothelial venules which serve as entry and exit 
points for migrating cells (Girard and Springer, 1995). 
1.2.2.2 Unique features of the follicle-associated epithelium 
The follicle-associated epithelium of the small intestine is the best described. It 
contains unique epithelial M cells that transport foreign macromolecules, particles 
and microorganisms to antigen-presenting cells within and under the epithelial layer 
of the mucosa (Hathaway and Kraehenbuhl, 2000; Neutra and Kraehenbuhl, 1992). 
M cells lack brush border microvilli, do not secrete mucus and have a large 
invagination of the basolateral membrane that forms a pocket containing 
lymphocytes. In the human M-cell pocket, it has been shown that there are equal 
numbers of lgM-producing B cells and memory helper T cells (Farstad et al., 1994 ). 
It is postulated that the M-cell pocket may be the site for initial antigen encounter by 
lymphocytes and may play a part in oral tolerance in the gut (Brandtzaeg et al., 
1999a). However, the specific role of these lymphocytes at this site has not been 
elucidated (Neutra et al., 2001 ). 
The deep invagination of the M cell acts to bring the basolateral surface into close 
proximity of the apical membrane, so that transcytotic vesicles have only a short 
distance to travel. Secretory lgA in the lumen can bind to M-cell apical membranes 
and be taken up into the M-cell pocket. It is postulated that this mechanism allows 
for the reprocessing of antigen, delivered by the secretory lgA to the mucosal 
immune inductive sites, and further promotes local contact of intact antigens and 
pathogens with the follicle-associated epithelial surface (Weltzin et al., 1989). 
Certain pathogenic bacteria and viruses exploit the characteristics of M-cell 
adherence and transport mechanisms, to cross the epithelial barrier and invade the 
host (Neutra et al., 1996a; Neutra and Kraehenbuhl, 1992). The strategies employed 
by these organisms have in turn been exploited in vaccine design by using 
attenuated pathogens to deliver antigen to mucosal surfaces (Neutra et al., 2001 ). A 
diagrammatic representation of the gut-associated lymphoid tissues with the 
organised lymphoid structures is shown in Figure 1.2. 
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Figure 1.2 A schematic representation of the gut-associated lymphoid tissues 
with the organised lymphoid structures 
Peyer's patches and isolated lymphoid follicles (ILF) - and the diffuse tissue of the 
epithelium and the lamina propria are shown. Beneath the follicle-associated 
epithelium (FAE) containing M cells, are areas containing dendritic cells (DC, teal) 
and B-cell follicles with germinal centres (GC) surrounded by T cells (green). The 
diffuse tissues of the lamina propria contain large numbers of plasma cells (PC, red), 
T and B cells (pink), stromal cells (SC, brown) and DC. Secreted IgA is transported 
across the epithelium into the gut lumen. (Diagram adapted from Fagarasan and 
Honjo, 2003) 
Gut lumen 0 
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1.2.2.3 Presentation of antigen 
Antigen-presenting cells are specialised cells that take up antigen and pathogens 
and process them into peptide fragments by intra-cellular mechanisms. These 
fragments are presented on the cell surface of the antigen-presenting cells by a 
specialised group of proteins termed the major histocompatibility complex (MHC) 
(Germain, 1994). These peptide binding-proteins are of two types, MHC class I, 
recognised by T-cell receptors on cytotoxic T cells (CD8) and MHC class II 
recognised by helper T cells (CD4) (Schwartz, 1984; Zinkernagel and Doherty, 
1979). Antigens derived from different types of pathogens are displayed on a 
particular class of MHC molecule (Morrison et al., 1986). The most effective of the 
antigen-presenting cells is the dendritic cell but macrophages and B cells can also 
activate na"ive CD4 T cells (Kupfer et al., 1986; Underhill et al., 1999). Dendritic cells 
are dedicated antigen-presenting cells as their only known function is the 
presentation of antigen to T cells (Banchereau and Steinman, 1998). 
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Dendritic cells are central to the induction of the adaptive immune response. 
Recognition of antigen occurs through signalling via the Toll-like receptors (TLR), 
proteins which are a crucial link between the innate and adaptive immune system 
(Akira et al., 2001 ). Binding of antigen by specific receptors on dendritic cells 
initiates and modulates dendritic cell maturation, and different antigens result in 
functionally different effector subsets of dendritic cells (Iwasaki and Kelsall, 1999; 
Iwasaki and Kelsall, 2000). In addition to antigen, signals from inflammatory tissue 
play a role in dendritic cell activation and migration to T-cell-rich areas. These 
activated, mature dendritic cells are no longer phagocytotic but display a repertoire of 
molecules, including co-stimulatory molecules and cell-adhesion molecules and they 
secrete a range of cytokines (Banchereau and Steinman, 1998). 
1.2.2.4 T cell activation 
The next vital step in the induction of an immune response is the activation of na'ive T 
cells by antigen-presenting cells. The initial interaction of T cells with antigen-
presenting cells is mediated by cell-adhesion molecules (Gunzer et al., 2000). These 
adhesion molecules include leukocyte functional antigen-1 (LFA-1) and members of 
the intercellular adhesion molecule (ICAM) family and are described more fully in 
Section 1.2.3.4 below. Activation of na'ive T cells requires two independent signals: 
firstly, binding of the antigen-MHC complex by the T-cell receptor and secondly, T-
cell binding to co-stimulatory molecules CD40 and 87, also expressed on antigen-
presenting cells (Wang et al., 2000a). Initial T-cell activation is indicated by 
expression of interleukin-2 (IL-2) and its receptor, IL-2R, which does not occur in the 
absence of the co-stimulatory signal. Production of IL-2 by T cells is essential for the 
proliferation and differentiation of na'ive T cells and the cytokine acts in an autocrine 
manner (Minami et al., 1993). 
Na'ive CD8 cells differentiate into cytotoxic cells that function in the cell-mediated 
immune response (Mosmann et al., 1997). The differentiation of CD4 cells is more 
complex and at this stage they can differentiate into either a T helper (Th) 1 cell, 
secreting IL-2, interferon-gamma (IFN-y) and lymphotoxin or Th2 cell, secreting IL-4, 
IL-5, IL-6 and IL-10 (Mosmann, 1992). The Th type that the T cell develops into is 
determined by many factors including the subset of dendritic cells presenting antigen 
and the cytokine profile at the site of T-cell activation. IL-12 promotes Th1 cells and 
activates cell-mediated immunity, while IL-4 induces Th2 cells and an antibody 
response. The production of one Th cell type directly inhibits the other, for example 
IFN-y is an autocrine agonist for Th1 and antagonist for Th2 cells. In contrast, IL-4 
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enhances Th2 cell differentiation while IL-1 O inhibits Th1 cells (Mosmann and Sad, 
1996). 
The activation of na"ive T cells by antigen-presenting cells leads to their proliferation 
and differentiation of their progeny into effector cells. Th1 cells function 
predominantly in cell-mediated immunity but also induce B cells (via IFN-y) to 
produce opsonising lgG2 isotype antibody (Snapper et al., 1988). T cells with a Th2 
cytokine profile are required for the induction of B cells to produce lgA, lgG1 and lgE 
(Croft and Swain, 1991 ). 
The overall effect of presentation of antigen by antigen-presenting cells is the 
activation and proliferation of T cells. Most activated T cells become effector cells, 
while a proportion under the influence of IL-15 become memory T cells (Yajima et al., 
2002). Memory T cells are more sensitive to antigen than are na"ive lymphocytes and 
respond rapidly on re-exposure to the antigen that originally induced them (Grayson 
et al., 2002; Rogers et al., 2000). 
1.2.2.5 B-cell activation 
The first requirement for 8-cell activation is the binding of antigen by 8-cell surface 
immunoglobulin, the 8-cell receptor. The antigen is processed within the B cell and 
presented on the cell surface in association with MHC molecules. Effector CD4 T 
cells interact with the antigen-presenting cells and are stimulated to produce IL-4 and 
the ligand for CD40 (CD40L or CD154), a co-stimulatory signal for B cells. These 
factors in turn stimulate the B cells to proliferate and differentiate (Grewal and Flavell, 
1996). The initial immune response produces lgM antibody of low affinity that can 
bind the target antigen and serve as an immediate protection for the infected host. 
In the next stage of the immune response, the B cells undergo proliferation and a 
number of important modifications, including class-switch, somatic hypermutation and 
clonal selection. This occurs in the germinal centres which form around follicular 
dendritic cell networks and provide a specialized microenvironment when activated B 
cells migrate into lymphoid follicles. Germinal centres can be divided by morphology 
into a dark zone, rich in proliferating B cells and a light zone, which contains the 
dendritic cells and B cells undergoing somatic hypermutation (Maclennan and Gray, 
1986). At the periphery of the germinal centres are the CD4 T cells. 
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1.2.2.6 B-cell class-switch 
In a mucosal response, after the initial first reaction there is a switch in production 
from the lgM isotype antibody to lgA. Class-switch recombination occurs in the 
germinal centres, knowledge of this process coming from in vitro studies using mice 
(Snapper et al., 1995). Class-switch recombination involves looping and deletion of 
DNA segments and the immunoglobulin gene heavy-chain constant-region is 
changed from lgM type to lgA. Activation-induced cytidine deaminase (AID), an 
RNA-editing enzyme, has been recently identified for its essential involvement in this 
process (Okazaki et al., 2002). AID-deficient mice accumulate a large number of lgM 
B cells and lgM plasma cells in their lamina propria (Fagarasan et al., 2001 ). While 
general antigenic specificity of the new immunoglobulin isotype does not change, the 
new immunoglobulin isotype has different biological properties. 
The class-switch to the lgA isotype is under the influence of helper T cells and 
cytokines (Husband et al., 1999; McIntyre and Strober, 1999). Experiments using B 
cells have identified several factors that direct or enhance class switching to lgA, 
with transforming growth factor-beta (TGF-P) produced by T cells shown to be the 
most potent (Kim and Kagnoff, 1990; Lebman and Edmiston, 1999). Cells are 
required to be in the activated state before TGF-P has its effect (Lebman et al., 
1990). The drive for class switch to lgA is more pronounced in the gut-associated 
lymphoid tissues than other mucosal-associated lymphoid tissue sites and is 
reflected in the predominance of lgA plasma cells in the gut-associated lymphoid 
tissues over other isotypes. This may reflect the microenvironment of cytokine 
profiles and accessory cells (Brandtzaeg et al., 1999b). 
1.2.2. 7 B-cell somatic hypermutation and selection 
A process to change the affinity as well as increase the specificity of the 
immunoglobulin also occurs in the germinal centres. Somatic hypermutation of the 
immunoglobulin variable region results in the generation of a family of variant 
immunoglobulin (Neuberger and Milstein, 1995). The variable region of the 
immunoglobulin gene undergoes a high rate of point mutations that creates additional 
diversity within the expanding 8-cell clone. Similar to class-switch recombination, 
somatic hypermutation is dependent on the enzyme AID (Honjo et al., 2002; 
Kinoshita and Honjo, 2001 ). Iterative cycles of somatic hypermutation and 
proliferation form populations of 8-cell clones. Clonal expansion of plasmablasts is 
influenced by cytokines including IL-2, IL-5 and IL-10 (Burdin et al., 1995; Collins and 
Oldham, 1995; Harriman et al., 1988). To ensure B cells with higher affinity for 
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antigen are selected and those with lower affinity are not, signals for survival are 
required by the B cell. This process requires simultaneous cross linking of the high-
affinity B-cell receptor to antigen on follicular dendritic cells, and of CD40 with CD40L 
(CD154) on CD4 T cells (Han et al., 1995). Therefore, CD40L (CD154) not only 
provides a powerful stimulus to initiate B-cell activation but also plays a role in the 
final steps of the process. 
Recent studies have shown that a member of the tumour necrosis factor (TNF) 
super-family, B-lymphocyte stimulator (BLyS), and one of its three receptors, B-cell-
activating factor receptor (BAFF-R) expressed by B cells, are essential components 
for prolonging survival of mature B cells (Schneider et al., 1999; Schneider et al., 
2001 ). This has been demonstrated experimentally with BLyS-deficient mice that 
have an almost complete loss of follicular B cells (Schiemann et al., 2001 ). BLyS 
was discovered by several groups looking for TNF homologues in the human 
genome and can also be found in the literature under several other names including 
BAFF (B-cell-activating factor belonging to the TNF family), THANK (TNF homologue 
that activates apoptosis, nuclear factor-KP and c-Jun NHrterminal kinase) and TALL-
1 (TNF-and ApoL-related leukocyte-expressed ligand) (Moore et al., 1999; 
Mukhopadhyay et al., 1999; Schneider et al., 1999; Shu et al., 1999). 
The end of the somatic hypermutation and selection process results in a large 
number of high affinity lgA plasmablasts destined to secrete antibodies at the effector 
site. A population of memory B cells is also generated that provides immunological 
memory for secondary infection or re-immunisation (Berek et al., 1987). 
1.2.3 Homing of effector cells 
1.2.3.1 From inductor site to effector site 
In the gut-associated lymphoid tissues, precursors of the lgA plasma cell leave the 
mucosal inductive sites and migrate to mesenteric lymph nodes where they continue 
to divide and differentiate. Finally they exit the lymph nodes and drain with the 
efferent lymph into the peripheral blood circulation via the thoracic duct where the 
majority track back to the lamina propria in the gut (McDermott and Bienenstock, 
1979). The local antigen repertoire appears to play a role in the site-specific 
accumulation of plasmablasts and may explain the preference of effector cells from 
the gut-associated lymphoid tissue to traffic back to the lamina propria, to the site 
where the antigen introduction occurred. Immunisation studies in animals have 
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illustrated that the antibody response in local secretions (for example, milk) 
corresponds to local antigen exposure (Chang et al., 1981; Husband and Gowans, 
1978; Lascelles et al., 1981 ). 
Confirmation of this intestinal homing pattern of effector B cells, derived from gut-
associated lymphoid tissues, has been shown in several studies. Sequences of 
immunoglobulin variable heavy-chain region genes of B cells from human Peyer's 
patch germinal centres were found to be clonally related to those from plasma cells 
of ileal lamina propria (Dunn-Walters et al., 1997). In the intestinal lamina propria the 
plasmablasts complete their differentiation into mature lgA-secreting plasma cells 
and begin the generation of antibody (lijima et al., 2001 ). At this stage of terminal 
differentiation, lgA plasmablasts are unresponsive to receptor binding of antigen but 
require CD40 stimuli provided by CD4 T cells expressing CD40L (CD154) (McIntyre 
and Strober, 1999). In the mouse, IL-5 and IL-6 cytokines have been shown to be 
important for lgA terminal differentiation (Goodrich and McGee, 1999; Yan et al., 
1997), whereas IL-10 appears to be important for this process in humans (Burdin et 
al., 1995; Defrance et al., 1992). These cytokines are all produced by Th2 type T 
cells. 
1.2.3.2 Regulation of trafficking 
The immunoglobulin isotype ultimately expressed by plasma cells is influenced by 
the site in the body where antigen is presented, the type of antigen and the site at 
which plasma cell differentiation occurs (Kantele et al., 1997). The migration of 
immune cells is controlled by complex interactions between lymphocyte cell-surface 
receptors, the expression of receptor ligands on the vascular endothelium of target 
tissues and chemical cascades produced by chemokines. Studies have shown that 
the regional specificity of lymphocyte trafficking is governed by specific sets of 
interacting local vascular endothelial receptors and their respective counter-receptors 
on circulating lymphocytes (Butcher et al., 1999; Picker, 1994; Radi et al., 2001 ). 
Initial homing properties of mature na'ive lymphocytes to secondary lymph organs are 
determined developmentally before, or in association with, emigration from the 
thymus or bone marrow (Butcher, 1999). When na'ive lymphocytes are activated by 
contact with antigen, they differentiate into memory or effector cells that are 
reprogrammed with different homing properties. In this way, the distribution and 
trafficking of systemic and mucosal lymphocytes, both na'ive and memory/effector 
cells, demonstrate quite different recirculation properties. This may provide a 
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mechanism for segregating the specialised immune responses and contribute to the 
efficiency of immune responses (Butcher et al., 1999). For example, a memory T cell 
for intestinal antigens displaying gut-specific homing receptor would circulate 
preferentially to the gut where it would most likely re-encounter its specific antigen. 
1.2.3.3 The multi-step model of lymphocyte recruitment 
The recruitment of circulating lymphocytes from the blood into tissues begins with 
interactions between the lymphocytes and the vascular endothelium. The 
mechanism involves a multi-step process in which specialised cell-adhesion and 
signalling molecules contribute to, and mediate, a series of essential steps (Butcher 
et al., 1999; Picker, 1994). A diagram of the multi-step process of lymphocyte 
recruitment is shown in Figure 1.3. 
Figure 1.3 A schematic representation of the multi-step process of lymphocyte 
recruitment 
Circulating lymphocytes can tether to, and roll on, the vascular endothelium through 
interactions between selectins and integrins and their complementary receptors 
displayed on cell surfaces. Adherent lymphocytes migrate across the endothelium 
into the extravascular space directed by a cascade of chemokines. (Diagram 
adapted from Kunkel and Butcher, 2003) 
'Q' 'Q' lntegnn I I Selectin i . + Active integrin ~ Chemokine receptor I I Selectin ligand lntegrin ligand Chemokine 
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The process begins when active adhesion receptors projecting from the microvilli of 
circulating lymphocytes tether to the vascular endothelium and initiate rolling of the 
cell along the vessel wall. This primary adhesion slows the transit of the lymphocytes 
and allows sufficient time for the lymphocyte to sample the endothelium surface for 
signals such as chemokines. These signals activate integrins on the lymphocyte 
surface which in turn trigger the firm adhesion of the lymphocyte to the endothelium. 
The process is also reversible. If, for example, the cell does not receive additional 
signals within a short time, the adherent cell will begin to roll again and return into the 
blood circulation. Alternatively, if the correct signalling does occur, the adherent 
lymphocyte will undergo the process of passage through the tight junctions of the 
endothelium into the extravascular space. From there, the lymphocyte is directed by 
gradients of chemokines towards specific targets such as sites of inflamed tissue. 
1.2.3.4 Adhesion molecules involved in mucosa! homing 
The interplay of adhesion molecules and their ligands directs the circulation of 
lymphocytes between inductive and effector sites. There are several families of 
adhesion molecules including the immunoglobulin super-family members, integrins 
and selectins. A list of cell-adhesion molecules, their distribution and ligands are 
shown in Table 1.1. 
The mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) is the primary 
adhesion molecule for intestinal tissues. It is a member of the immunoglobulin super-
family, related to other vascular adhesion molecules including vascular cell-adhesion 
molecule-1 (VCAM-1) and the intercellular adhesion molecules (ICAM-1, 2, and 3) 
(Briskin et al., 1993). MAdCAM-1 is constitutively expressed by post-capillary 
venules in the intestinal lamina propria and gut-associated lymphoid tissues, 
especially in Peyer's patches and mesenteric lymph nodes (Briskin et al., 1997; 
Streeter et al., 1988a). While MAdCAM-1 has been shown to be very important for 
intestinal lymphocyte trafficking, it appears to play only a minor role in their homing to 
several other mucosal locations including pulmonary, bronchial and oral vascular 
endothelium (Abitorabi et al., 1996; Briskin et al., 1997; Csencsits et al., 2002; Picker 
et al., 1994 ). 
Increased expression of MAdCAM-1 has been detected on inflamed intestinal lamina 
propria in both humans and mice (Briskin et al., 1997; Viney et al., 1996) and has 
been implicated in the pathogenesis of the gut mucosa in diseases such as colitis 
(Kato et al., 2000). It has also been demonstrated on the high endothelial venules of 
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the mouse mammary gland (Streeter et al., 1988a; Tanneau et al., 1999; Van der 
Feltz et al., 2001). MAdCAM-1 is displayed by follicular dendritic cells of mucosal but 
not peripheral lymph nodes (Szabo et al., 1997) and is thought to have a role in 
selecting and binding lymphocytes at this site. 
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The receptor for MAdCAM-1 is the integrin a4p7 (Berlin et al., 1993). The integrins 
are a large group of heterodimeric transmembrane glycoproteins (Poupon and Cerf-
Bensussan, 1999). The p subunits can associate with several different a subunits, 
giving sub-groups of integrins. The p1, p2, and p7 integrins are the main p chains 
expressed by lymphocytes. Similar to other adhesion receptors, a4p7 is expressed 
on the microvilli projections of lymphocytes (Berlin et al., 1995). The molecule is 
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expressed in relatively inactive or low-avidity states on most na"ive lymphocytes. 
However, high expression can be induced on subsets of circulating memory B and T 
cells, in particular by chemoattractant receptors on the high endothelial venules 
during the multi-step process of extravasation (Butcher et al., 1999; Campbell et al., 
1998). The chemokine receptors differ for T cells and B cells and will be discussed 
more fully in Section 1.2.3.5 below. 
An in vitro study has shown that a4p7 also binds to VCAM-1 (Andrew et al., 1994 ), 
although another study has not been able to demonstrate this (Tidswell et al., 1997). 
VCAM-1 primarily binds to the integrin a4p1 (also termed very late activation antigen-
4, VLA-4) which is expressed on most lymphocytes (Osborn et al., 1989). Current 
data suggest that interactions between a4p7 and MAdCAM-1, and between a4p1 
and VCAM-1 are largely independent of each other and play a major role in the 
differential trafficking of intestinal versus non-intestinal memory and effector 
populations in vivo (Butcher, 1999). VCAM-1 is predominantly displayed in the skin, 
heart, central nervous system and joints, and expression is increased during 
inflammation (Butcher, 1999; Mackay et al., 1992; Osborn et al., 1989). It is only 
weakly expressed on intestinal endothelial cells and inflamed mucosa. 
The p7 chain also associates with the aE chain to form aEp7. This integrin is 
expressed on > 90% of epithelial-associated lymphocytes in the intestine and lung. T 
cells infiltrating inflamed epithelium in the epidermis, mammary gland and salivary 
glands have been shown to express aEP7 (Cerf-Bensussan et al., 1988; Kruschwitz 
et al., 1991 ). 
Another important molecule involved in lymphocyte homing is L-selectin (CD62L), a 
member of the sub-family of lectins including P-selectin (CD62P) and E-selectin 
(CD62E). L-selectin was first described as a peripheral lymph node homing receptor 
for the peripheral lymph node addressin (PNAd) (Streeter et al., 1988b). L-selectin is 
expressed by most circulating lymphocytes, including all na"ive lymphocytes of the 
adaptive immune system and a major fraction of memory T cells and B cells (Picker 
et al., 1993). In addition to peripheral lymph node homing, L-selectin has been 
shown to play a role in homing activated lymphocytes to both intestinal and non-
intestinal mucosal sites (Bargatze et al., 1995; Csencsits and Pascual, 2002). P-
selectin and E-selectin are displayed on activated endothelium during inflammation 
and are involved in the extravasation process of neutrophils and monocytes by 
tethering them to the vascular surface (Kansas, 1996). 
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The leukocyte functional antigen-1 (LFA-1) is a p2 family integrin, aLp2. It is 
expressed by most circulating lymphocytes and, similar to a4P7, its expression can 
be triggered by lymphocyte activation through chemoattractant signals. It is not 
found on the projected microvilli but on the planar body of the cell (Bargatze et al., 
1995). This may explain its function at the activation-triggered arrest stage of the 
multi-step endothelial interaction, rather that the initial contact. Its receptors are 
members of the ICAM family. ICAM-1 and ICAM-2 are largely expressed on 
endothelial cells activated by inflammatory cytokines and ICAM-3 is constitutively 
expressed on T cells (Radi et al., 2001 ). The high-affinity binding of ICAM-3 to the 
lectin DC-SIGN is unique to the T-cell interaction with dendritic cells (Geijtenbeek et 
al., 2000). 
In summary, migration and homing of immune cells is largely orchestrated by tissue-
specific adhesion molecules expressed by the vascular endothelium. Lymphocytes 
recognize and differentially adhere to endothelium in different sites in the body by 
binding through their counter-receptors. Cells can be directed to specific locations 
because lymphocytes display a different array of receptors, dependent on their cell 
phenotype (see Table 1.2) while vascular endothelium displays a range of adhesion 
molecules dependent on their location and the physiological state of the tissues (see 
Table 1.1). 
Table 1.2 Lymphocyte homing receptors and their counter-receptors on 
endothelial cells in different tissues 
(Adapted from Butcher et al., 1999) 
Lymphocytes 
a4P 110 a4pi0 
L-selectin ++ LFA-1 ++ 
a4p7hi 
a4P 110 L-selectin± 
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1.2.3.5 Trafficking of lgA plasmablasts: the influence of chemokines 
As activated B cells differentiate into plasma cells, they complete a final series of 
migration steps that take them to sites where they can most efficiently carry out their 
effector functions, i.e. secreting antibodies. Until recently, only part of the 
mechanism for the homing of plasmablasts was understood. Regional specificity 
was known to be governed by adhesion molecules and their counter-receptors on 
circulating lymphocytes, but it had been proposed some years ago that a factor 
derived from mucosal and/or exocrine epithelium may be also involved in selectively 
attracting mucosal plasma cells (Czinn and Lamm, 1986). Recent work has now 
established a key role for chemokines in directing plasmablast movement within the 
secondary lymphoid organs where they are generated (Bowman et al., 2000; Okada 
et al., 2002), as well as guiding them to their effector sites (Bowman et al., 2002; 
Hausereta/.,2002). 
Chemokines are small, mostly secreted, chemoattractant cytokines first characterised 
for their role in helping to recruit inflammatory cells to sites of inflammation and 
priming these cells for full activation (Cyster, 1999). To date, about 40 chemokines 
have been identified. The first chemokine to be identified was IL-8 (Yoshimura et al., 
1987), now renamed CXCL8. Its receptor CXCR 1 was the first chemokine receptor 
to be cloned (Holmes et al., 1991 ). Chemokines have been reclassified according to 
the configuration of cysteine residues in primary sequences near the amino-terminus 
(Murphy et al., 2000). There are four major groups: CC, CXC, C and CX3C. As 
knowledge of the family has grown, it has emerged that different chemokines help 
recruit appropriate subsets of cells for a particular type of inflammatory response and 
others are constitutively expressed in lymphoid tissues to guide the movement of 
circulating lymphocytes. As a consequence, the fundamental role of chemokines and 
their receptors is now recognised as controlling immune cell distribution (Rossi and 
Zlotnik, 2000; Sallusto et al., 2000). The key chemokines involved in the trafficking of 
T cells and B cells are listed in Table 1.3, along with their distribution and receptors. 
B cells first develop responsiveness to chemokines during their maturation in the 
bone marrow (Bowman et al., 2000). During an immune response to antigen, the 
recruitment of mature B cells into lymphoid follicles involves signalling through the 
CXC-chemokine receptor 5 (CXCRS) and its ligand CXC-chemokine ligand 13 
(CXCL 13). CXCL 13 is made by stromal cells within the B-cell zones in spleen, lymph 
nodes and Peyer's patches (Cyster et al., 2000; Okada et al., 2002). CCL 19 and 
CCL21 are made by stromal cells in the T-cell zone and their receptor CCR? is 
required by T cells and dendritic cells for migration to this region in lymphoid tissue 
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(Forster et al., 1999; Luther et al., 2002). Within a few hours of antigen encounter, B 
cells increase their expression of CCR? and in response to CCL 19 and CCL21, re-
localise to the boundary of follicles and T-cell zones (Reif et al., 2002). It is 
characteristically in this zone that the first plasmablasts are formed (Toellner et al., 
1996). 
Table 1.3 The key chemokines involved in the trafficking of T cells and B cells, 







T zone in spleen, lymph 
nodes, PP 
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nodes, PP and HEV 
Small intestine epithelium 
and endothelium 
Salivary glands, trachea 
and bronchi, large and 
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CXCL9, 10, 11 Inflamed tissue 
CXCL 12 Bone marrow and gut 
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CXCL 13 B zone in spleen, lymph 
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HEV - High endothelial venules 











Luther et al., 2000 
Cyster, 1999; 
Luther et al., 2000 
Kunkel et al., 2000; 
Zabel et al., 1999 
Pan et al., 2000; 
Wang et al., 2000 
Qin et al., 1998 
Ma et al., 1999; 
Kawabata et al., 1999 
Cyster et al., 2000; 
Okada et al., 2002 
Systemically-produced lgG and lgM plasmablasts preferentially travel through the 
blood to the bone marrow (Hauser et al., 2002). Stromal cells in the bone marrow 
produce the chemokine CXCL 12 where it has a major role in the development and 
retention of precursor B cells (Bleul et al., 1996). This ligand is also the attractant for 
lgG plasmablasts which display its receptor, CXCR4. Studies have shown that mice 
deficient in CXCR4 accumulate fewer lgG plasmablasts in the bone marrow following 
immunisation and consequently have higher circulating levels of lgG plasmablasts 
(Hargreaves et al., 2001 ). CXCL 12 is also expressed in the spleen and secondary 
lymph nodes (Kawabata et al., 1999; Ma et al., 1999). Interaction between this 
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ligand and its receptor on plasmablasts in these organs may play a role in lgG 
plasmablasts exiting from these organs but this has yet to be fully established 
(Cyster, 2003; Wehrli et al., 2001 ). 
Mucosal-derived lgA plasmablasts can up regulate the expression of two different 
chemokine receptors, CCR9 and CCR10. CCR9 expression appears to have a 
narrow role and is largely associated with lgA plasmablasts but not lgM or lgG 
plasmablasts (Bowman et al., 2002). In both the mouse (Lazarus et al., 2003) and 
the human (Kunkel et al., 2003), CCR9 is expressed by lgA plasmablasts from 
mesenteric lymph nodes and Peyer's patches but not by those from non-intestinal 
mucosal lymphoid tissues. Similarly, the CCR9 ligand, CCL25 is expressed at high 
levels in the small intestine but shows low or zero expression at other mucosal sites 
(Kunkel et al., 2000). CCR9 and CCL25 also mediate the homing of a subset of 
memory T cells to the small intestine (Kunkel et al., 2000). 
In contrast, almost all lgA plasmablasts express CCR10 and respond to its ligand 
CCL28 (Kunkel et al., 2000; Lazarus et al., 2003). Few lgG plasmablasts display this 
receptor, highlighting the unique association of CCR 1 O with lgA plasma blasts 
(Kunkel et al., 2003). CCL28, originally named as mucosal-associated epithelial 
chemokine (MEC), is expressed by many human mucosal sites including the 
stomach, small intestine, colon, salivary gland, mammary gland, and trachea (Pan et 
al., 2000; Wang et al., 2000b). 
Another chemokine receptor, CXCR3, is involved in homing plasmablasts (Hauser et 
al., 2002) and effector T cells (Qin et al., 1998) to sites of inflammation. This receptor 
binds to three different ligands, CCL9, CCL 10 and CCL 11 which are all strongly 
expressed in response to IFN-y, an inflammatory cytokine (Amichay et al., 1996). 
Chemokines have been shown to be important in the multi-step extravasation of 
lymphocytes from the blood into tissues. The unique patterns of expression of CCR9 
and CCR10 may allow for the different patterns of dissemination of lgA plasmablasts 
observed following mucosa immunisation by different routes. CCL25, expressed by 
endothelial cells in the gut-associated lymphoid tissues and its receptor, CCR9, 
expressed on mucosal lymphocytes, has been suggested to play a role, along with 
a4p7, in homing lymphocytes to mucosa I surfaces (Zabel et al., 1999). CXCL 12 has 
also been shown to promote cell-adhesion via a1 p7and VCAM-1 (Sanz-Rodriguez et 
al., 2001 ). 
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There is now strong evidence that chemokines and their receptors play key roles, 
together with adhesion molecules, in directing plasmablast trafficking within 
secondary lymphoid organs, to the bone marrow and to mucosa! effector sites. 
1.2.3.6 Plasma cell differentiation and longevity 
Plasma cells represent the terminal stage of differentiation for all antigen-activated B 
cells. Antigen deposition at the site of differentiation is thought to have an effect on 
this process by inducing T-cell activation, with these cells then providing important 
cytokine signals (Brandtzaeg et al., 1999b). IL-6 is essential in the first phase (Morse 
et al., 1997). This has been illustrated using an IL-6 knockout mouse model in which 
significantly reduced numbers of intestinal plasma cells and poorly developed lgA 
responses to mucosal immunisation were observed (Ramsay et al., 1994a). 
Plasmablast differentiation itself can be tracked by the sequential expression and 
silencing of transcriptional factors with a central role for B-lymphocyte-induced 
maturation protein (BLIMP-1) (Turner et al., 1994). 
Bone marrow plasma cells are characterised by the down-regulation of several cell 
surfaces markers; MHC II, CD45, 8220, and B-cell receptor. In contrast, cell-surface 
markers expressed by plasma cells include the chemokine receptor CXCR4, the 
integrins VLA-4 and LFA-1, an adhesion/growth factor receptor (syndecan-1) and the 
receptor for hyaluronic acid (CD44) which is involved in binding cells to the 
extracellular matrix (Calame, 2001; Cassese et al., 2003). These factors may be 
involved in the retention and/or longevity of these cells along with as yet unknown 
factors produced in their microenvironment (Cassese et al., 2003). 
There has been debate about the lifespan of plasma cells and until recently the 
immunological dogma held that plasma cells were short-lived with a half-life of a few 
days (Slifka et al., 1998). In humans, antibody titres to viral pathogens have been 
shown to persist for decades (Manz et al., 2002), although it has been suggested that 
this sustained antibody titre may be due to antigen-independent polyclonal activation 
of memory B cells resulting in a new population of plasma cells rather than long-lived 
plasma cells (Bernasconi et al., 2002). Using specific antibody titres as an indicator 
of plasma cell survival, a recent study in the mouse demonstrated the lifespan of 
plasma cells to be at least a year (Slifka et al., 1998). Others have shown the 
plasma cells can be both short- and long-lived dependent on their precursor cell type 
(O'Connor et al., 2002). 
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Recent in vitro studies using mice plasma cells derived from bone marrow have 
shown that IL-5, IL-6, TNF-a, CXCL 12 and CD44 are all specific signals required for 
the survival of plasma cells and they act in combination synergistically (Cassese et 
al., 2003). That the cells only survived approximately five days in culture indicates 
that other unidentified factors may be involved in plasma-cell longevity (Cassese et 
a/., 2003). This supports the hypothesis that plasma-cell survival is not intrinsic but 
dependent on stimuli provided by their niche microenvironment (Manz and Radbruch, 
2002). 
The sole function of plasma cells is to secrete soluble immunoglobulin molecules. 
The nucleus shows a characteristic pattern of peripheral chromatin condensation. 
There is a marked increase in the steady-state amounts of immunoglobulin heavy 
and light chain mRNA, and for lgA secretion, J chain mRNA (Mestecky and McGhee, 
1987). Plasma cells have an increased cytoplasm-to-nuclear ratio and prominent 
amounts of endoplasmic reticulum and secretory granules. lmmunoglobulin makes 
up 10 - 20% of all the protein synthesised by the cell (Janeway et al., 2001 d). 
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1.3 lgA 
lgA, produced by plasma cells, is the principal immunoglobulin of the mucosal 
system. It is present in most mucosal secretions in greater concentrations than any 
other immunoglobulin isotype, although there are species differences. For example, 
in the ruminant mammary secretions lgG1 predominates, not lgA (Butler, 1969). 
Mucosal surfaces of the body provide a large interface between the outside world 
and the interior of the body. The mucosal surfaces are colonized by commensal 
bacteria and the gut is constantly exposed to food antigens and occasionally 
potentially pathogenic microorganisms and viruses. lgA antibodies provide a first line 
of defence against pathogens by helping prevent their adherence and penetration of 
the mucosal epithelium (Lamm, 1997). On average, a human produces 5 - 15 g of 
lgA at mucosal surfaces per day (Mestecky and McGhee, 1987). 
1.3.1 Structure and function 
The basic immunoglobulin structure consists of two light-chains (25 kDa) and two 
heavy-chains (50 - 80 kDa) giving a total molecular mass of approximately 150 kDa 
(Janeway et al., 2001c). The light chains are of two types, kappa and lambda, which 
are present in all immunoglobulin classes. In contrast, the heavy chain is unique to 
each isotype of immunoglobulin. There are constant and variable regions on the 
chains. The variable (hypervariable) regions are the site of antigen-binding. 
Disulphide bonds link the heavy and light chains and the two heavy chains. The 
molecule is flexible at the hinge region and this is the site where proteolytic enzymes 
act, such as pepsin and trypsin. Pepsin can cleave the immunoglobulin molecule 
into two fragments termed Fab, containing the antigen-binding hypervariable region, 
and Fe, containing the effector region of the heavy chains. The immunoglobulins are 
members of the immunoglobulin super-gene family and related molecules are 
present on the surface of immune cells, for example CD4 and COB, (Barclay et al., 
1993; Classon et al., 1992). 
lgA consists of two basic immunoglobulin units (330 kDa) which are connected in a 
tail-to-tail formation by a J chain, a glycoprotein (15 kDa), covalently bound to the lgA 
dimer (Koshland, 1975). J chain has been shown to be a requirement for lgA 
polymerisation (Della Corte and Parkhouse, 1973). A second glycoprotein, secretory 
component (80 kDa), is bound to the lgA dimer heavy chain region by covalently 
linking to the heavy chain region of one lgA monomer (Beale, 1987). The complex of 
lgA dimer, J chain and secretory component is termed secretory lgA (SlgA) and has 
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a molecular weight of approximately 420 kDa. A diagrammatic representation of 
secretory lgA is shown in Figure 1.4. 
Figure 1.4 A schematic representation of the structure of secretory IgA 
A: Showing the basic immunoglobulin unit with the configuration of the heavy and 
light chains, the constant and variable regions and the site of antigen binding. B: 
Showing the configuration of SigA with two immunoglobulin units, J chain and 
secretory component. The hinge regions are indicated. (Diagram adapted from the 
website - www.biotech.ubc.ca/Biomedicine/ mucosal immunity) 
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Secretory component is an enzymatically cleaved portion of the polymeric 
immunoglobulin receptor (plgR) that is involved in the transfer of lgA into secretions 
(Beale, 1987; Crago et al., 1978). Secretory component binds only to polymeric 
immunoglobulin and the ability of lgA to bind secretory component is dependent on 
its J chain content (Johansen et al., 2001 ), although secretory component and J 
chain are not mutually linked. Secretory component can also be found in a free form 
in external secretions (Porter and Noakes, 1970). Secretory component, bound to 
lgA, interacts to stabilize the quaternary structure of lgA and importantly, may 
increase the resistance of lgA to proteolytic enzymes (Crottet and Corthesy, 1998; 
Lindh, 1975; Mestecky and McGhee, 1987; Renegar et al., 1998). The lgA protein 
has a greater resistance than lgG to proteases and this is thought to be due in part to 
differences in the hinge region composition (Crottet and Corthesy, 1998). The 
resistance of secretory lgA to proteolytic attack is very important as lgA must function 
in enzymatically hostile conditions. Secretory lgA is more resistant to proteolytic 
attack by trypsin, chymotrypsin, and pepsin than monomeric or dimeric lgA (Brown et 
al., 1970; Renegar et al., 1998; Shuster, 1971) and more resistant to digestion by 
intestinal secretions than lgG and lgM (Brock et al., 1977; Butler and Kennedy, 1978; 
Horsfall et al., 1978). 
In primates there are two forms of the alpha heavy chain, giving rise to different lgA1 
and lgA2 isoforms. The two isoforms appear to have few distinct biological properties 
but are distinguished by their different susceptibility to bacterial lgA1 proteases (Kilian 
et al., 1983; Plaut, 1983). Also unique to primates, circulating lgA in serum is 
monomeric. Unlike the general functions of secretory lgA, the in vivo functions of 
serum lgA are poorly understood (Macpherson et al., 2001; Russell et al., 1999). 
lgA provides a specialised defence at the interface between mucosal surfaces and 
the external environment. The primary function of lgA at mucosal surfaces is to 
inhibit entry of antigens and eliminate antigens which do gain access to the body. 
This is achieved by two main mechanisms: Firstly, by specifically binding mucosal 
pathogens, lgA provides protection from invasion against a variety of bacteria, 
parasites and viruses. Human in vivo studies have demonstrated the protective 
effects of lgA after immunisation with antigen by both oral and intranasal routes 
(Jertborn et al., 1998; Jertborn et al., 1986; Onorato et al., 1991; Smith et al., 2001; 
Tomoda et al., 1995). Passive immunisation using monoclonal lgA antibodies 
secreted by 'back-pack' hybridomas have shown protective effects in mice 
challenged with viruses (Kraehenbuhl and Neutra, 1992; Ruggeri et al., 1998) and 
bacteria (Neutra et al., 1991; Winner et al., 1991 ). 
27 
In the intestine, antibody binding can occur in the mucosal lamina propria before 
secretion into the intestinal lumen. Immune complexes formed in the lamina propria 
can then be eliminated locally by phagocytic cells or secreted via the plgR-mediated 
transport of lgA into the mucosal lumen (Kaetzel et al., 1991 ). Equally, lgA immune 
complexes can be translocated from the lumen into the lamina propria via M cells for 
further immune processing of pathogen (Weltzin et al., 1989). During its normal 
transport process, lgA has also been shown to be able to bind viruses that are 
migrating through the cell to the lamina propria thereby neutralising them before they 
can cause damage (Mazanec et al., 1992). 
The second mechanism by which lgA exerts its protective properties is related to its 
heavy chain, Fe structure and not due to the specific binding of antigens by the 
hypervariable region. As already described above, one of the most important 
structural properties of secretory lgA, the linkage with secretory component, imparts 
resistance to proteolytic degradation and therefore allows it to function in the 
enzymatically hostile environment of mucosal surfaces. 
The adherence of microorganisms to a mucosal surface is the first step in 
colonisation; therefore, inhibition of adherence by lgA is a major protective function. 
The hinge region of lgA is richly glycosalated with 0-linked oligosaccharides and 
these have been shown to interact with bacterial attachment receptors, thereby 
inhibiting adhesion of bacteria to epithelial surfaces (Schroten et al., 1998). Other 
studies have illustrated that lgA prevents bacterial colonisation of intestinal and oral 
epithelia and to tooth enamel (Dickinson et al., 1998; Hajishengallis et al., 1992; 
Vudhichamnong et al., 1982). lgA also prevents pathogenic bacteria and virus 
adherence by altering the physicochemical properties of the microbial surface. 
Studies have shown that the Fe-secretory component region of lgA is hydrophilic 
(Magnusson and Stjernstrom, 1982), a characteristic that allows it to associate with 
mucus. Microorganisms bound by hydrophilic lgA are more readily entrapped by the 
mucus layer and eliminated by dynamic processes such as peristalsis in the 
gastrointestinal tract and mucociliary movement in the airways (Phalipon et al., 
2002). 
Compared with lgG, lgA is a poor opsonin and a weak activator of both the classical 
and alternative complement pathways (Russell et al., 1999). However, as lgA acts in 
an environment where macrophages and complement are not usually present, lgA 
does not normally have the opportunity to activate these systems. The advantage of 
not activating complement systems is that elimination activities occur in the absence 
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of an inflammatory response, in contrast to the action of lgG. lgA in conjunction with 
secretory component prevents the influx of inflammatory cells and the release of 
immunological effectors that could increase membrane permeability due to tissue 
damage (Marshall et al., 2001; Motegi et al., 2000). This property is especially useful 
in mucous membranes where the immune system continuously interacts with foreign 
substances and toxins. 
1.3.2 Transport into secretions 
lgA is transported into external secretions by the polymeric immunoglobulin receptor 
(plgR) (Kaetzel et al., 1991 ). A transmembrane glycoprotein, plgR is selectively 
expressed on mucosal and secretory epithelial cell surfaces. The primary structure 
of plgR has been determined for several species by molecular cloning of 
complementary DNA and shows several highly conserved features (Piskurich et al., 
1995). PlgR is a member of the immunoglobulin super-family and the extracellular 
ligand-binding region contains five immunoglobulin domains. The plgR is a sacrificial 
receptor and is only used once for transport of lgA. For every molecule of lgA 
secreted, the epithelial cell produces one molecule of plgR. 
It has been suggested that the production of plgR may be limiting to the amount of 
lgA transported into secretions (Scicchitano et al., 1986; Sheldrake et al., 1984). The 
expression of plgR in epithelial cells appears to depend on the physiological 
conditions and on the tissue itself. In the rat and rabbit, expression of plgR has been 
shown to be under hormonal control in some tissues, including the uterus and 
mammary gland (Rosato et al., 1995; Sullivan et al., 1983; Sullivan and Wira, 1983). 
Research using transgenic mice that over-express plgR in the mammary gland has 
shown that lgA concentrations in the milk are 1.5 - 2.0 times higher than those in 
non-transgenic mice (de Groot et al., 2000). 
The receptor-mediated transport of lgA begins with the synthesis of plgR in the 
endoplasmic reticulum. Following exit from the Golgi, plgR is delivered directly to the 
basolateral membrane where it binds dimeric lgA. This binding is dependent on the J 
chain (Johansen et al., 2001 ), therefore, plgR can also transport lgM. However, its 
binding affinity for lgA is greater (Brandtzaeg, 1985). The plgR-lgA complex is 
endocytosed and transported through a series of endosomal compartments across 
the cell to the apical membrane (Apodaca et al., 1994). At some stage during the 
epithelial translocation, lgA becomes covalently bound to plgR (this does not occur 
with lgM) by disulphide links (Fallgreen-Gebauer et al., 1993). At the apical 
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membrane, plgR is proteolytically cleaved (Musil and Baenziger, 1987) and the 
complex, including the extra-cellular binding domain of the receptor and dimeric lgA, 
is released into the mucosal secretions as secretory lgA. Figure 1.5 illustrates the 
multiple mechanisms for immune exclusion of pathogens involving lgA, plgR and 
secretory component. 
Figure 1.5 The multiple mechanisms for immune exclusion of pathogens involving 
IgA, pigR and secretory component 
la: Transcytosis of IgA across the epithelial cell by pigR with release of SigA into 
the lumen. lb: Transport of free secretory component into the lumen. 2: 
Transcytosis of IgA bound to antigen across the epithelial cell by pigR with release 
of the complex into the lumen. 3: During transcytosis, IgA binds antigen present in 
the cell. 4: Association of IgA with mucus via secretory component provides a 
barrier for pathogens. 5: Free secretory component acts as a non-specific microbial 
scavenger. 6: pigR may be exploited by pathogens to translocate them across the 
epithelial barrier into the lamina propria. (Diagram adapted from Phalipon and 
Corthesy, 2003) 




pigR - polymeric immunoglobulin receptor 
SC - secretory component 
* ~, ~ plgR >< dimeric lgA 




As described above, secretory component bound to dimeric lgA acts to protect the 
complex from proteolytic degradation. In addition, secretory component has a direct 
effect on the ability of lgA to localise to mucus (Phalipon et al., 2002) and is thereby 
crucial for one of the protective mechanisms of lgA at mucosal surfaces. Free plgR, 
unbound by immunoglobulin, also translocates to the apical surface and secretory 
component is released in a free form into secretions. Free secretory component can 
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act as a non-specific microbial scavenger and it has been shown to reduce the 
effects of toxins (Dallas and Rolfe, 1998) as well as bacteria by binding to fimbrial 
colonisation factors (de Oliveira et al., 2001 ). Free secretory component may also 
have a role in homeostasis as it binds the cytokine IL-8 thereby modifying the pro-
inflammatory effects of this cytokine (Marshall et al., 2001 ). Recent studies have 
shown that human plgR can be co-opted by bacteria to translocate them from the 
lumen across the respiratory epithelium in a receptor-dependant manner which may 
lead to colonisation by the bacteria and result in disease (Zhang et al., 2000). This 
phenomenon may be limited to specific strains and cell types (Brock et al., 2002). 
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1.4 Bovine mammary gland immunology 
1.4.1 Bovine mammary gland 
A cow's udder consists of two separate halves each containing two mammary glands 
(quarters). The glands are made up of two main tissue types, secretory and ductal, 
which together are termed the parenchyma. Other components, skin, connective 
tissue, adipose tissue, blood and lymph vessels and nervous tissue, are collectively 
called the stroma. 
The secretory tissue has been described by Holmes et al. (1984b) as being 
composed of alveoli. Alveoli are formed by groups of secretory epithelial cells 
arranged in a single layer lining a hollow lumen with myoepithelial cells stretched 
over their outer surface. The mammary secretory epithelium is probably unique in 
that fat, protein and carbohydrate are secreted by a single type of cell. Groups of 
alveoli are encapsulated by connective tissue to form lobules and groups of lobules 
form lobes. Secretions produced by the alveoli drain consecutively into ductules, 
larger ducts and finally into a gland cistern at the base of each quarter. Mammary 
secretions accumulate in the cistern until released via the teat (Holmes et al., 1984b). 
The mammary gland is richly supplied with blood vessels, with 400 - 500 I of blood 
flowing through the udder for every litre of milk produced (Holmes et al., 1984b). In 
addition, tissue fluid, similar to the volume of milk produced, is drained from interstitial 
areas by lymphatic vessels to two major supramammary lymph nodes situated on the 
dorsal surface of the udder above the rear teats (Holmes et al., 1984b). Efferent 
lymph from these nodes eventually drains via the thoracic duct into the blood system. 
The main function of the mammary gland is the production of milk. This is a phasic 
process with growth and development of the gland occurring during puberty and 
pregnancies (mammogenesis), initiation of milk secretion at parturition (lactogenesis}, 
maintenance of lactation (galactopoiesis) and cessation of milk production 
(involution) at weaning (Mepham, 1987). In most species, including ruminants, the 
major lobuloalveolar growth occurs during pregnancy. A marked change occurs in 
the morphology of the gland as first the ducts and then the lobules grow into the 
stroma, displacing adipose tissue. By parturition, the growth of the gland is 
essentially complete and during the lactation period there is a gradual progressive 
regression of the mammary gland (Holmes et al., 1984a). For the dairy cow, 
involution is initiated when milking is abruptly stopped. The accumulation of milk 
causes alveoli tight junctions to break down, the alveolar cells undergo apoptosis and 
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there is an infiltration of phagocytic cells that remove casein, fat and cellular debris. 
Progressively the parenchyma regresses and is replaced with connective and 
adipose tissue (Sordillo and Nickerson, 1988a). A schematic diagram illustrating the 
structure of a group of alveoli in the bovine mammary gland is shown in Figure 1.6. 
Figure 1.6 A schematic representation of the structure of a group of alveoli in 
the bovine mammary gland 






Mammary secretions produced by the gland vary markedly in composition, 
depending on the stage of the lactation cycle. Secretions can be obtained from a 
cow as early as mid-pregnancy. Six weeks prior to parturition the volume in the 
gland increases as colostrum, the mammary secretion immediately post-partum, is 
formed. Colostrum contains more protein and fat and less lactose than later milk. 
The higher protein content is largely due to a high immunoglobulin concentration, 
with levels up to 60 g/1. The transition from colostrum to mature milk takes 3 - 4 days 
post-partum (Mepham, 1987). 
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Milk is a complex mixture of water, fat, carbohydrate, protein, salts and trace 
elements and provides the sole source of nutrients for the mammalian neonate. 
Many of the constituents are unique to milk, being synthesised in the secretory 
epithelium of the mammary gland from nutrients delivered in arterial blood. Cows' 
milk, perhaps the best characterised of mammary secretions, contains at mid-
lactation approximately 3.0 - 6.0% fat, 4.4 - 5.3% lactose and 3.0 - 4.8% protein 
(Holmes et al., 1984a). The major milk protein, casein, can be readily precipitated at 
acid pH, thereby forming the characteristic milk curd and leaving an aqueous fraction 
termed whey. Milk whey contains the soluble milk proteins, including 
immunoglobulins, ~-lactoglobulin, a-lactalbumin, and serum albumin. Other proteins 
present in lesser amounts are lactoferrin and transferrin, the growth factors and a 
large number of different enzymes (Mepham, 1987). 
1.4.2 Ruminant mammary gland immunity 
The mammary gland has two distinct immunological roles. First milk plays a crucial 
function in protecting the neonate from disease and infection, in addition to providing 
its sole source of nutrients. By far the most significant protective effects for the 
neonate are provided by the transfer of maternal immunoglobulin and immune type 
cells via mammary secretions. The second role is providing immunological protection 
for the gland itself. 
1.4.2.1 Immune protection for the neonate 
The neonatal ruminant is singularly dependent for survival on passive immunity 
provided by lacteal factors, principally immunoglobulin and immune cells. In the 
ruminant, there is no placental transport of maternal immunoglobulin in utero and 
neonates are born agammaglobulinaemic (Brambell, 1970; Hanson and Johansson, 
1970). This differs from the human where transfer of lgG does occur via the placenta 
(Brambell, 1970; Hanson and Johansson, 1970). Prior to gut closure at 24 - 36 h 
post-partum, the ruminant neonate absorbs ingested maternal immunoglobulin 
directly across the intestinal epithelium into the blood circulation (Kruse, 1970). 
Studies have shown that all immunoglobulin are absorbed with relatively equal 
efficiency and since lgG1 is the predominant immunoglobulin in colostrum, it is 
absorbed in the greatest amounts (Brandon and Lascelles, 1971 ). After gut closure, 
as in the human, the major function of milk immunoglobulin in the ruminant is 
believed to be a protective role in the lumen of the intestine (Butler, 1981 ). 
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In addition to maternal immunoglobulin, milk contains other immune components that 
provide passive transfer of specific cellular immunity by way of maternal leukocytes. 
Mammary secretions contain approximately 2.0 x 106 cells/ml just prior to parturition, 
consisting of macrophages, lymphocytes and polymorphonuclear leukocytes 
(Concha, 1986; Duhamel et al., 1987; Park et al., 1992). Studies have demonstrated 
that colostral leukocytes can cross the intestine of the ruminant neonate and 
modulate host defence mechanisms (Liebler-Tenorio et al., 2002; Riedel Caspari, 
1993; Sheldrake and Husband, 1985). Once lactation is established, cell counts in 
the milk from a healthy animal fall to < 105 cells/ml (Dosogne et al., 2003). 
Other soluble milk components provide non-specific defence against environmental 
pathogens. For example, lactoferrin is thought to exercise an inhibitory effect on 
microbial growth in the newborn intestine by binding essential iron required for 
growth by many microorganisms (Outteridge and Lee, 1988); lactoperoxidase and 
xanthine oxidase, two enzymes associated with the milk-fat globule membrane, 
inhibit bacterial metabolism by oxidative processes (Outteridge and Lee, 1988). 
1.4.2.2 Immune protection of the mammary gland 
Mammary gland defence mechanisms provide protection against a variety of 
contagious and environmental pathogens including mastitis-causing bacteria such as 
Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus). Features of the 
physical, biochemical and cellular defence components of the bovine mammary 
gland have been described in several reviews (Kehrli and Harp, 2001; Mallard et al., 
1998; Nickerson, 1989; Sordillo et al., 1997; Sordillo and Streicher, 2002; Watson, 
1980). The gland utilises both innate and adaptive immune mechanisms for 
protection. Innate defences are mediated by the physical barrier of the teat and by 
neutrophils, macrophages and Natural Killer cells, and by soluble factors, including 
lactoferrin and lysozyme. The adaptive immune system is activated when the 
pathogen evades or is not completely eliminated by the innate system, or with a 
protective vaccination. 
The teat is the first line of defence for the mammary gland, acting as a physical 
barrier to invading pathogens (Nickerson, 1987). Keratin, a waxy protein in the teat 
canal, provides not only a physical obstruction during the non-lactating period but 
also contains antimicrobial substances. Microorganisms that breach this barrier 
initiate an innate immune response. This response is characterised by a large 
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increase in the number of neutrophils in the gland (> 106 cells/ml) compared with the 
relatively low numbers(< 105 cells/ml) in the healthy cow (Leitner et al., 2000b). 
Neutrophils circulating in the blood are recruited to the site of infection by changes in 
the expression of adhesion molecules on vascular endothelium cell walls. These 
changes are induced by pro-inflammatory molecules released by pathogens or 
macrophage-derived cytokines and chemokines. During the extravasation process, 
neutrophils shed the CD62L receptor and up-regulate the Cd11a/Cd18 receptor 
(LFA-1) (Jutila et al., 1989a; Jutila et al., 1989b; Radi et al., 2001). Under the 
influence of pro-inflammatory cytokines, neutrophils are activated to express 
specialised receptors, including those for lipopolysaccharide (LPS), complement and 
Fe, to facilitate pathogen recognition and phagocytosis (Burton and Erskine, 2003). 
Their bactericidal effects are mediated through a respiratory burst that produces 
hydroxyl and oxygen radicals (Heyneman et al., 1990). 
In cattle, neutrophils express a specific high-affinity Fe receptor for lgG2. lgG2 acts as 
an opsonin for neutrophils by specifically binding antigens on bacterial-cell surfaces. 
This is an important mode of defence against mastitis, as demonstrated by the high 
frequency of mastitis in Danish Red cows, animals with a genetic defect for lgG2 
production (Nansen, 1972). Interestingly, there appears to be evidence of 
generalised immune suppression in the cow during the week before and after 
parturition, as evidenced by reduced IFN-y and IL-2 levels in mammary secretions 
(Sordillo et al., 1991 b) and susceptibility to infection (Kehrli et al., 1989; Mallard et al., 
1998). In part, this is thought to be due to a reduced infiltration of neutrophils into the 
mammary gland due to a decreased expression of the neutrophil adhesion molecule, 
L-selectin (Monfardini et al., 2002). The overall mechanisms of periparturient 
immunosuppression remain unknown and may involve pregnancy-associated 
hormones and metabolites (Mallard et al., 1998; Paape et al., 2002a). 
Resident macrophages are prevalent in the milk and tissues of healthy cows 
(Outteridge and Lee, 1981 ). Similar to neutrophils, macrophages destroy bacteria by 
phagocytosis. In addition, macrophages secrete cytokines and chemokines involved 
in the extravasation and chemotaxis of activated neutrophils (Pighetti and Sordillo, 
1994 ). Macrophages also have a role in the specific immune response through 
antigen processing and presentation (Fitzpatrick et al., 1992). 
Lymphocyte populations in normal non-infected ruminant mammary glands have 
been well characterised in secretions (Asai et al., 2000; Dosogne et al., 2003; 
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Duhamel et al., 1987; Jensen and Eberhart, 1981; Leitner et al., 2000a; Park et al., 
1992; Wilson et al., 1986; Yang et al., 1997) and tissue samples (Lee et al., 1989; 
Nickerson et al., 1984; Shafer-Weaver et al., 1996; Sordillo and Nickerson, 1988b; 
Tatarczuch et al., 2000; Yamaguchi et al., 1999; Yang et al., 1988). Determination of 
cell populations in mammary secretions at different physiological stages of the 
mammary gland, using flow cytometry analysis, has shown that cows have a greater 
percentage of CD4 than CD8 T cells during the dry period. The proportion of CD4 T 
cells decreases at parturition and remains lower throughout lactation in an inversely-
related manner to that of CD8 T cells. At drying off, CD4 T cells increase again 
(Dosogne et al., 2003; Yang et al., 1997). The T cells have been shown to be 
predominantly memory cells (Taylor et al., 1994). Overall, about 80 - 90% of the 
lymphocytes have been found to be T cells, with the percentage of B cells low (5%) 
or negligible (Duhamel et al., 1987; Leitner et al., 2000a; Yang et al., 1997). Just 
prior to parturition, B cells in secretions show an increase to 25% of the lymphocytes 
(Park et al., 1992). Although yo T cells have been shown to be highly represented in 
ruminant immunity, compared with humans and mice (Hein and Mackay, 1991 ), this 
phenotype was found to be extremely low in cow's milk throughout lactation (Asai et 
al., 2000; Yang et al., 1997). The percentage of macrophages and 
polymorphonuclear leukocytes were lower in early lactation compared with middle 
and late lactation (Dosogne et al., 2003). 
Early studies on pregnant and non-pregnant sheep tissues have found that the 
mammary gland is heavily infiltrated with lymphocytes and macrophages (Lee and 
Lascelles, 1969a; Lee and Lascelles, 1969b; Lee and Lascelles, 1970). The majority 
of lymphocytes were later shown to be CD8 T cells located in the alveolar and ductal 
epithelium (Lee et al., 1989; Tatarczuch et al., 2000; Yamaguchi et al., 1999). B cells 
were present in lower numbers and located mainly in the periductal and intra-lobular 
connective tissues. T cells were also observed congregated around venules. In 
tissues examined at involution, the predominant leukocytes in the alveolar and ductal 
lumen were neutrophils. CD8 T cells were present in the alveolar and ductal 
epithelium, while CD4 T cells predominated in the inter-alveolar and periductal areas 
(Tatarczuch et al., 2000). Dendritic cells have recently been described in the 
mammary gland, identified by their characteristic extensive cytoplasmic processes 
(Tatarczuch et al., 2000). 
The adaptive immune response in the mammary gland has been best characterised 
by vaccination studies to induce antibodies in milk for increased passive protection 
for the neonate. These are described in Section 1.5.1 below. 
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1.4.3 Bovine milk immunoglobulins 
1.4.3.1 lgG 
lgG, a monomer of the basic structural immunoglobulin unit (- 150 kDa), is the main 
immunoglobulin of ruminant colostrum and milk (- 70 - 90% of total, Table 1.4). Two 
major subclasses have been characterized, lgG1 and lgG2. A minor third class has 
been identified, termed either lgG2b (Butler et al., 1987) or lgG3 (Knight et al., 1988), 
that is thought to be an allotype of lgG2 (Butler et al., 1987). lgG is derived directly 
from blood into ruminant colostrum and milk (Dixon et al., 1961; Newby and Bourne, 
1977), and although the two major subclasses occur in relatively equal amounts in 
serum, lgG1 comprises > 90% of the total lgG in ruminant mammary secretions 
(Butler, 1981 ). The selective transport of lgG1 into milk appears to involve lgG1-
specific heavy-chain Fe receptors on the membranes of alveolar cells (Kemler et al., 
1975). In the cow, as much as 500 g of lgG1 per week is transported into the 
mammary gland in the three weeks pre-partum (Brandon et al., 1971 ). Colostral lgG1 
averages 48 g/1 but levels decrease to approximately 0.5 g/1 in established lactation. 
Comparative data for concentration and relative percent of immunoglobulin in serum 
and mammary secretions of the human and cow are shown in Table 1.4. 
Antigenic and physicochemical differences between the lgG1 and lgG2 of ruminants 
are more pronounced than in other species and they have distinctly different 
biological activities as well as having some activities in common (Butler, 1983; Butler, 
1986). Both lgG1 and lgG2 fix bovine complement and have excellent agglutination 
properties. Bovine macrophages have membrane receptors for both lgG1 and lgG2 
but the lgG2 subclass is more efficient at inducing phagocytosis by neutrophils. It is 
of interest to note that in cattle, lgG1 is more resistant than lgG2 to trypsin and 
chymotrypsin but not papain and pepsin (Brock et al., 1977; Butler and Kennedy, 
1978). 
It has been suggested that lgG1 may function as a secretory immunoglobulin in the 
ruminant (Chang et al., 1981; Morgan et al., 1981). This was based largely on the 
observation that ruminants have high concentrations of lgG1 in lacteal secretions, 
achieved by a unique selective transport mechanism involving the mammary 
epithelium. 
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Table 1.4 Comparison of the amount of the various classes of immunoglobulins in 
serum and mammary secretions for humans and cows 
Species lg Concentration (g/1) % of total lg 
Serum Colostrum Milk Serum Colostrum Milk 
Humana lgG 12.10 0.43 0.04 78.0 2.0 3.0 
lgA 2.50 17.35 1.00 16.0 90.0 87.0 
lgM 0.93 1.59 0.10 6.0 8.0 10.0 
Cowb lgG1 11.20 46.40 0.58 47.0 75.5 71.6 
lgG2 9.20 2.87 0.06 38.6 4.7 7.4 
lgA 0.37 5.36 0.08 1.6 8.8 9.9 
lgM 3.05 6.77 0.09 12.8 11.0 11.1 
Ig - immunoglobulin 
a (Butler, 1974) 
b (Butler, 1983) 
1.4.3.2 lgA 
The structure of lgA in ruminants is similar to that of other species, as previously 
described in Section 1.3.1. The main difference is that, in ruminants, serum lgA 
exists as a dimer in contrast to humans where serum lgA is a monomer (Mestecky 
and McGhee, 1987). 
Similar to other mammals, in the ruminant, lgA is the primary immunoglobulin of 
mucosal secretions with the exception of mammary secretions. In colostrum the level 
of lgA is 5.4 g/1 and in milk 0.1 g/1. This represents approximately 9% of the total 
immunoglobulins in comparison to human mammary secretions where lgA represents 
approximately 90% (Table 1.4). lgA plasma cells are the most numerous in the gut-
associated lymphoid tissues (Lee and Lascelles, 1970) and lgA is the predominant 
immunoglobulin in intestinal secretions (Cripps et al., 197 4 ), in contrast to lgG and 
lgM which are present in low concentrations. A similar distribution of immunoglobulin 
isotypes is seen in ruminant saliva (Cripps and Lascelles, 1976). lgA is the most 
abundant immunoglobulin in the upper respiratory tract but lgG is found in higher 
concentrations in the lower respiratory tract (Gorin et al., 1979). Studies have shown 
indirectly that following antigen stimulation, lgA plasma cells from the intestine travel 
to the respiratory tract, demonstrating the common mucosal immune system in the 
39 
ruminant (Scicchitano et al., 1984 ). Effector functions of ruminant lgA are similar to 
other species, as described in Section 1.3.1. 
In ruminant mammary secretions, the function of lgA is less well defined. During the 
initial suckling period it is likely that all classes of immunoglobulin provide local 
protective immunity in the gastrointestinal tract of the young ruminant but later lgA 
may be the most effective. This concept is based on the known functional activities 
of lgA, and on the increase in the relative occurrence of lgA compared with lgG1 
when concentration data in mammary gland secretions is expressed relative to 
albumin and serum levels of immunoglobulin (Butler, 1994). 
1.4.3.3 lgM 
lgM is a large polymeric immunoglobulin (1000 kDa) formed from five units of the 
basic immunoglobulin unit cross linked by disulphide bonds. Similarly to lgA, lgM 
has additional glycoprotein associated with it. A single J chain is covalently bound to 
each pentameric lgM molecule and appears to play a role in the polymerisation of the 
molecule (Della Corte and Parkhouse, 1973). Polymeric lgM is thought to be 
transported through the mucosal epithelium via plgR by a similar mechanism to lgA 
(Brandtzaeg, 1985; Eskeland and Brandtzaeg, 1974). 
lgM is a minor lacteal immunoglobulin and concentrations in ruminant colostrum and 
milk are similar to that of humans (see Table 1.4). Levels of lgM in cows' colostrum 
are approximately 6.8 g/1, declining to 0.09 g/1 in mature milk. 
lgM in ruminant mammary secretions is believed to be of both serum and local origin 
(Newby and Bourne, 1977). In ruminants, as in other mammals, lgM antibodies are 
produced at an early stage in response to antigenic challenge. lgM antibodies are of 
low affinity but the molecule has the ability to bind antigen with up to ten binding 
sites. The major function of lgM is fixation of complement, being 10 - 20 times as 
effective as lgG, and lgM also has effective agglutination and neutralization 
characteristics (Butler, 1983; Butler, 1986). 
1.4.4 Bovine plgR 
The transport of polymeric immunoglobulin into ruminant mammary secretions is via 
the polymeric immunoglobulin receptor (plgR), as in other species. It has been 
suggested that the low levels of lgA in ruminant milk may be due to there being low 
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levels of plgR expression (Scicchitano et al., 1986; Sheldrake et al., 1984). The 
bovine plgR was cloned several years ago (Kulseth et al., 1995; Verbeet et al., 1995) 
and the gene was found to be expressed in the lactating bovine mammary gland 
(Verbeet et al., 1995), however, expression levels at other stages of the mammary 
gland development are unknown. Recent work in the sheep during pregnancy and 
lactation has shown that plgR expression increases in the third stage of pregnancy 
and reaches its highest levels during established lactation (Rincheval-Arnold et al., 
2002). Further investigation using hormones suggested that the expression of plgR 
is under the control of prolactin and glucocorticoids (Rincheval-Arnold et al., 2002). 
Bovine secretory component, the extracelluar component of plgR, is well studied and 
was the first secretory component to be isolated in free form in any species (Groves 
and Gordon, 1967). The first 11 amino acids residues of bovine secretory 
component are homologous with secretory component from various species (Labib et 
al., 1976). 
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1.5 Induction of bovine milk antibodies 
1.5.1 Milk antibodies as health treatments 
The majority of bacterial and viral pathogens enter the body through, or remain 
localized on, mucosal surfaces in the intestinal tract, lung or nose. Enteric infections 
are characterized by diarrhoea and dehydration caused by the sloughing off of the 
absorptive cells in the intestine. These diseases are increasing due to a number of 
factors including a rise in global travel, HIV-immunocompromisation and the 
continuing malnutrition in poorer areas of world. Current treatments or prophylaxis is 
often ineffective or results in further health problems. In addition, widespread 
antibiotic use is resulting in development of resistant strains of pathogens. 
Hyper-immune milk products derived from the milk or colostrum of cows have been 
used for treatment, or prevention of enteric diseases in both animals and humans. 
To obtain the products, cows have been hyper-immunised during the dry period of 
their pregnancy with pathogenic antigens in order to induce specific antibodies in 
their colostrum and milk. These products provide protection through passive 
immunisation and an increasing number of studies have demonstrated that immune 
milk products can be effective against diseases caused by enteropathogenic 
organisms. These have been reviewed recently (Hosseini et al., 2001; Korhonen et 
al., 2000; Ruiz, 1994; Weiner et al., 1999). 
It has been shown in animal studies that colostrum or milk from cows hyper-
immunised with rotavirus can provide protection against challenge by the virus in 
newborn calves (Castrucci et al., 1984; Fernandez et al., 1998; Saif et al., 1983; 
Snodgrass et al., 1980) and lambs (Fahey et al., 1981). Similarly ruminant neonates 
fed milk from mothers immunised with E. coli were protected from subsequent 
challenge with the pathogen (Altmann and Mukkur, 1983; Snodgrass et al., 1982). 
Some researchers noted that the degree of passive immunity achieved by young 
animals was variable. In some studies complete protection was achieved while in 
others there was only partial or no protection. The variability in results was thought 
to be attributable to antibody titre and volume consumed, and the timing of the 
feeding may have been important also (Fahey et al., 1981; Snodgrass et al., 1980). 
There have now been a large number of human studies trialling treatments with 
therapeutic milk antibodies. In the main, these have focussed on the diseases 
caused by pathogenic E. coli, rotavirus and Cryptosporidium parvum. Controlled 
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clinical trials suggest that the oral administration of immunoglobulin preparations 
containing high titres of specific antibodies can provide effective prophylactic 
protection and, to some extent, may also be of therapeutic value against 
gastrointestinal infections in humans. Immune preparations have also been found to 
be protective and to some extent of value to treat rotavirus infection in children 
(Davidson et al., 1989; Ebina et al., 1992; Ebina et al., 1983; Hilpert et al., 1987; 
Sarker et al., 1998). 
A protective or therapeutic effect of immune milk has been demonstrated in humans 
against enteropathogenic or enterotoxigenic E. coli infections in some trials 
(Freedman et al., 1998; Mietens et al., 1979; Tacket et al., 1988) but it was not 
always effective (Brunser et al., 1992; Casswall et al., 2000). In treatment of 
immune-suppressed patients, hyper-immune milk containing specific antibodies 
against Cryptosporidium parvum has shown promise (Greenberg and Cello, 1996; 
Nord et al., 1990; Tzipori et al., 1987). Other hyper-immune milk products target 
other pathogens including Helicobacter pylori (Casswall et al., 1998; Korhonen et al., 
1994 ), Clostridium difficile (Kelly et al., 1996), Vibrio cholerae (Boesman-Finkelstein 
et al., 1989), Streptococci mutans (Loimaranta et al., 1999; Loimaranta et al., 1997), 
Candida albicans (Tollemar et al., 1999) and Shigella flexneri (Tacket et al., 1992). 
Overall, where protection was poor or not achieved, the low concentration of antibody 
in the preparation was thought to be the cause. Based on the immunisation regimen 
used to induce the antibody response, the predominant antibody in these bovine milk 
products was almost certainly lgG, not lgA. Studies have shown that the lgG 
antibody isotype is not as stable as lgA in the enzymatically hostile environment of 
the gut (Brown et al., 1970; Butler and Kennedy, 1978; Lindh, 1975) and this may 
also account for the poor protection achieved using some of the hyper-immune milks. 
1.5.2 Immunisation 
Ruminant milk is a rich source of naturally occurring antibodies and the concept of 
transferring passive immunity via lacteal antibodies dates back to the 1950s 
(Lascelles, 1963). Various immunisation regimens have been employed to induce 
antibody responses in ruminant mammary secretions, both for use in the ruminant 
neonate and as a therapeutic agent for treatment of human enteric disease. 
Immunisation has been used to boost maternal antibody levels in domestic livestock 
to induce a more comprehensive passive immunity in offspring. The most commonly 
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targeted pathogens have been rotavirus and pathogenic E. coli, as these are a major 
cause of neonatal disease in ruminant livestock. The immunisation regimen was 
generally multiple intramuscular (IM) injection (Altmann and Mukkur, 1983; Crouch et 
al., 2001; Fahey et al., 1981; Snodgrass et al., 1982) or IM injection at involution 
followed by intra-mammary (IMM) immunisation at milk formation (Saif et al., 1984; 
Schaller et al., 1992). The antibody produced was largely of the lgG class, with 
relatively little lgA, although the antibody class was not always characterized but 
assumed to be lgG1 (based on the knowledge that ruminants selectively transfer lgG1 
from serum into milk). The poor lgA response of the ruminant mammary gland was 
thought in some cases to be attributable to local environmental factors perhaps 
influenced by the lactational status of the gland (Lascelles et al., 1986). In rats and 
mice, sequestration of lgA plasma cells to the mammary gland has been shown to be 
under hormonal control (Weisz-Carrington et al., 1978). 
In view of the demonstrated potential for cells generated in gut-associated lymphoid 
tissues to populate the mammary gland in other species, elevating lgA levels in 
ruminant mammary secretions by priming the intestinal mucosal immune system 
using intra-peritoneal (IP) immunisation was studied by some investigators. IP 
injection prior to IMM infusion was shown to enhance the antigen-specific antibody 
response in mammary secretions, compared with IP or IMM immunisation alone 
(Sheldrake et al., 1985b), but these antigen-specific antibodies were predominantly 
of the lgG1 class. Although in that study intestinal lgA plasma cells were substantially 
increased in the sheep immunised by the IP route, there was no evidence of 
relocation of antigen-specific lgA plasma cells to the mammary gland. Antigen-
specific lgA antibody did appear in mammary secretions but the origin of this 
antibody was unclear. It is of interest to note that non-lactating ewes immunised by 
the IMM route alone had a significant number of antigen-specific lgA plasma cells in 
jejunal tissues and these cells were shown to be of gut-associated lymphoid tissues 
rather than mammary origin (Sheldrake et al., 1985a). This appears to suggest that 
the gut-mammary axis does function in the ruminant at least in the reverse direction, 
i.e. from the mammary gland to the gut. 
Other groups have immunised cows to produce a variety of products for humans, 
including immune milk for infants, or patients with immunodeficiency disorders 
(Casswall et al., 2000; Davidson et al., 1989; Ebina et al., 1992; Ebina et al., 1983; 
Tzipori et al., 1987). Similar to the production of such items for animal applications, 
cows were immunised by the IM route (Davidson et al., 1989; Ebina et al., 1983), or 
the combination of the IM and IMM routes (Hilpert et al., 1987; Mietens et al., 1979). 
44 
The resulting antibody was often not classified, as only neutralization tests were 
performed to determine antibody activity in the milk. When antibody class was 
determined, lgG1 was the predominant isotype. 
In addition to the route and timing of immunisation, other factors were also found to 
influence titre and isotype of ruminant milk antibody responses. These included the 
immunogenic properties of the antigen, the antigen dose and the adjuvant used. The 
differences in response between soluble and particulate antigens have been 
compared (Nashar et al., 1991 ). IMM immunisation using soluble antigen was shown 
to induce an lgG response in serum, but there was little evidence of a response in 
the mammary gland. In contrast, the particulate antigen induced a sustained lgA 
response in the milk. Studies using attenuated live bacteria as a treatment for 
mastitis infection were found to be more effective than killed bacteria (Watson, 1981; 
Watson, 1984). 
Freund's adjuvant, either complete or incomplete, or a combination of both was the 
most commonly used adjuvant for IM and IP immunisation (Crouch, 1985; Fernandez 
et al., 1996; Opdebeeck and Norcross, 1984; Snodgrass et al., 1980). Other 
adjuvants, including aluminium hydroxide gel and bordetella pertussis (Opdebeeck 
and Norcross, 1984; Snodgrass et al., 1982) have been tried, but the oil-based 
adjuvants were generally thought to be more effective (Crouch et al., 2000). This 
was especially so for IP immunisation where Freund's adjuvant was the most 
effective for eliciting intestinal responses. This was thought to be due to the adjuvant 
increasing the permeability of the serosa allowing greater penetration of the antigen 
into Peyer's patches (Lascelles et al., 1986). 
Adjuvants have usually not been employed for the IMM route. Antigen has generally 
been administered up the teat in a sterile solution to minimize the risk of mammary 
infection detrimental to subsequent milk production (Lascelles et al., 1981; Sheldrake 
et al., 1988). In IMM immunisation studies where immunogen was emulsified in 
Freund's incomplete adjuvant, no adverse effects were noted (Fernandez et al., 
1996; Saif et al., 1984). In another study, immunogen emulsified in Freund's 
incomplete adjuvant and injected directly into the supramammary lymph node 
resulted in high antibody titres. Adverse reactions to this procedure were noted in 
some animals (Opdebeeck and Norcross, 1984). 
More recent immunisation strategies for general mucosal vaccines have focused on 
new adjuvants and delivery modes (lijima et al., 2001; McGhee et al., 1999). 
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Mucosal tolerance to oral immunisation has been circumvented with the use of 
cholera toxin subunit B or E. coli subunit B as adjuvants. These subunits of 
enterotoxins induce an lgA response together with the co-administered antigens 
(Nashar et al., 1996; Nashar et al., 1998). Another new adjuvant approach has been 
to employ the use of cytokines in their intrinsic roles, either using recombinant protein 
(Bao et al., 1998; Pighetti and Sordillo, 1995; Pighetti and Sordillo, 1996) or 
introducing the cytokine by way of a viral DNA vector (Ramsay et al., 1994b). Other 
alternative strategies have modified the physical form of the antigen, for example by 
microencapsulation using immune-stimulating complex matrix (ISCOM), liposomes or 
microspheres (Bowersock et al., 1998; De Haan et al., 1995; Mutwiri et al., 2002; 
Sjolander et al., 2001 ), or have presented the unmodified antigen via genetically 
engineered mucosa-binding viral or bacterial vectors (Mestecky et al., 1997). 
1.5.3 The AgResearch multi-site immunisation regimen 
1.5.3.1 Rationale 
At AgResearch, we have developed an immunisation protocol for induction of lgA in 
bovine milk for use as a therapeutic agent or bioactive food ingredient for human 
applications. The rationale for this strategy is as follows: firstly, the body of available 
evidence from the literature appears to indicate that bovine lgA, rather than lgG, 
would be a functionally superior preventative treatment for enteric diseases in the 
human. In human colostrum, antibodies of the lgA class predominate and in 
response to mucosal infections, humans normally elicit lgA responses as opposed to 
the lgG responses of systemic infections (Janeway et al., 2001a). Secondly, due to 
its array of effector functions, lgA is known to play a major role in preventing 
colonization of pathogens at mucosal surfaces and aiding their elimination. And 
thirdly, mucosal lgA is known to be more resistant to the enzymatic conditions in the 
gastrointestinal tract than other classes of immunoglobulin (Butler and Kennedy, 
1978; Lindh, 1975). 
Overall, the above points strongly suggest that antibodies of the lgA class would be a 
more efficacious choice for treatment and/or protection against pathogenic infection 
of the human gastrointestinal tract. However, lgA class antibodies are normally at 
relatively low concentrations in bovine colostrum and milk, compared with lgG. In 
order for lgA treatments to be viable, there was a clearly a need to develop 
technologies to increase both antigen-specific and total lgA concentrations in 
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mammary secretions of the cow. This was the rationale for our original decision to 
develop an lgA immunisation regimen for the ruminant. 
1.5.3.2 Development of the multi-site immunisation regimen 
As described in Section 1.5.2 above, a number of investigators have used a variety 
of immunisation strategies in attempts to induce specific antibodies in cows' milk. 
These included multiple intra-muscular (IM) approaches, intra-mammary 
immunisation (IMM) alone, and IM or intra-peritoneal (IP) treatments followed by IMM 
immunisation. However, when taken together, it was apparent that no one had 
combined all three routes in an immunisation regimen in order to target lgA 
production. In the work of others the timing of treatments was also varied, with some 
investigators choosing to treat at involution, others during later gestation and finally, 
still others, during lactation itself. 
As a consequence, we hypothesised that a protocol involving multiple immunisations 
by all three routes during the pre-partum period of colostrum formation would be an 
effective strategy for inducing lgA in mammary secretions. We proposed a protocol 
to treat pregnant non-lactating animals using injection of antigen by combined IP and 
IM routes followed later by IMM immunisation with booster doses of antigen to all 
three sites being given subsequently. The protocol is outlined in Table 1.5 with the 
first immunisation by the IP/IM routes being administered eight to ten weeks prior to 
parturition. 





IP - intra-peritoneal 
IM - intra-muscular 











In 1993, we undertook a trial to test the hypothesis using pregnant sheep and E. coli 
as a model antigen. Early studies showed a marked increase in antigen-specific lgA 
antibody in sheep colostrum, with lower but sustained levels in established milk 
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(Hodgkinson and Hodgkinson, 2003). We also found that if one side of the udder 
was immunised but not the other, then antibody was only produced in the side that 
had been immunised. This suggested that the lgA was being produced locally in the 
mammary gland and not transported into secretions from blood in the manner of 
lgG1. Antigen was found to be a key component of the intra-mammary immunogen, 
because adjuvant alone did not elicit an lgA response. Subsequent trialling in sheep 
showed that the regimen could be applied to other antigens including proteins and 
yeasts. In 1997, we successfully tested the immunisation regimen in cows. A key 
finding from the early trialling in the cow was that total lgA was elevated in addition to 
the induction of antigen-specific lgA. Through a series of refinement trials to the 
present time, the protocol has been used to treat approximately 2 500 animals under 
close ethical and veterinary scrutiny and no significant deleterious effects of the 
treatment have been observed. 
The body of data from this early investigative work confirmed the hypothesis that the 
multi-site immunisation regimen could be used to elevate lgA in ruminant mammary 
secretions. However, the method has been developed empirically without a clear 
understanding of the molecular and cellular mechanisms underlying the lgA 
response. A greater understanding of our lgA multi-site immunisation regimen is 
required to optimise and enhance the procedure for wide spread application in the 
dairy industry. 
Development of this understanding is the justification for the programme of research 
undertaken in this thesis. 
In the next section, I propose a hypothesis of the molecular and cellular mechanisms 
that may be involved in our lgA multi-site immunisation regimen. It combines the 
available evidence from the literature based on research findings from several 
different species, because many details of the process in the ruminant are not yet 
known, and extrapolates the available evidence to our immunisation regimen. 
1.5.3.3 Proposed mechanism of lgA production 
The proposed procedure begins with an initial priming dose of antigen emulsified in a 
standard oil-based adjuvant (Freund's incomplete adjuvant). This is administered via 
the intra-peritoneal (IP) route. Recognition of antigen as 'foreign' initiates the 
production of factors such as Toll-like receptors and inflammatory cytokines. These 
factors activate dendritic cells to take up the antigen and transport it to the numerous 
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lymph nodes in the abdomen and thoracic cavities. The transport occurs via the 
extensive network of sub-serosal lymphatics located on the external surface of the 
abdominal viscera. Dendritic cells degrade the antigen and present fragments on 
their cell surface in association with the MHC class peptide-binding proteins. 
Macrophages can also act as antigen-presenting cells. 
In the mucosal gut-associated lymphoid tissues, antigens presented by dendritic cells 
activate na"i"ve T lymphocytes that in turn prime na"ive B lymphocytes to become 
memory or effector B cells. These cells can be distinguished by the different homing 
receptors that they express on their cell surface. The homing receptors bind 
adhesion molecules (vascular addressins) which are expressed on vascular 
endothelial cells of the post-capillary venules. The initial effector B cells differentiate 
into short-lived plasma cells that are mainly responsible for the lgM primary 
response. 
A second dose of antigen is administered, again via the IP route. This acts to 
stimulate the memory B cells to undergo clonal expansion, proliferation and 
differentiation into plasmablasts. These processes occur under the influence of 
certain cytokines (for example, IL-2, IL-5, IL-6, TGF-~) secreted by helper T cells and 
antigen-presenting cells. The plasmablasts migrate via lymph vessels to the thoracic 
duct, then into the blood to circulate throughout the body including distant secretory 
effector sites, for example the mammary gland. 
At the same time as the second dose to the peritoneum is administered, the 
mammary gland is exposed to antigen with an intra-mammary immunisation (IMM). 
Resident dendritic cells and/or macrophages are activated by antigen to secrete 
cytokines and in turn activate other immune cells. It is thought that this signalling 
process is required to recruit the circulating plasmablasts, presumably by adhesion 
molecule receptors and/or chemokine receptors on the lymphocytes and adhesion 
molecule and chemokine expression on the vascular endothelium in the gland. In the 
mammary gland the plasmablasts are terminally differentiated into lgA-producing 
plasma cells by the cytokine microenvironment produced by helper T cells, antigen-
presenting cells and stromal cells. 
At the same time as the IP immunisations, the animal is also given antigen via the 
intra-muscular (IM) route. Our experiments have shown that this increases the 
magnitude of the response and also the proportion of animals responding, but the 
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reason for this is unclear. In the literature, there is evidence to suggest that the 
systemic and mucosal immune systems are not totally segregated. 
The plasma cells produce lgA and J chain, which form a complex of two lgA 
molecules and a J chain. The polymeric immunoglobulin receptor (plgR) binds this 
complex at the basolateral surface of the mammary secretory epithelium and it is 
translocated to the lumen by endocytosis and transcytosis. A portion of the plgR 
becomes covalently linked to the lgA molecule during the transport process and 
remains bound to lgA as secretory component when secretory lgA is released by 
cleavage at the apical surface into mammary secretions. 
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1.6 Aims of this thesis 
The overall aim of this thesis is to develop a greater understanding of the molecular 
and cellular immunological mechanisms that are involved in the local induction of lgA 
secretion in the ruminant mammary gland. Cows immunised using our regimen to 
induce high levels of lgA in mammary secretions were utilised to study these 
mechanisms. The focus of the investigation was on key elements of the response 
that are identified in the proposed mechanism of action of the multi-site immunisation 
regimen outlined above in Section 1.5.3.3 and that are, as yet, unknown for the cow. 
It is hypothesised that production of lgA in the bovine mammary gland is dependent 
on recruitment of primed lymphocytes of mucosal origin that are induced by the intra-
peritoneal and intra-muscular immunisations. This recruitment may be mediated by 
changes in the microenvironment of the mammary gland due to exposure to antigen 
by the intra-mammary immunisation. Within the mammary gland, lymphocyte 
trafficking is regulated by expression of adhesion molecules on vascular 
endothelium, with selection determined by adhesion molecule receptor expression 
patterns on lymphocytes. The adhesion molecules responsible for the homing of 
lymphocytes to the bovine mammary gland have not been classified. One objective 
was to identify which vascular addressins are present in the untreated bovine 
mammary gland at four different physiological stages of the gland. 
The immune cells that are involved in the local induction of lgA secretion in the 
bovine mammary gland have not been characterised. Another objective was to study 
the cellular changes induced in the mammary gland by intra-mammary immunisation 
following an initial priming of the animal via the intra-peritoneal and intra-muscular 
routes. To achieve this, the tissues of immunised bovine mammary glands were 
compared with non-immunised glands and differences in the immune cell types and 
their numbers were identified. This work also investigated whether or not the lgA 
immunisation regimen induced the expression of the mucosal vascular addressin, 
MAdCAM-1, in the bovine mammary gland. 
The rate of immune cells trafficking into the bovine mammary gland in response to 
the intra-mammary immunisation is unknown. Another objective was to determine 
the kinetics of the cellular response induced in mammary secretions over an 
extended time course before and after the intra-mammary immunisations. The main 
focus was to look at changes induced in the T- and B-lymphocyte populations and to 
compare the differences between animals that produce high and low levels of lgA. 
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The cytokines involved in inducing local secretion of lgA in the bovine mammary 
gland have not been identified. Another objective was to determine which key 
cytokines were being expressed by mammary tissues of untreated animals and 
compare this with the gene expression profiles in mammary tissues from immunised 
animals. In addition, cytokine expression profiles were determined in cells isolated 
from secretions collected over an extended time course, before and after intra-
mammary immunisations. This knowledge of the changes in gene regulation would 
help give a better understanding of the immune response that is being initiated by the 
intra-mammary immunisation, for example, a Th1 or Th2 type response. 
Development of analytical methods to undertake some of this work was required. 
The overall aim of the investigation into the different molecular and cellular changes 
induced by the intra-mammary immunisation was to gain insight into the mechanisms 
of the process. This insight was expected to point to ways that our immunisation 
regimen may be further developed and enhanced to achieve consistent, elevated lgA 
antibody production in individual animals and to make the lgA immunisation and 
resulting human treatments commercial realities. 
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Chapter 2 
General materials and methods 
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This chapter lists the source of materials and describes the general methodologies 
used for the studies described in Chapters Three, Four, Five and Six. Any 
developmental work of these methodologies is described in the relevant chapter. 
2.1 Materials 
Common laboratory chemicals and reagents were obtained from Ajax Chemicals, 
BDH, lnvitrogen, and Sigma. Specialised reagents, equipment and commercially 
sourced kits that were used in this study are detailed in the relevant Materials and 
Methods sections. 
2.1.1 Solutions 
Common solutions are listed in Table 2.1 and were made using Milli Q (Barnstead) 
purified water (MQ-H20). 










80 mmol/1 sodium acetate 
pH adjusted to 5.4 with acetic acid 
10 Dulbecco A phosphate-buffered saline (PBS) 
tablets (Oxoid) dissolved in 1000 ml MQ-H20 
then autoclaved 121°C, 30 min 
1 % (v/v) fetal bovine serum (FBS; Gibco ™, lnvitrogen) 
in D-PBS 
16 mmol/1 sodium carbonate 
35 mmol/1 sodium hydrogen carbonate 
17 mmol/1 tris(hydroxymethyl)aminomethane 
pH adjusted to 7.65 














1.9 mmol/1 sodium dihydrogen orthophosphate 1-hydrate 
8.4 mmol/1 disodium hydrogen orthophosphate 2-hydrate 
150 mmol/1 sodium chloride 
0.05% (v/v) Tween 20 
in PBS 
242 g tris(hydroxymethyl)aminomethane 
57 .1 ml acetic acid 
100 ml 0.5 mol/1 ethylenediaminetetraacetic acid disodium 
salt 2-hydrate (pH 8.0) 
adjusted to 1000 ml 
TAE (50X) diluted 5-fold 
TAE (50X) diluted 50-fold 
17 mmol/1 tris(hydroxymethyl)aminomethane 
3 mmol/1 tris(hydroxymethyl)aminomethane hydrochloride 
150 mmol/1 sodium chloride 
1 % (v/v) Tween® 20 
in TBS 
1.21 g tris(hydroxymethyl)aminomethane 
2ml 0.5 mol/1 EDTA (pH 8.0) 
pH adjusted to 7.5 
adjusted to 1000 ml 
3,3'-diaminobenzidine hydrochloride (FAST DAB 
peroxidase substrate tablet set; 1 ml tablets dissolved in 
MQ-H20; D4168, Sigma) 
0.1 % (v/v) diethyl procarbonate in MQ-H20 
mixed overnight, then autoclaved 121°C, 30 min 
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Solution 










40% (v/v) glycerol 
TAE (10X) 
0.25% bromophenol Blue 
2 mol/1 sulphuric acid 
250 µI 10% 3,3',5,5'-tetramethylbenzidine in 
dimethylsulphoxide 
250 µI 0.45% hydrogen peroxide 
in 25 ml acetate buffer 
0.1 % (w/v) haematoxylin (C.I. 75290, BDH) 
5.0% (w/v) aluminium potassium sulphate 
0.02% (w/v) sodium iodate 
22 mmol/1 sodium dihydrogen orthophosphate 1-hydrate 
78 mmol/1 disodium hydrogen orthophosphate 2-hydrate 
4% (w/v) paraformaldehyde 
RPMl-medium 1640 (1X; lnvitrogen) 
31 mmol/1 sodium hydrogen carbonate 
1% Penicillin/Streptomycin (15140-148; Gibco™, 
lnvitrogen) 
5% FBS 
pH adjusted to 7.2, sterile filtered 
Antibodies used in this study were obtained from Amersham Biosciences, Bethyl, 
Dako, Jackson, Pharmingen and VMRD, as listed in the Materials section of 
Chapters Three, Four and Five in which they were used. 
Anti-human MAdCAM-1 monoclonal antibody was a gift from Dr M. Briskin, 
Millennium Pharmaceuticals, Cambridge, MA, USA. Anti-human VCAM-1 
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monoclonal antibody was a gift from Dr T. Tedder, Duke University, Durham, NC, 
USA. Anti-mouse 137 subunit monoclonal antibody was a gift from Dr E. Butcher, 
Stanford University, Stanford, CA, USA. 
2.1.3 Animals 
Healthy Friesian breed heifers were used for samples of untreated mammary tissues 
at different physiological stages. The animals were selected at four different 
physiological stages of the mammary gland: 40 - 50 days pre-partum (late 
pregnancy), two days post-partum (colostral phase), 90 days post-partum (lactation 
phase) and three days after the cessation of milking (involution phase). Animals 
were managed using standard farm practices. 
For immunisation trials, multiparous, pregnant cows of mixed breed and age were 
selected based on general health, udder palpation and recent somatic cell count 
history. Throughout the trials, farm management practices continued as normal and 
the health of the animals was monitored by farm staff. 
All animal use and experimental protocols for this thesis were approved by the 
Ruakura Animal Ethics Committee. 
2.1.4 Normal sera 
Normal sera were used in immunohistochemical protocols to reduce non-specific 
binding of secondary antibodies. The species of normal sera used in each protocol 
was the same species as the animal source of the secondary antibody, i.e. if the 
secondary antibody was raised in goats the normal serum used in that assay would 
be goat serum. Normal goat serum was obtained from Gibco™ (lnvitrogen). Normal 
donkey serum was sourced 'in house'. 
2.2 Methods 
2.2.1 Immunisation procedure 
Animals were immunised using our multi-site regimen (Hodgkinson and Hodgkinson, 
2003) at three different sites; intra-muscular (IM), intra-peritoneal (IP) and intra-
mammary (IMM), according to the schedule outlined in Table 2.2. For IM 
immunisations, 4 ml of immunogen was injected into the anterior neck muscle using 
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an 18 gauge needle. For IP immunisations, 4 ml of immunogen was injected into the 
peritoneal cavity, at a location 5 cm in front of the hip bone and 5 cm below the small 
ribs on the left hand side of the cow, using an 18 gauge needle. For IMM 
immunisations, 2 ml of immunogen was injected up each of the teat canals using a 
Bovi-Vet teat infusion syringe tip (Shoot). Prior to injection, IM and IP sites were 
cleaned and swabbed with 70% ethanol, and teats were cleaned using ethanol 
wipes. After immunisation, sites were sprayed with Stock iodine (Bomac). Cows 
were monitored for adverse reactions to the immunisation using standard animal 
husbandry practices. 





IP - intra-peritoneal 
IM - intra-muscular 











The antigen used for immunisations and the antigen-specific lgA ELISA (see Section 
2.2.6.1) was a heat-killed whole-cell preparation of Candida albicans (C. albicans, 
ATCC 10231) prepared from a fermentation culture (batch CDA/008) by Biotech 
Australia. The protein concentration of the stock antigen was measured using the 
BioRad DC™ Protein Assay Kit (see Section 2.2.7). The antigen was then diluted to 
500 µg protein/ml sterile saline (0.9% sodium chloride; Baxter) and emulsified with 
Freund's incomplete adjuvant (one part aqueous: three parts oil; Sigma) using a 
homogeniser (Ultra Turrax T-25, IKA-Werke). 
The initial immunisation was 10 - 20 weeks before the group's averaged estimated 
calving date. In some experiments, cows were immunised in one side of the udder 
only. This allowed for the other side of the udder to act as a non-immunised control 
for that animal. 
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2.2.2 Sample collection and preparation 
2.2.2.1 Tissues 
Cows were slaughtered at the Ruakura abattoir and mammary glands excised for 
dissection. Tissue samples were collected from the alveolar and cisternal areas of 
the mammary gland, and the supramammary lymph nodes. Peyer's patch tissues 
and mesenteric lymph nodes were also obtained to represent typical gut-associated 
lymphoid tissue. 
Frozen tissues for total RNA extraction: Tissue samples were cut into approximately 
50 x 20 x 20 mm pieces, wrapped in tinfoil and snap-frozen in liquid nitrogen. Frozen 
tissues were ground under liquid nitrogen, by mortar and pestle, and stored at -B0°C. 
Frozen tissues for immunohistochemistry: Tissue samples were cut into 10 x 10 x 5 
mm pieces, placed into tinfoil boats that had been partially filled with Tissue Tek 
O.C.T. compound (Bayer Diagnostics) and then completely covered with O.C.T. 
compound. The tissues were then snap-frozen in liquid nitrogen and stored at -B0°C. 
Ethanol-fixed tissues: Tissue samples were cut into 1 O x 10 x 2-3 mm pieces, placed 
into Tissue-Tek Unicassettes (Bayer Diagnostics}, and submerged in PBS (Table 2.1) 
containing 0.01 % (w/v) sodium azide, with gentle mixing for 24 h at 4°C. Cassettes 
were then transferred to a solution of 95% (v/v) ethanol for 24 h at 4°C. The fixed 
tissues were processed overnight in a Leica JungTP1050 fully enclosed vacuum 
tissue processor (Cambridge Instruments) following the protocol in Table 2.3. 
Table.2.3 Protocol for paraffin treatment 
Solution Time 
70% (v/v) ethanol, twice 60 min 
95% (v/v) ethanol, twice 60 min 
100% ethanol, twice 45 min 
toluene, twice 60 min 
paraffin 60 min 









At the completion of the process, the tissues were embedded in blocks of paraffin 
wax (Paramat pastillated; BDH), using a Thermolyne Histo-Centre 11-N embedding 
machine (Barnstead). Embedded tissues were stored at room-temperature. 
2.2.2.2 Colostrum and milk 
Colostrum samples were manually obtained from the udder while the animals were in 
the dairy on the milking platform. For milk, animals were machine-milked in the dairy 
on the milking platform. Samples were kept refrigerated for up to 2 h, until 
centrifuged (1 650 g, 10 min, 4°C). The fat layer was removed and the defatted 
colostrum/milk was recentrifuged (11 000 g, 60 min, 4°C) to pellet the casein and the 
whey supernatant was removed for storage at -20°C. 
2.2.2.3 Non-lactating mammary secretions and cells 
Mammary secretions collected from pregnant, non-lactating (dry) animals were 
sampled in the dairy on the milking platform. Teats to be sampled were cleaned 
using ethanol wipes and the keratin plug from each teat was manually expelled using 
a milking action. Sterile saline (25 ml) was injected up the teat canal, using a Bovi-
Vet teat infusion syringe tip. The udder quarter was gently massaged then 25 ml of 
sample was collected into a 50 ml test tube by hand milking. Stock iodine was 
applied to the teat when finished. In the first few days following intra-mammary 
immunisations the infusion of saline was not required due to oedema of the gland. 
The samples collected were centrifuged (350 g, 1 O min, 4°C) and then the fat layer 
was aspirated from the top and a sample of supernatant removed for storage at 
-20°C. The remaining supernatant was aspirated to waste. The cell pellet was 
resuspended in 10 ml D-PBS (Table 2.1) and centrifuged (350 g, 10 min, 4°C). The 
supernatant was aspirated to waste and the cell pellet resuspended in 5 ml D-PBS 
then filtered through 100 µm mesh. An aliquot of cell suspension was diluted (1 :20) 
in 0.4% Trypan Blue Stain (Gibco ™, lnvitrogen) and viable (i.e. unstained) cells were 
counted using a haemocytometer. The remainder of the cell suspension was 
centrifuged (350 g, 1 O min, 4°C) and the cells resuspended in D-PBS to a 
concentration of 5 x 106 cells per ml. Cells required for flow cytometry were used 
immediately. Cells for total RNA extraction were frozen at -80°C, 2 ml of suspension 
per tube. 
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Non-lactating mammary secretions containing red blood cells: Mammary secretion 
samples that contained red blood cells were treated with lysis buffer (Table 2.1) prior 
to the step of resuspending in 5 ml of D-PBS and filtering. This treatment involved 
resuspending the cell pellet in 1 O ml of lysis buffer and incubating for 1 O min at 37°C 
prior to centrifugation (180 g, 3 min, room-temperature). The cell pellet was then 
washed twice by resuspending in 10 ml D-PBS and recentrifuging (180 g, 3 min, 
room-temperature). The pellet was then resuspended in 5 ml D-PBS then filtered, 
counted and resuspended at 5 x 106 cells per ml D-PBS as for normal samples. 
Non-lactating mammary secretions containing gelatinous precipitate: Some 
mammary secretion samples contained a gelatinous precipitate, especially during the 
first few days after intra-mammary immunisation. These samples were treated 
differently from samples that were clear. Mammary secretions were centrifuged (350 
g, 10 min, 4°C). The fat layer was aspirated from the top and then a sample of 
supernatant was removed for storage at -20°C. The remaining supernatant was 
aspirated to waste. D-PBS (20 ml) was added, the sample mixed, then centrifuged 
(75 g, 10 min, 4°C). The supernatant containing the cells was transferred to a clean 
50 ml test tube. D-PBS (20 ml) was mixed with the remaining sample and the 
sample recentrifuged (75 g, 10 min, 4°C). The supernatant was removed and mixed 
with the supernatant from the previous centrifuging. The combined supernatants 
were centrifuged (350 g, 1 O min, 4°C) and the supernatant discarded. The cell pellet 
was resuspended in 5 ml of D-PBS then filtered, counted and resuspended at 5 x 106 
cells per ml D-PBS as for normal samples. 
2.2.3 lmmunohistochemistry 
2.2.3.1 Frozen sections 
Frozen tissues embedded in Tissue Tek O.C.T. compound were equilibrated to -20°C 
and 6 µm serial sections cut using a Leica Cryocut 1800 (Cambridge Instruments). 
Sections were mounted (three per slide) on Esco Polysine™ slides (Biolab Scientific), 
and left to dry at room-temperature overnight. Slides were stored in sealed boxes at 
-80°C. Directly prior to immunostaining, the sealed boxes were re-equilibrated to 
room-temperature before the slides were removed, to prevent condensation forming 
on the sections. Slides were then fixed in ice-cold ethanol for 10 min and air dried for 
1 h. 
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2.2.3.2 Ethanol-fixed sections 
Ethanol-fixed, paraffin-embedded tissue blocks were cut into 6 µm ribbon sections on 
a Leitz Type 1212 microtome. A ribbon of four sections was floated onto 42°C water 
and collected on an Esco Polysine ™ slide and left to dry on a heating plate for 2 h at 
60°C. Mounted sections were stored in boxes at room-temperature. Prior to 
immunostaining, the slides were deparaffinised and rehydrated as outlined in Table 
2.4. 
Table.2.4 Protocol for removing paraffin and rehydrating paraffin sections 
Procedure Time 
xylene, twice 5 min 
100% ethanol, twice 2 min 
95% (v/v) ethanol 2 min 
70% (v/v) ethanol 2 min 
50% (v/v) ethanol 2 min 
MO-H20 10 min 
2.2.3.3 lmmunostaining 
lmmunostaining enabled the detection of target cells by utilising a primary antibody 
directed against chosen cell-surface antigens then the sequential application of 
biotinylated secondary link antibody, an avidin-enzyme complex and a chromogenic 
substrate. The end product allowed for visualisation of the target cells in situ. The 
procedure was based on a described method (Hsu et al., 1981) and utilised an 
avidin-biotin-peroxidase complex and 3,3'-diaminobenzidine hydrochloride (DAB) as 
the detection method. Specific details of the antibodies used for immunostaining are 
described in the Materials and Methods section of Chapters Three and Four. 
All incubations were performed at room-temperature in a humidity box, unless 
otherwise stated. Between incubation steps, slides were transferred to a glass slide-
staining dish for washing (3 times, 10 min) with TBS-T (Table 2.1 ), unless otherwise 
stated. Individual tissue sections on slides were circled with a hydrophobic solution 
using a PAP pen (Dako) to contain assay reagents (50 µI). 
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Slides were first equilibrated with TBS (Table 2.1 ), and then endogenous peroxidase 
was inactivated with 3% H202 for 5 min. Slides were washed (3 times, 10 min) in 
TBS then endogenous biotin was blocked using the Dako Biotin Blocking Kit, 
incubating with reagents pre-diluted to 20% in TBS-T, for 20 min. After the slides 
were washed, non-specific background was reduced by incubation with blocking 
buffer (3% normal serum in TBS-T) for 30 min. The species of normal serum used in 
the assay was the same species as the animal source of the secondary antibody. 
Excess blocking buffer was tapped off prior to the addition of primary antibody, 
diluted to optimised concentrations in reagent buffer (1.5% normal serum in TBS-T), 
and the slides then incubated overnight at 4°C. For each tissue sample, a control 
was run to check for non-specific binding, adding reagent buffer only for the primary 
antibody step. The following day, slides were re-equilibrated to room-temperature 
and washed (6 times, 10 min). Biotinylated secondary antibody, diluted to optimised 
concentrations in reagent buffer, was incubated with sections for 120 min. Slides 
were washed (6 times, 10 min) and sections were then incubated for 30 min with 
streptavidin biotinylated horse radish peroxidase (HRP) complex (Amersham 
Biosciences). In the next step, DAB (Table 2.1) was incubated with the sections for 5 
min, to form an insoluble brown end-product with the HRP. Slides were washed in 
TBS (3 times, 10 min) to stop the reaction. Finally, the sections were counterstained 
with Mayer's haematoxylin (Table 2.1 ), dehydrated with ethanol, cleared with xylene 
(Andrew Industrial) and coverslips mounted with D.P.X. mountant (BDH). Sections 
were viewed using an Olympus BXSO microscope and images captured using a Spot 
colour camera (SciTech). 
lmmunostaining to detect lgG cell-surface antigen utilized a primary antibody directly 
conjugated to HRP and therefore, a reduced protocol was required. After 
equilibration with TBS, blocking with H20 2, avidin and normal serum, slides were then 
incubated for 120 min with primary antibody conjugated to HRP and washed (6 
times, 1 Omin). Following this, sections were reacted with DAB, washed, 
counterstained, dehydrated, cleared and coverslips mounted as described in the 
protocol above. 
2.2.4 Molecular Biology 
2.2.4.1 RNA extraction and purification 
Total ribonucleic acid (RNA) was extracted from tissues or cells using TriZOL 
(lnvitrogen) according to the manufacturer's protocol. 
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Tissue RNA extraction: For tissue, 150 mg of frozen pulverized sample was 
homogenised with 1.5 ml TriZOL using an Ultra Turrax T-25 homogeniser (IKA-
Werke). After 5 min incubation at room-temperature, the mixture was centrifuged (11 
000 g, 10 min, room-temperature). The supernatant was transferred to a clean tube, 
300 µI chloroform was added and the tube shaken for 15 s. Following incubation at 
room-temperature for a further 3 min, the sample was centrifuged again (11 000 g, 
15 min, room-temperature). Approximately 700 µI of the upper aqueous phase was 
transferred to another clean tube and total RNA precipitated with 750 µI isopropanol. 
After standing for 10 min, total RNA was pelleted by centrifugation (11 000 g, 10 min, 
room-temperature) and the supernatant removed. The pellet was washed by 
resuspending in 750 µI 75% (v/v) ethanol and recentrifuging (11 000 g, 10 min, room-
temperature). The pellet was then redissolved in 50 µI DEPC-H20 (Table 2.1 ). An 
aliquot of the RNA was diluted 200-fold with MQ-H20 and the absorbance measured 
at 260 nm using a spectrophotometer. The concentration was calculated using the 
formula: 
Concentration (µg/ml) = A260 x 40 x 200 (inverse of dilution of sample). 
Samples were stored at -80°C. 
Cell RNA extraction: Frozen cells (107 per tube) were lysed using 1 ml TriZOL. 
Lysates were pipetted several times to shear genomic deoxyribonucleic acid (DNA). 
After 5 min incubation at room-temperature, 200 µI chloroform was added and the 
tube shaken for 15 s. Following incubation at room-temperature for a further 3 min, 
the sample was centrifuged (11 000 g, 15 min, room-temperature). Approximately 
500 µI of the upper aqueous phase was transferred to a clean tube and total RNA 
precipitated with 500 µI isopropanol. After standing for 10 min, total RNA was 
pelleted by centrifugation (11 000 g, 10 min, room-temperature) and the supernatant 
removed. The pellet was washed by resuspending in 750 µI 75% (v/v) ethanol and 
recentrifuging (11 000 g, 1 O min, room-temperature). The pellet was then 
redissolved in 50 µI DEPC-H20. The concentration of RNA was determined as 
described in the section above. Samples were stored at -80°C. 
RNA purification: Deoxyribonuclease I (DNase I, Amplification grade; lnvitrogen) was 
used according to the manufacturer's kit protocol to digest any contaminating DNA in 
the extracted RNA samples. For each µg total RNA, 1 µI DNase I and 1 µI DNase I 
buffer (10X) was added to the RNA, plus a volume of DEPC-H20 to bring the total 
volume to 10 µI. After incubating for 15 min at room-temperature, the DNase I was 
deactivated by the addition of 2.5 mmol/1 EDTA and heating for 10 min at 65°C. 
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Tubes were placed on ice and DEPC-H20 added to give a total volume of 100 µI. An 
RNeasy® Mini kit (Qiagen) was then used to clean up the digestion mixture, 
according to the manufacturer's protocol. Buffer containing guanidine isothiocyanate 
(350 µI) and ethanol (250 µI) were added to the DNased RNA sample to ensure 
optimal binding of the RNA to the silica-gel membrane. The mixture was applied to 
the RNeasy® column and the RNA bound to the column allowing the contaminants to 
be washed away using Wash buffer. RNA was finally eluted from the column with 30 
- 50 µI DEPC-H20. Samples were stored at -80°C. 
2.2.4.2 First-strand cDNA synthesis 
Synthesis of first-strand complementary DNA (cDNA) for subsequent polymerase 
chain reaction (PCR) used Superscript™ II Reverse Transcriptase (lnvitrogen). 
Using a Superscript First-Strand Synthesis System for RT-PCR kit (lnvitrogen), 
reverse transcriptase reactions were performed according to the manufacturer's 
protocol. For the reaction, 0.5 µg oligo (dT)12_18 was annealed to 1 - 5 µg total 
purified RNA in a 1 O µI reaction containing 1 mmol/1 dNTP mix. The annealing 
reaction was incubated at 65°C for 5 min then tubes were chilled on ice. A second 
reaction mixture containing reverse transcriptase buffer (1 X), 10 mmol/1 magnesium 
chloride, 20 mmol/1 dithiothreitol, and 40 U RNaseOUT was prepared and 9 µI was 
added to the first reaction mixture. The resultant mixture was incubated at 42°C for 2 
min then 50 U Superscript II reverse transcriptase was added and the complete 
mixture incubated at 42°C for 50 min, followed by incubation at 70°C for 20 min. 
Finally, RNase H (2 U) was added and the mixture was incubated at 37°C for 20 min. 
The cDNA was stored at -20°C. 
2.2.4.3 PCR with Platinum® Taq 
The PCR process uses multiple cycles of template denaturation, primer annealing, 
and primer elongation to amplify DNA sequences. Platinum® Taq DNA Polymerase 
(lnvitrogen) was used for PCR amplifications. This recombinant Taq polymerase is 
complexed to an antibody that blocks polymerase activity until after the first 94°C 
denaturation step in PCR cycling. Using a Superscript First-Strand Synthesis System 
for RT-PCR kit (lnvitrogen), amplifications were performed according to the 
manufacturer's protocol. PCR reactions (20 µI) contained 0.2 mmol/1 dNTPs, 200 
nmol/1 forward primer, 200 nmol/1 reverse primer, 0.4 U Platinum® Taq DNA 
Polymerase, PCR buffer (1X), 1.5 mmol/1 magnesium chloride and 0.8 µI cDNA from 
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the reverse transcriptase reaction (Section 2.2.4.2). A GeneAmp PCR system 9700 
(Applied Biosystems) or an Eppendorf Mastercycler (Eppendorf) was used for PCR 
thermo-cycling. Following initial denaturation at 94°C for 2 min, the target DNA was 
amplified with 35 cycles, each cycle consisting of a denaturation step at 94°C for 30 
s, annealing for 30 s and extension at 72°C for 30 s. The last cycle was terminated 
at 72°C for 5 min. Specific temperatures for annealing were primer dependent and 
are described in the Methods section of the relevant chapters along with the primer 
pairs. 
2.2.4.4 Electrophoresis of DNA 
Separation of DNA products following PCR reactions was performed using agarose 
gel electrophoresis. Agarose gels, 1 - 1.5% (w/v) agarose, depending on the size of 
DNA fragments to be separated, were prepared using TAE (1X) buffer (Table 2.1) 
containing ethidium bromide (400 ng/ml). DNA samples were premixed with DNA 
loading dye (Table 2.1) prior to loading on the gel. A 1 kb Plus DNA ladder 
(lnvitrogen) was loaded on each gel to enable the base pair size of the DNA products 
to be determined. Electrophoresis was carried out in Horizon tanks (lnvitrogen) 
containing TAE (1X) buffer, at 80 - 100 V until the required separation was achieved. 
DNA was illuminated and photographed using the Gel Doc system (Bio-Rad). 
2.2.4.5 Purification of DNA 
DNA samples that had been separated using agarose gel electrophoresis (see 
Section 2.2.4.4) were recovered and purified using an Agarose Gel DNA Extraction 
Kit (Roche) according to the manufacturer's protocol. A slice of agarose gel 
containing the DNA fragment of interest was cut from the gel using a scalpel blade 
and incubated with 300 µI Agarose Solubilization buffer per 100 mg gel, plus 10 µI 
Silica Suspension, for 10 min at 60°C. The silica was pelleted by centrifugation (11 
000 g, 30 s, room-temperature), the supernatant removed and the silica-bound DNA 
incubated briefly with Nucleic Binding buffer. After centrifugation (11 000 g, 30 s, 
room-temperature), the silica-bound DNA was washed twice by resuspending in 
Washing buffer and recentrifuging (11 000 g, 30 s, room-temperature). DNA was 
eluted from the silica by resuspending in two separate volumes (15 µI) of TE buffer 
(Table 2.1) and incubating for 10 min at room-temperature, followed each time by 
centrifugation (11 000 g, 30 s, room-temperature). Purified DNA was stored at -20°C. 
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2.2.4.6 Quantitative real-time PCR 
Real-time PCR was used to determine the relative quantity of mRNA template of the 
target gene in samples. This was achieved by monitoring the amplification of DNA in 
real-time utilising a fluorescent dye that only emits a signal when bound to double-
stranded DNA (Higuchi et al., 1993; Wilhelm and Pingoud, 2003). The amount of 
target DNA generated by a given number of PCR cycles is dependent on the initial 
amount of target gene and the efficiency of the amplification of the sequence. (The 
maximum efficiency possible in PCR is two, where every PCR product is replicated 
every cycle.) This can be expressed in an equation (Rasmussen, 2001 ): 
Tn = To(Et 
where T n is the amount of target sequence at cycle n, TO is the initial amount of target 
and Eis the efficiency of the reaction. 
Real-time (quantitative) PCR utilised a LightCycler instrument (Roche) to perform the 
PCR reaction, including induction and detection of the fluorescent signals. A ready-
to-use hot start reaction master mix (Roche) containing FastStart Taq DNA 
Polymerase, reaction buffer, MgCl2, SYBER green 1 fluorescent dye and dNTP mix 
was used. The real-time PCR reaction mixture (10 µI) contained 400 nmol/1 forward 
primer, 400 nmol/1 reverse primer, 2 µI Lightcycler FastStart DNA Mastettus SYBER 
Green I (3515869, Roche) and 5 ng reverse-transcribed RNA. The reactions were 
performed in glass capillary tubes (1909339, Roche). 
The LightCycler protocol consisted of pre-incubation for 10 min at 94°C followed by 
amplification of target cDNA with 45 cycles, each cycle consisting of a denaturation 
step at 94°C for 1 O s, annealing for 5 s and extension at 72°C for 1 O s. Specific 
temperatures for annealing were primer dependent and described in the Methods 
section of the relevant chapters along with the primer pairs. The specificity of the 
reaction was checked by melting curve analysis at the conclusion of the amplification 
cycles. In addition, an end-product sample of DNA from the real-time PCR reaction 
for each gene was analysed by gel electrophoresis (see Section 2.2.4.4) to confirm 
the expected size of the product and verify the presence of a single band. 
LightCycler software calculated the cycle number at the crossing point for each PCR 
reaction, i.e. the point where the fluorescent signal generated by the reaction is 
visible above the background fluorescence of the sample. The cycle where each 
reaction first rises above background is dependent on the amount of target template 
present at the beginning of the real-time PCR reaction. The smaller the cycle 
67 
number at the crossing point the larger the amount of target template in the original 
sample. 
To determine the efficiency of the reaction for each primer pair, five serial dilutions 
(10-fold) of a purified PCR product (see Section 2.2.4.3, Section 2.2.4.4 and Section 
2.2.4.5) generated by RT-PCR using the primer pair, were measured by real-time 
PCR. From the data, the cycle number at the crossing point was plotted versus the 
log concentration of the dilution of PCR product. Using the slope of the line and the 
equation (Rasmussen, 2001 ): 
E = 1 o(-1ts1ope) 
the Lightcycler software was able to calculate the value for the efficiency of the 
reaction. An equation that correlates the cycle number at the crossing point and the 
efficiency of the real-time PCR reaction was used to calculate the relative amounts of 
mRNA in unknown samples (Wilkening and Bader, 2004). 
The relative concentration= 1.12 x 1010/EcN 
where E is the efficiency of the reaction and CN is the cycle number at the crossing 
point. 
Samples of interest were analysed for the target gene and an endogenous control 
gene, p-actin. For each sample, the expression levels of the target gene were 
reported relative to the expression levels of p-actin. This adjusted for any variation in 
the quantity of total mRNA used for each reaction. 
2.2.5 Flow cytometry 
Using a panel of antibodies specific for lymphocyte cell-surface antigens, cells were 
indirectly labelled with fluorescent dyes then measured using a flow cytometer. Thus 
percentages of T and B cells were calculated. Double labelling of cells using 
antibodies coupled to two different dyes allowed for the further distinction of sub-
populations of cells. Specific details of antibodies used for immunostaining and 
negative isotype control sera are described in the Materials and Methods section of 
Chapter Five. 
Fresh cells isolated from mammary secretions, processed and resuspended in D-
PBS at 5 X 106 cells per ml (see Section 2.2.2.3), were dispensed (200 µI) into a V 
bottom 96 well plate (MicroWell™ plates; Nunc). The plate was centrifuged (200 g, 2 
min, room-temperature) and the supernatant flicked off the cells into a waste 
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container. Cells were resuspended with 50 µI of primary antibodies directed against 
lymphocyte cell-surface antigens, diluted at optimal concentration with RPMI (Table 
2.1 ), and incubated for 30 min at 4°C in the dark. Cells were then washed using 100 
µI D-PBS-FBS (Table 2.1) per well, the plate centrifuged (200 g, 2 min, room-
temperature) and the supernatant flicked off the cells. Cells were then rewashed 
twice by resuspending in 200 µI D-PBS-FBS, recentrifuging the plate (200 g, 2 min, 
room-temperature) and flicking the supernatant off the cells. Cells were then 
resuspended with 50 µI of secondary antibodies (directed against the primary 
antibody isotype) conjugated to fluorescent dyes, diluted to optimal concentration in 
RPMI, and incubated for 30 min at 4°C, in the dark. Cells were washed three times 
as described above. Following the washes, 200 µI D-PBS-FBS was added to each 
well, the cells resuspended and filtered through 100 µm mesh into Falcon FACS 
tubes (352052; BO) containing 200 µI D-PBS-FBS. Cells were fixed with 100 µI 4% 
paraformaldehyde (Table 2.1) and stored at 4°C, in the dark, until analysed by the 
flow cytometer. Analysis took place either that day or the following day. 
Non-specific binding of antibodies to cells was determined by the addition of RPMI 
only or negative isotype control serum for the primary antibody step. This 
percentage of non-specific binding was subtracted from the total to give a corrected 
value for each sample. 
Cells were analysed using a FACScan™ flow cytometer (BO). The machine was 
calibrated using CaliBRITE™ 3 beads (BO) to set the forward scatter (FSC) and side 
scatter (SSC) parameters and compensation for the two fluorescent channels (FL 1 
and FL2). The compensation for FL 1 and FL2 was corrected using cells separately 
labelled with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) dyes, 
respectively. A test sample was used to identify and gate the lymphocyte population 
of cells. Dead cells and debris were excluded from the count by setting the threshold 
at 150. Data was acquired for 10 000 events and analysed using the Cellquest™ 
software (BO). 
2.2.6 Enzyme-linked immunoassay 
2.2.6.1 ELISA for specific anti-C. albicans lgA 
Specific anti-C. albicans lgA was measured using a non-competitive indirect enzyme-
linked immunoassay (ELISA) protocol based on described methods (Clark and 
Engvall, 1980; Hodgkinson et al., 1995). All washes were carried out by an 
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automated plate washer (ELP-35; Bio-Tek) using PBS-T (Table 2.1 }, all samples and 
reagents were diluted with PBS-T containing 1 % w/v bovine serum albumin (BSA; A-
7906, Sigma) and all reagent addition volumes were 100 µI, unless otherwise stated. 
ELISA plates (Maxisorp F-96 immunoplates; Nunc) were coated with stock antigen as 
used for immunogen (see Section 2.2.1 ), diluted to 10 µg/ml in ELISA coating buffer 
(Table 2.1 ), incubated overnight at 4°C and washed three times. Remaining 
activated sites on immunoplates were blocked by adding 250 µI PBS-T containing 
1 % w/v BSA to each well and incubating the plate for 2 h at room-temperature. After 
washing the plates twice, four 10-fold serial dilutions of test sample (primary 
antibody: 1: 100; 1: 1 000; 1: 10 000; 1: 100 000) were added to duplicate wells. Plates 
were incubated for 2 h at room-temperature then washed three times and the 
secondary antibody consisting of rabbit anti-bovine lgA heavy-chain specific (diluted 
1 :70 000; Bethyl) was added. Plates were incubated overnight at 4°C, then washed 
three times prior to the addition of antibody-enzyme conjugate, goat anti-rabbit 
immunoglobulin conjugated to HRP (diluted 1 :12 000; Dako). After incubation for 2 h 
at room-temperature, the plates were washed twice with PBS-T then twice with PBS 
containing no Tween® 20, and then freshly prepared ELISA substrate solution (Table 
2.1) was added to each well. Following 30 min incubation at room-temperature on an 
automatic shaker (IKA-Werke), 50 µI of ELISA stopping solution (Table 2.1) was 
added and the optical density measured at 450 nm using an automated plate reader 
(ELP-35; BioTek). 
All ELISA plates were run with positive and negative control samples (FBS, diluted 
1: 1000). The median optical density between the maximum value for the positive 
control and the value for the negative control was used as a reference point 
(reference optical density) to determine test sample antibody titres. The reciprocal of 
the test sample dilution equivalent to the reference optical density was given as the 
antibody titre. Values were calculated using Prism software (GraphPad). The titre 
value for the positive control sample, run with each assay, was used to monitor inter-
assay variation. 
2.2.6.2 ELISA for total bovine lgA 
Total bovine lgA was measured using a non-competitive sandwich ELISA method 
with kit reagents from Bethyl used according to the manufacturer's protocol. All 
standards, samples and reagents were diluted with PBS-T containing 1% w/v BSA 
(A-7906; Sigma}, all reagent addition volumes were 100 µI and all washes were 
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carried out by an automated plate washer (ELP-35; BioTek) using PBS-T, unless 
otherwise stated. 
ELISA plates (Maxisorp F-96 immunoplates; Nunc) were coated with sheep anti-
bovine lgA heavy-chain specific (Bethyl) diluted 1 :200 in ELISA coating buffer. After 
incubation overnight at 4°C, the plates were washed three times. Remaining 
activated sites on immunoplates were blocked by adding 250 µI PBS-T containing 
1 % w/v BSA to each well and incubating the plate for 30 min at room-temperature. 
After washing the plates three times, standards (range 88 - 1 000 ng/ml, Bethyl) and 
test samples (colostrum diluted 1:5 000 and 1:10 000; milk diluted 1:500 and 1:1 000; 
non-lactating mammary secretions diluted 1: 1 000, 1: 5 000 and 1: 20 000) were 
added to duplicate wells. Plates were incubated for 60 min at room-temperature then 
washed three times and sheep anti-bovine lgA heavy-chain specific conjugated to 
HRP (diluted 1 :85 000; Bethyl) was added. After incubation for 60 min at room-
temperature, the plates were washed twice with PBS-T, then twice with PBS 
containing no Tween® 20 and then freshly prepared ELISA substrate solution was 
added. Following 30 min incubation at room-temperature on an automatic shaker 
(IKA-Werke), 50 µI of stopping solution was added and the optical density measured 
at 450 nm by an automated plate reader (EL311s, Bio-Tek). 
A standard curve was generated using Prism software (Graphpad) and values of 
unknown samples were determined. A quality control sample was run with each 
assay to monitor inter-assay variation. 
2.2. 7 Protein assay 
Total protein concentrations were measured using the Bio-Rad DC™ protein assay 
based on the method of Lowry (Lowry et al., 1951 ). The assay was performed 
according to the manufacturer's Microplate Assay protocol. 
Six standards (range 0.0625 - 2.0 mg/ml) were prepared using BSA (A-7906; Sigma) 
diluted in PBS. If required, samples were also diluted in PBS. In a microtitre plate, 5 
µI standard or sample dilutions, 25 µI Reagent A (alkaline copper tartrate solution) 
and 200 µI Reagent B (dilute Folin reagent) were added to duplicate wells. The 
plates were incubated for 15 min on an automatic shaker (IKA-Werke) and then the 
optical density was measured at 750 nm by an automated plate reader (EL311 s, Bio-
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Tek). OD values for standards were used to generate a standard curve using Prism 
software (Graphpad) and values of unknown samples were determined. 
2.2.8 Statistical analysis 
Values, where appropriate, were expressed as mean ± standard error of the mean 
(SEM). A two tailed t-test was used to determine significant differences between two 
data sets, the test parameters depending on the data set to be analysed. For 
example, when the two data sets were compared from the same group of animals at 
different time points then a paired t-test was used. When the two data sets were 
compared from two different groups of animals at the same time point then a t-test 
with equal variance was used. 
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Chapter 3 
Expression of vascular addressins in the 
untreated bovine mammary gland 
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3.1 Introduction 
The overall objective of this thesis is to investigate the molecular and cellular 
mechanisms involved in the local induction of lgA secretion in the bovine mammary 
gland. Based on findings in the literature, it is hypothesised that production of lgA in 
the bovine mammary gland (resulting from our multi-site immunisation regimen), is 
dependent on recruitment of primed lymphocytes of mucosal origin arising from the 
intra-peritoneal (IP) and intra-muscular (IM) immunisations. This recruitment may be 
mediated by changes in the microenvironment of the mammary gland due to 
exposure to antigen by the intra-mammary (IMM) immunisation. 
The homing of lymphocytes in blood and lymph to specific tissues is an important 
part of the immune response and is required for an efficient and targeted response to 
antigenic challenge. Homing is not a random process but regulated by the interplay 
of cell-surface adhesion molecules on lymphocytes and complementary receptors 
(vascular addressins) expressed on the vascular endothelium (see Section 1.2.3.4). 
Trafficking of lymphocytes to particular regions is directed by the specific sets of local 
vascular addressins and their ligands on circulating lymphocytes (Butcher et al., 
1999; Picker, 1994; Radi et al., 2001 ). 
The mammary gland requires lymphocytes not only for immune protection from 
invading environmental pathogens but also to generate antibodies for secretion into 
milk. In addition, immune cells are also transferred into colostrum that are of benefit 
to the neonate (Liebler-Tenorio et al., 2002). Lymphocyte populations in the 
ruminant mammary gland have been well characterised (see Section 1.4.2.2) but 
little is known about the vascular addressins that are involved in their recruitment. In 
contrast to this, as early as 1988 a report was published describing the expression of 
the mucosal addressin cell-adhesion molecule-1 (MAdCAM-1 ), in the lactating gland 
of the mouse (Streeter et al., 1988a). 
MAdCAM-1 is a 58 - 66 kDa glycoprotein adhesion receptor that belongs to the 
immunoglobulin super-family. It has a unique sequence whose only significant 
homology is with two other protein family members VCAM-1 and ICAM-1, as shown 
in Figure 3.1 (Shyjan et al., 1996). DNA sequence homology for mouse and human 
MAdCAM-1 is poor (42%), while the sequence homology for the expressed protein is 
even weaker at 39% (Briskin et al., 1993; Shyjan et al., 1996). While MAdCAM-1 is 
commonly believed to be the mucosal cell-adhesion molecule, its expression in 
mucosal tissues varies widely. It has little or no role to play in homing lymphocytes to 
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bronchial or oral mucosal tissues (Abitorabi et al., 1996) and is expressed in 
combination with VCAM-1 in genitourinary tracts (Kelly and Rank, 1997). VCAM-1 
predominates in homing lymphocytes to inflamed tissues (Butcher et al., 1999; 
Mikulowska-Mennis et al., 2001; Neumann et al., 1997). 
Figure 3.1 Comparison of murine and human MAdCAM-1 protein structures 
Areas of homology with family members VCAM-1 and ICAM-1, are shown. 
(Schematic adapted from Shyan et al., 1996) 
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Studies on homing mechanisms in the mammary gland have largely focused on the 
mouse. In this species, it has been shown that mammary gland B cells 
predominantly originated from gut-associated lymphoid tissues (GALT) and they 
began to traffic into the gland as lgA plasmablasts around parturition, followed by a 
major rise in middle and late lactation (Tanneau et al., 1999; Weisz-Carrington et al., 
1977). This was reflected in the milk lgA concentration which increased over the 
lactation period (Van der Feltz et al., 2001 ). 
In the mouse, T-cell migration to the mammary gland displayed an inverse pattern, 
with a rise during late pregnancy and fall during lactation. This corresponded to the 
amount of MAdCAM-1 expressed on the mammary gland vascular endothelium 
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(Tanneau et al., 1999). In contrast, no relationship was observed between levels of 
MAdCAM-1 expression and numbers of lgA plasmablasts (Tanneau et al., 1999) 
although binding of B lymphocytes to the murine mammary gland during mid-
lactation was inhibited by antibodies to MAdCAM-1 (Van der Feltz et al., 2001). A 
factor in milk but not serum has been shown to have chemoattractant properties for 
GALT-derived lgA B cells (Czinn and Lamm, 1986) and it has been postulated that in 
addition to MAdCAM-1, chemoattractants may play a role in lgA plasmablast 
recruitment (Tanneau et al., 1999). VCAM-1 was also detected in the lactating 
mammary gland but associated with larger blood vessels, not high endothelial 
venules where the diapedesis of lymphocytes takes place (Tanneau et al., 1999). 
A separate murine study was unable to demonstrate the expression of MAdCAM-1 in 
the mammary gland, but found strong evidence for a role for VCAM-1 in the 
recruitment of lgA plasmablasts to the mammary gland (Finke and Acha-Orbea, 
2001 ). This study transferred activated B and T cells from mice infected with 
mammary tumour virus into na"ive mice and monitored the movement of the 
lymphocytes. The T cells migrated to secondary lymph nodes and to the large 
intestine whereas the B cells migrated to the mammary gland, lung and liver. The B 
cells expressed the integrin a4p1: its counter receptor VCAM-1, was detected in the 
mammary gland (Finke and Acha-Orbea, 2001 ). 
Current literature suggests that the profile of addressins in ruminants is similar to that 
of other species, with MAdCAM-1 predominating in Peyer's patches and mesenteric 
lymph nodes, and with PNAd the main vascular addressin in peripheral lymph nodes. 
Based on expression of a4P7 and L-selectin, studies have shown that subsets of 
ovine T cells migrate preferentially to their corresponding cell-adhesion molecule 
MAdCAM-1 and PNAd, respectively (Mackay et al., 1996; Premier and Meeusen, 
1998). Experiments on sheep demonstrated that lymphocytes homing to the lung 
expressed low levels of a4p7 and L-selectin and it was suggested that other 
(unidentified) molecules may be involved in migration to the lung and associated 
lymphoid tissues (Abitorabi et al., 1996). Work by Rebelatto et al. (2000) in the cow 
has shown that nasal-associated lymphoid tissue and palatine and pharyngeal tonsils 
are similar to Peyer's patches in their distribution of B and T cells but there is dual 
expression of intermediate levels of MAdCAM-1 and PNAd. This combination of 
mucosal and peripheral phenotype in the cow is similar to that in the mouse 
(Csencsits et al., 2002). 
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Expression of vascular addressins in the ruminant mammary tissues has not been 
described, but a small number of investigations have demonstrated the expression of 
homing receptors on lymphocytes in bovine milk. In one study, the expression of L-
selectin and aLP2 (LFA-1) on T-cell subsets was examined (Van Kampen et al., 
1999). These molecules were shown to be expressed at high levels on na"ive 
lymphocytes. While LFA-1 did not change, the L-selectin expression decreased over 
the lactation period and it was suggested that there was a possible role for this 
molecule in T-cell trafficking to the mammary gland (Van Kampen et al., 1999). 
Other experiments have shown aLP2 to be important in the diapedesis of bovine 
neutrophils from blood into milk (Smits et al., 2000; Smits et al., 1998). 
Very recently a study has compared the expression of the adhesion molecules, L-
selectin, aLP2 (LFA-1), a4p7 (LPAM-1), and CD44 on T-cell subsets in milk and 
blood samples collected from dairy cattle infected with Johne's disease (Harp et al., 
2004). L-selectin, aLP2 and a4p7 were expressed on a significantly higher 
percentage of all T-cell subsets in milk than in blood at various times after parturition. 
It was suggested that these adhesion molecules are involved in selectively trafficking 
lymphocytes from blood into the mammary gland. 
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3.2 Aim and approach 
The aim of the work in this chapter was to characterise the vascular addressins 
expressed in the bovine mammary gland of untreated animals. The main focus was 
to identify, at four different physiological stages of the mammary gland, the 
distribution and abundance of MAdCAM-1, VCAM-1 and PNAd in alveolar and 
cisternal tissues and the supramammary lymph node (SMLN). The aim was also to 
define the vascular addressin receptors expressed on T and B cells present in the 
mammary tissues collected at the four different physiological stages. 
The first objective of this work was to develop immunohistochemical methodology for 
the molecules of interest: 
• MAdCAM-1, VCAM-1 and PNAd - vascular addressins 
• von Willebrand factor (vWf) - expressed on vascular endothelial cells 
• CD3 - pan T cells 
• CD4, CD8 - T-cell subpopulations 
• B-82 - pan B cells 
• CD62L and a4(37 - vascular addressin receptors expressed on lymphocytes 
The second objective was to collect alveolar, cisternal and SMLN tissue samples 
from untreated cows at each of four different physiological stages of the mammary 
gland: 
• Late pregnancy 
• Colostral phase 
• Lactation phase 
• Involution phase 
and to analyse these mammary tissues by immunohistochemical methods for 
expression of vascular addressins on endothelial cells and vascular addressin 
receptor expression on lymphocytes. 
In addition, to verify and quantify the expression of MAdCAM-1 mRNA in the 





Primary antibodies used in the optimised immunohistochemistry methods are listed in 
Table 3.1. The cell-differentiation (CD) antigen for the monoclonal antibody BAQ44A 
does not have a known human equivalent, unlike the other CD antigens used in this 
study. The antigen for BAQ44A is expressed by the majority of mature B cells in the 
blood (Letesson et al., 1991; Mukwedeya et al., 1996). 
Table 3.1 Primary antibodies for immunohistochemistry 
Clone Target 
antigen 
MM1A Bovine CD3 
ILA-11A Bovine CD4 
CACT80C Bovine CD8 
















Mu - mouse 
Rb - rabbit 




associated with T-cell 
antigen receptor 
MHC class II T cell 
MHC class I T cell 
Pan B cell 
(Non-lg marker) 
Band T cells 
monocytes, NK cells 






































There are few antibody reagents for measuring bovine cell-adhesion molecules and 
therefore, antibodies directed against mouse and human antigens, known to cross-
react with the cow, were used (Rebelatto et al., 2000; Van Kampen and Mallard, 
2001). 
Reagents used for the detection of the primary antibodies in the immunohisto-
chemistry methods are listed in Table 3.2. 
Table 3.2 Immunohistochemistry detection reagents 
Binding Reactivity 
2° Reagents 
Mouse lgG & lgM (H+L) 








Streptavidin 1 :200 
biotinylated-HRP 













Primers used in RT-PCR and real-time PCR for detection of MAdCAM-1 and p-actin 
mRNA expression in mammary alveolar tissues are listed in Table 3.3. The primer 
set for MAdCAM-1 was developed 'in house' (see Section 3.4.3.1 ). The primer set 
for p-actin was from a published bovine gene database (Coussens and Nobis, 2002). 




bp - base pair 
F - forward primer 
R - reverse primer 












3.4.1 Sample collection and preparation 
Healthy untreated pregnant Friesian heifers were used to obtain samples of 
mammary tissues. Four animals were selected at each of four different physiological 
stages of the mammary gland: 40 - 50 days pre-partum (late pregnancy), two days 
post-partum (colostral phase), 90 days post-partum (lactation phase) and three days 
after the cessation of milking (involution phase). These cows were part of a larger 
trial that was conducted to obtain tissues from the mammary gland for gene 
expression analysis. 
Cows were slaughtered at the Ruakura abattoir and mammary glands excised for 
dissection. Tissue samples were collected from the alveolar and cisternal areas of 
the mammary gland, and from the SMLN. Peyer's patch tissues and mesenteric 
lymph nodes were also obtained to represent typical gut-associated lymphoid tissue. 
Tissue samples for immunohistochemical analysis were processed and frozen as per 
the protocol outlined in Section 2.2.2.1 and serial sections were cut from these tissue 
samples as described in Section 2.2.3.1. Tissues samples for RT-PCR and real-time 
PCR were processed and frozen as per the protocol outlined in Section 2.2.2.1. 
3.4.2 lmmunohistochemistry 
3.4.2.1 lmmunohistochemical protocol development 
lmmunohistochemical methods for the detection of lymphocyte subsets and cell-
adhesion molecules in mammary tissues were not available 'in house' and 
development work was required. The immunohistochemical scientific and 
manufacturers' literature for detecting lymphocyte subsets and cell-adhesion 
molecules and 'in house' immunohistochemical procedures for other tissue-specific 
antigens were adapted and modified. 
The general procedure was: 
• Freeze tissue samples in Tissue Tek O.C.T. compound 
• Cut 6 µm frozen serial sections from the tissue samples and mount on Esco 
Polysine TM slides 
• Dry sections and fix 
• Block endogenous peroxidase and biotin activity 
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• lmmunostain with primary antibody directed against the antigen of interest 
• React primary antibody with a secondary link antibody conjugated to biotin 
• Detect secondary antibody with enzyme-avidin complex and chromogenic 
substrate 
• Counterstain, dehydrate, and place coverslips on slides 
• Observe cellular staining using a light microscope 
A variety of reagents was trialled and tested in order to determine optimal 
concentrations and incubation times. Some parameters were not tested but kept the 
same as 'in house' immunohistochemical standard protocols, including cryostat 
sectioning, immunohistochemical buffers (TBS and TBS-T), incubation temperatures, 
washing procedures between different reagent applications and counterstaining with 
haematoxylin. 
For the detection of cell-surface membrane antigens on lymphocytes using 
monoclonal antibodies, preservation of tissue samples by snap-freezing in liquid 
nitrogen is considered preferable to preserving tissues in formalin (Gutierrez et al., 
1999; Pollard et al., 1987). The procedure used for these studies involved immersing 
tissue samples in Tissue Tek O.C.T. compound (Bayer) and freezing rapidly in liquid 
nitrogen. There is very often a 'trade off in the quality of the morphology of the 
tissue section using frozen tissues, this being poorer than in those tissues preserved 
with formalin and paraffin-embedded. The advantage is that the cell-surface 
antigens are not masked by cross-linked protein aggregates or damaged by harsh 
processes. Therefore, antigens retain their reactivity with antibodies (Boenisch, 
2001). 
Tissue fixing for frozen tissue samples was performed after sectioning. A variety of 
fixatives for the mounted frozen sections have been used by different laboratories 
and a selection of these was trialled: methanol (room-temperature), ethanol (ice-
cold), acetone (ice-cold), 1 % paraformaldehyde (room-temperature) and 4% 
paraformaldehyde (room-temperature). The fixatives were compared in the 
immunohistochemical protocol using the CD3 primary antibody, an antibody that 
gave strong positive staining of cells. Ice-cold ethanol gave the best quality 
morphology with retention of strong positive staining of cells and was used for the 
new protocols. 
Primary antibodies were titrated to determine the optimal concentration for use in the 
immunohistochemistry protocols (Section 2.2.3.3). The optimal concentration was 
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judged as the dilution of antibody that gave the strongest staining of cell-surface 
antigen with minimal non-specific background staining. Frozen sections of Peyer's 
patch and SMLN tissues were used for these tests. A dilution series of 1:100, 1 :300, 
1 :1 000, 1 :3 000, and 1 :1 O 000 was tested for each individual antibody. The 
exception to this was the antibody Fib 30, which had a very low antibody 
concentration and was tested neat and at dilutions of 1:3, 1:10, 1:30 and 1:100. The 
optimal antibody concentrations found are listed in Table 3.4. Detection reagents 
were used at the manufacturers' recommended dilutions (see Table 3.2). Non-
specific binding of detection reagents was determined by substituting buffer for the 
primary antibody. 
Table 3.4 Optimal concentrations for primary antibodies used for immuno-
histochemical staining 
Clone Target antigen Optimal concentration 
MM1A bovine CD3 1 :1 000 
ILA-11A bovine CD4 1:100 
CACT80C bovine CD8 1:5 000 
8AQ44A bovine 882 1:3 000 
8AQ92A bovine CD62L 1:100 
Fib 30 mouse p7 integrin 1 :3 
MECA-79 mouse PNAd 1 :1 000 
7G11 human MAdCAM-1 1:100 
Hae 2a human VCAM-1 1:500 
Rabbit polyclonal human vWf 1:30000 
Protocols for CD4 and CD62L proved difficult to develop because no positive staining 
of cells could be achieved. After exhaustive testing of other parameters in the 
assays, it was decided that the problems were largely due to the primary antibody. 
For CD4, five other monoclonal antibodies were trialled and of these, one worked for 
a time. The reason for this variation was not able to be ascertained and the protocol 
for this antigen was never fully validated. A second antibody was tested for CD62L 
and this gave good staining of lymphocytes but tended to also have some non-
specific background staining in mammary gland tissues. 
83 
An immunohistochemical protocol for MAdCAM-1 also proved difficult to develop. 
The initial antibody used to develop the protocol was a commercially sourced 
antibody; clone MECA-367, from Pharmingen. This antibody was raised in rats 
against endothelial cells isolated from BALB/c mouse mesenteric lymph nodes. 
Trials with this antibody to stain MAdCAM-1 in bovine Peyer's patch tissue proved 
unsuccessful with no positive staining achieved. Although the antibody did not work 
in bovine tissues, it did positively stain endothelial venules in mouse Peyer's patches. 
The conclusion was that the antibody worked in the protocol but did not cross react 
with bovine MAdCAM-1, in agreement with other studies in sheep (Premier and 
Meeusen, 1998). A second antibody raised in mice against human MAdCAM-1 
(7G11; gifted by Dr Briskin) successfully stained endothelial venules in bovine 
Peyer's patches. This antibody was used in the studies in this thesis. It had been 
used previously in one other bovine study detecting MAdCAM-1 in nasal-associated 
lymphoid tissues (Rebelatto et al., 2000). 
Attempts to set up immunohistochemical protocols to detect lgA-, lgG- and lgM-
positive B cells were unsuccessful due to background staining of soluble 
immunoglobulin in the frozen tissue samples. A solution to this problem was found 
after searching the literature and discussing options with other researchers in their 
field of expertise. Details of this solution are described in Chapter Four. 
3.4.2.2 lmmunohistochemical analysis 
Serial sections of frozen alveolar, cisternal and SMLN tissues from four untreated 
cows at each of four different physiological stages of the mammary gland were 
immunostained with antibodies specific for vascular addressins to identify the 
presence and distribution of the addressins in the mammary gland. All vascular 
endothelial cells were identified by immunostaining with an antibody for von 
Willebrand factor (vWf), an antigen expressed on vascular endothelium. Samples 
and analyses were: 
• serial sections of alveolar, cisternal and SMLN tissues 
• four untreated animals per stage 
• four physiological stages of the mammary gland - late pregnancy, colostral 
phase, lactation phase, involution phase 
• vascular addressins - MAdCAM-1, VCAM-1, PNAd 
• control for vascular endothelial cells - vWf 
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A semi-quantitative subjective measure of vascular addressin expression was made 
by a visual comparison of the vascular endothelium in serial sections of tissue that 
were stained by the addressins and the vascular endothelium stained by vWf. The 
level of expression of vascular addressins was expressed as the proportion of 
venules stained for vWf that also stained for addressins. Expression was graded 
from O - 4: 0 = no addressin expression; 1 = 1 - 25% venules stained with addressin 
that stained with vWf; 2 = 25 - 50%; 3 = 50- 75%; 4 = 75-100%. 
Serial sections of frozen alveolar, cisternal and SMLN tissues from four cows at each 
of four physiological stages of the mammary gland were also immunostained with the 
following antibodies to identify the lymphocyte subsets present in the mammary 
gland. 
• CD3 - pan T-cell population 
• 882 - pan 8-cell population 
• CD62L - counter receptor expressed on lymphocytes for PNAd 
• 137 - counter receptor expressed on lymphocytes for MAdCAM-1 
(NB: 137 detection does not distinguish between a4137 and aEl37) 
3.4.3 MAdCAM-1 RT-PCR 
3.4.3.1 Primer development for MAdCAM-1 RT-PCR 
For the amplification of mRNA by RT-PCR, oligonucleotide primers are required 
based on the DNA sequence of the target gene. Although the human and mouse 
sequences for MAdCAM-1 are available in the public domain, there is no published 
sequence for the bovine homologue. RT-PCR primers for use in these studies were 
first designed based on the human sequence using a bioinformatics software 
programme, Vector NTI (lnformax, lnvitrogen). Using mRNA extracted from Peyer's 
patch tissues and mesenteric lymph nodes as described in section 2.2.4.1, these 
primers were used for RT-PCR amplification of the MAdCAM-1 DNA sequence using 
the protocol outlined in Section 2.2.4.2 and Section 2.2.4.3. The resultant DNA 
products were separated using agarose gel electrophoresis using the protocol 
outlined in Section 2.2.4.4. However, no detectable bands were seen at the 
expected base pair size (526 bp). 
A variety of conditions were tested to try and improve the annealing of primer to 
template. The PCR reaction was run at a range of different annealing temperatures 
(52 - 68°C) with variable concentrations of magnesium chloride (1.0 mmol/1, 1.5 
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mmol/1, 2.0 mmol/1, and 3.0 mmol/1) and with the absence or addition of 2.5 µI 
dimethylsulphoxide (DMSO), but there was no improvement and no DNA products 
were detected at the expected base pair size (526 bp). 
A line-up comparison of the MAdCAM-1 amino acid sequences for human, macaque 
and mouse (Figure 3.2) demonstrated similarities in some domains but divergence in 
others (Shyjan et al., 1996). A second set of primers was designed using areas of 
amino acid sequence with greater homology. These primers also failed to produce 
any product when used for RT-PCR amplification of mRNA from Peyer's patch 
tissues and mesenteric lymph nodes. A variety of conditions were tested to try and 
improve the annealing of primer to template, as for the first set of primers, but again 
no products were detected at the expected base pair size (440 bp). 
Failure of primers to detect bovine MAdCAM-1 DNA based on the human MAdCAM-1 
DNA sequence may not be unexpected. Species differences between the mouse 
and human MAdCAM-1 DNA have been well demonstrated (Shyjan et al., 1996). 
Therefore, there are very probably differences between the bovine and human 
sequences. 
In an attempt to locate a partial bovine MAdCAM-1 DNA sequence, the human 
MAdCAM-1 sequence (1608 base pairs, NCBI reference - NM_130761) was blasted 
against The Institute for Genomic Research (TIGR) database for cattle. This resulted 
in a hit for an expressed sequence tag (EST) DNA sequence (526 base pairs, TIGR 
reference - BE808468). There was 65% sequence similarity between this EST and 
the human sequence, with a score of 829, P = 3.8e-32. Figure 3.3 shows the line-up 
of the two DNA sequences. 
A third set of primers was designed using areas of DNA sequence with greatest 
agreement between the bovine TIGR EST (BE808468) and the sequence for human 
MAdCAM-1 (Figure 3.3). It should be noted that although there was an exact match 
between the bovine and human amino acid sequences for the primers, there were 
some differences in the corresponding nucleotide sequences. RT-PCR amplification 
of mRNA from Peyer's patch tissues and mesenteric lymph nodes using this third set 
of primers produced a DNA product at the expected base pair size (250 bp). 
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Figure 3.2 Comparison of the mouse, macaque and human MAdCAM-1 amino acid 
sequences 
Amino acid homology is shown with a greyed background. The location of the primer 
pairs designed from the human sequence are shown in red: the first primer pair 
designed are designated F:I & R:I; the second primer pair designed are designated 
F:II and R:II. (Figure adapted from Shyjan et al. 1996) 
Mouse ( 1) 
Macaque ( 1) 
Human ( 1) 
Mouse ( 4 6) 
Macaque (51) 
Human ( 4 8) 
Mouse ( 95) 
Macaque ( 101) 
Human ( 98) 
Mouse ( 145) 
Macaque ( 14 9) 
Human (147) 
Mouse ( 193) 
Macaque ( 199) 
Human ( 197) 
Mouse (242) 
Macaque (248) 
Human ( 24 6) 
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Figure 3.3 Comparison of bovine TIGR EST (BE808468) and human MAdCAM-1 
DNA sequences 
Identical DNA sequence is shown with a greyed background. The location of the 
primer pair designed from the bovine sequence and the amino acid sequences for the 
primers are shown in red. 
37 1 420 
Bovi ne (1) -----GG~CGTTGTGCCAGGGA GGACO~ G!GAGGTGGCCT~CACGGCCCaj 
E V A C T A H 
Human (371) TCCCCAGCAGCCCTGGTGCCTG~TGAC CGGAGGTGGCCTGTACGGCCCA 
42 1 470 
Bovi ne (4 6) ~ CGTCAOACOTCCT~GCCd TGA CCTCTC ATGTCCCTGCTCCTGG 
Human (42 1 ) CAAIAGTCA GCCCGTG ccqcAA GCGCTCTC TTCTCCCTGCTCGTCG 
471 
Bovine (96) GG 
Human ( 4 71) 
520 
GAAGCCCT---CCCG CGTGACTGAG 
CAAGCCCTGGGCCC GAGGT CAGGAG 
521 570 
Bovine (1 43) GAG---- - - ---CCCCAGQAA GCGAGGATTCGCTGTTCCAAGTGA CCA 
Human (521) GAGGAGGAGGAGCCCCAG GGGACGAGG~CGTGCTGTTCAGGGTGAOAGA 
571 620 
Bovine (184) GCGCTGG TGCTGC CACqTCAG GACOTOCAGC TGCGOACCCTOCACT 
Human (571) GCGCTGGGGGCTGCqGC CCCTG GGACCCOTGT CCCGdcq GCCCTOTACT 
621 670 
Bovine (234) GCCAGGT c;JACCATGAGGCTGCd CGGQCGGGAGC~G~ CCCACdACCGGACC 
T M R L P G 
Human (621) GCCAG~CCA GATGAGGCTGCOTGG TTGGAGCTC~ GCCAC GCOAGGCC 
67 1 720 
Bovine (284) A TCOAGTCCTGC~GGGC TGAOGTCCCCGGAGcqcccdAGCATCACCTC 
Human (671) ATCCCCGTCCTGC~CAGCCCGACCTCCCCGGAGC TCCCGACACCACCTC 
721 770 
Bovine (334) OT GA~CTGCCOACCATGACCCqTGBAAA C CAGqATCACAGCGTCCC 
Human (721) CCCGGA TCTCCOGAC~CCACc:;TCCCqGGAGTCTCCCGACACCACCTCCC 
77 1 820 
Bovi ne (384) CGGA CQCAOT GATACAACCACC CAGAGTCTTTT TC~TG~GCCCCCG 
Human (771) CGGAGTOTCCCGACACCACCTCCCAGGAGCCTCCCGAC~CCACCTCCCAG 
82 1 870 
Bovine (434) AAGCCTCCQATCACTACCTCCqCCGAG TGGCq TCCACOTAOAGCC CGC 




GQCCCGC GTCOT GCGCO CGT CCAGC~CAGCTCCACCA 
AAGA CTCCC G AGCCqGOCCCCCAGC~GGGCTCCACAC 
921 949 
Bovine (534) GGCCGTGCCTCCC----------------
Huma n (92 1 ) ACAq CCCCAGGAGCCCAGGCTCCACCAGG 
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3.4.3.2 MAdCAM-1 RT-PCR analysis 
Extraction and purification of mRNA from the alveolar mammary tissues of four 
untreated cows at each of four different physiological stages of the mammary gland 
was performed using the protocol outlined in Section 2.2.4.1. Peyer's patch tissues 
were included as positive control samples. RT-PCR was performed using the third 
primer set designed as described in the section above and the protocol outlined in 
Sections 2.2.4.2 and 2.2.4.3. 
The PCR reaction began with an initial denaturation step at 94°C for 2 min. This was 
followed by 35 thermo-cycling steps using the conditions: 
• Denaturation for 30 sat 94°C 
• Annealing for 30 s at 65°C 
• Extension for 30 s at 72°C 
At the end of the last cycle, the extension phase was run for a further 5 min at 72°C. 
DNA products were separated by agarose gel electrophoresis as outlined in Section 
2.2.4.4, then illuminated and photographed using the Gel Doc system (Bio-Rad). 
3.4.4 MAdCAM-1 real-time PCR 
3.4.4.1 Real-time PCR development for MAdCAM-1 
The MAdCAM-1 primers designed using the EST DNA sequence (BE808468) from 
the TIGR cattle database were validated for real-time PCR using the protocol 
outlined in Section 2.2.4.6. Annealing temperatures for real-time PCR for MAdCAM-
1 and the endogenous control gene p-actin were optimal at 65°C and 60°C, 
respectively. 
In order to determine the efficiency of the real-time PCR reaction, RT-PCR products 
for MAdCAM-1 and p-actin were prepared using the protocol in Section 2.2.4.3 and 
annealing temperatures of 65°C and 60°C for MAdCAM-1 and p-actin, respectively. 
Extracted mRNA from alveolar mammary tissue was used for p-actin sequence 
amplification and extracted mRNA from Peyer's patch tissue was used for MAdCAM-
1 sequence amplification. The products were isolated on agarose gel (see Section 
2.2.4.4) and purified (see Section 2.2.4.5) and five 10-fold serial dilutions prepared. 
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3.4.4.2 Real-time PCR analysis of MAdCAM-1 
Extracted, purified and reverse transcribed mRNA from the alveolar mammary 
tissues of four untreated cows at each of four different physiological stages of the 
mammary gland, used in the RT-PCR reactions (see Section 3.4.3.2), were analysed 
using real-time PCR. In addition four different samples of bovine Peyer's patch 
tissue were also analysed. Using the protocol outlined in Section 2.2.4.6 and the 
primers and annealing temperatures validated in Section 3.4.4.1, the mRNA levels of 
MAdCAM-1 and p-actin was determined for all the samples. Five 10-fold serial 
dilutions of the PCR product for both MAdCAM-1 and p-actin (see section 3.4.4.1) 
were also analysed by real-time PCR to determine the efficiency of the reaction and 
to calculate the relative quantity of mRNA in unknown samples, as described in 
Section 2.2.4.6. The mRNA levels of MAdCAM-1 in unknown samples were reported 
relative to the mRNA levels of p-actin. This adjusted for any variation in the quantity 
of total mRNA used for each reaction. The relative expression levels of MAdCAM-1 
in different alveolar mammary tissues and Peyer's patch tissues were compared. 
90 
3.5 Results 
3.5.1 lmmunohistochemical analysis of vascular addressin 
expression in the untreated mammary gland 
Illustration of the characteristic architecture of alveolar tissues collected from the 
untreated mammary gland at four different physiological stages and stained with 
haematoxylin is shown in Figure 3.4. The mammary gland during the stage of late 
pregnancy (40 - 50 days pre-partum) already had well developed alveoli 
interspersed within the stromal tissue. Lobes and ducts were also well defined. Two 
days post-partum, in the colostral phase, the alveoli had increased in number 
compared with late pregnancy but there were still interstitial spaces between the 
alveoli. By 90 days post-partum, the gland was in established lactation. At this 
stage, the alveoli had enlarged such that the epithelial walls of the individual alveoli 
were touching their neighbour within lobes. Three days after the cessation of milking, 
the involuting tissue from the mammary gland showed the beginnings of the 
breakdown of the integrity of the alveoli. Compared with lactation tissue the size of 
the alveoli had also diminished. There were no apparent differences in the 
characteristic architecture of the supramammary lymph node (SMLN) sampled from 
the four different physiological stages (data not shown). 
The results of the immunohistochemical characterisation of MAdCAM-1, VCAM-1 and 
PNAd expression in mammary gland tissues of untreated cows are described in the 
following sections. Illustrations of bovine Peyer's patch tissues, used as positive 
control tissues in the immunohistochemical protocols, stained with MAdCAM-1, 
VCAM-1 and vWf are shown in Figure 3.5. 
3.5.1.1 MAdCAM-1 
Expression of MAdCAM-1 was detected on the vascular endothelium of bovine 
Peyer's patch tissue (see Figure 3.5). However, no MAdCAM-1 expression was 
detected on the vascular endothelium in any of the mammary gland tissue samples 
tested. This included the alveolar, cisternal and SMLN tissue samples collected from 
all four physiological stages of the mammary gland. A comparison of MAdCAM-1, 
VCAM-1 and vWf staining in serial sections of alveolar tissue from the colostral 
phase is illustrated in Figure 3.6. 
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Figure 3.4 Representative illustration of haematoxylin stained frozen alveolar 
tissue from different physiological stages of the bovine mammary 
gland of untreated animals 
Pregnant Colostral phase 
Lactation phase Involution phase 
Black solid bar is lOOµm 
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Figure 3.5 Representative illustration of MAdCAM-1, VCAM-1 and vWf 
immunohistochemical staining on vascular endothelium in frozen serial 
sections of bovine Peyer's patch tissue 
MAdCAM-1 
VCAM-1 
von Willebrand factor 
Black solid bar is lOOµm 
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Figure 3.6 Representative illustration of MAdCAM-1, VCAM-1 and vWf 
immunohistochemical staining on vascular endothelium in frozen 





von Willebrand factor von Willebrand factor 
.. 
Black solid bar is lOOµm 
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3.5.1.2 VCAM-1 
The expression of VCAM-1 in mammary gland tissues from the four physiological 
stages was compared. The positive staining of VCAM-1 was most pronounced in the 
tissue samples from the colostral phase with expression in all four individual animals 
at this physiological stage. There was VCAM-1 expression detected in alveolar 
tissues of three individual animals from the lactation phase. There was little or no 
expression of VCAM-1 in tissues collected at other stages. Table 3.5 shows the 
number of untreated animals found to express VCAM-1 in the mammary gland at 
various physiological stages. 
Table 3.5 VCAM-1 expression in the mammary gland of untreated animals 
The number of animals where expression of VCAM-1 was detected in alveolar, 
cisternal and SMLN tissues at different physiological stages of the mammary gland 
is shown. 
Physiological stage of 





SMLN - supramammary lymph node 
Proportion of animals per group 
with VCAM-1 expression detected 
Alveolar Cisternal SMLN 
0/4 0/4 1/4 
4/4 4/4 4/4 
3/4 0/4 1/4 
0/4 0/4 1/4 
Positive staining in the alveolar and cisternal tissues was detected on larger venules 
that were also positively stained by vWf. The expression of VCAM-1 detected in 
alveolar tissue samples from the colostral phase of the mammary gland is illustrated 
in Figure 3.6. In alveolar tissues at this physiological stage, positive staining for 
VCAM-1 was also visible around a number of the alveoli (Figure 3.6). This area did 
not stain positively for vWf. 
In the colostral alveolar and cisternal tissue samples, VCAM-1 expression was seen 
on 50 - 100% of the vascular endothelium that was also stained positively with vWf, 
as shown in Table 3.6. The staining in the lactation tissue samples was less 
prevalent than that detected in the colostral stage, with VCAM-1 expression being 
seen on O - 50% of the vascular endothelium that was also stained with vWf. 
Expression was graded from O - 4: O = no VCAM-1 expression; 1 = 1 - 25% venules 
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stained with VCAM-1 that stained with vWf; 2 = 25 - 50%; 3 = 50 - 75%; 4 = 75 -
100% (see section 3.4.2.2). 
Illustration of positive staining of VCAM-1 in the SMLN is shown in Figure 3.7. 
VCAM-1 expression was detected in SMLN tissue samples on both large and small 
venules that were stained with vWf (Figure 3.7). In SMLN tissue samples, VCAM-1 
was expressed on O - 50% of the vascular endothelium that also stained positively 
with vWf (see Table 3.6). 
Table 3.6 Proportion of endothelial venules in the tissues of the mammary gland 
of untreated animals that stained positive for both VCAM-1 and vWf 
Alveolar, cisternal and supramammary lymph nodes tissues were collected from 
untreated animals at each of four physiological stages of the mammary gland. 
Expression was graded from O - 4: 0 = no VCAM-1 expression; 1 = 1 - 25'Yo venules 
stained with VCAM-1 that stained with vWf; 2 = 25 - 50%; 3 = 50 - 75'Yo; 4 = 75 -
100%. (Group average ± SEM, n = 4 ). Different lowercase letters in superscript 
indicate statistically significant differences for the tissue at different physiological 
stages (p < 0.05). 
Physiological 
stage of the 
mammary gland 
Proportion of vascular endothelium 
stained positive for VCAM-1 
that also stained positive for vWf 





SMLN - supramammary lymph node 
vWf - von Willebrand factor 
3.5.1.3 PNAd 
0.0 ± o.oa 
4.0 ± o.ob, 
1.8 ± 0.6c 
0.0 ± o.oa 
0.0 ± o.oa 0.8 ± 0.8a 
3.7 ± 0.3b 2.5 ± 0.5b 
0.0 ± o.oa 0.8 ± 0.8a 
0.0 ± o.oa 2.0 ± 1.4a, b 
The expression of PNAd detected in the SMLN is illustrated in Figure 3.7. Positive 
staining was seen in the SMLN samples of all animals, at all physiological stages of 
the mammary gland. PNAd expression was detected in 25-100% of the endothelial 
venules that were also stained with vWf. The proportion of PNAd staining compared 
with vWf staining for different physiological stages of the mammary gland is shown in 
Table 3.7. 
No PNAd was detectable in alveolar or cisternal mammary tissue samples from the 
pregnant, colostral, lactation or involution stages. 
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Figure 3.7 Representative illustration of VCAM-1. PNAd and vWf immuno-
histochemical staining on vascular endothelium in frozen bovine 
supramammary lymph node tissues from the colostral phase 
VCAM-1 
PNAd 
von Willebrand factor 
• 
" -
Black solid bar is lOOµm 
97 
Table 3.7 Proportion of endothelial venules in the supramammary lymph nodes of 
untreated animals that stained positive for both PNAd and vWf 
Supramammary lymph nodes were collected from untreated animals at each of four 
physiological stages of the mammary gland. Expression was graded from O - 4: 0 = 
no PNAd expression; 1 = 1 - 25'Yo venules stained with PNAd that stained with vWf; 2 
= 25 - 50%; 3 = 50 - 75%; 4 = 75 - 100%. (Group average± SEM, n = 4). Different 
lowercase letters in superscript indicate statistically significant differences at 
various physiological stages (p < 0.05). 
Physiological 






Proportion of vascular endothelium 
stained positive for PNAd 
that also stained positive for vWf 
2.3 ± 0.5a 
2.0 ± 0.7a 
4.o ± a.ob 
3.5 ± 0.3a, b 
3.5.2 lmmunohistochemical characterisation of vascular addressin 
receptor expression on lymphocytes in the untreated 
mammary gland 
Lymphocytes in the mammary gland were detected by immunohistochemical analysis 
using pan T cell (MM1A) and pan B cell (BB2) monoclonal antibodies. T cells were 
found to be widely distributed throughout the interstitial spaces of alveolar and 
cisternal regions, with no large variation in numbers apparent for the different 
physiological stages of the mammary gland. In contrast, no B cells were detected in 
alveolar or cisternal tissue samples at any physiological stage. In the SMLN, both T 
and B cells were evident. Similar to characteristic aggregation patterns described in 
other studies of lymph nodes and Peyer's patch tissue, B cells were isolated in 
follicular regions with T cells observed mostly at the periphery of follicles and also 
scattered throughout the tissue. Illustrations of immunohistochemical staining of pan 
T cells and pan B cells in Peyer's patches and the SMLN are shown in Figure 3.8 
and Figure 3.9, respectively. 
lmmunohistochemical analysis of alveolar and cisternal tissues and SMLN tissues 
revealed no lymphocytes expressing p7, the cell-surface receptor for MAdCAM-1. 
There was no evidence of these cells in the tissues at any physiological stage of the 
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Figure 3.8 Representative illustration of immunohistochemical staining of CD3-, 
BB2- and 137-positive cells in bovine Peyer's patch tissues 
CD3 
BB2 
Black solid bar is lOOµm 
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Figure 3.9 Representative illustration of immunohistochemical staining of CD3-, 




Black solid bar is lOOµm 
100 
mammary gland. However, the J37 monoclonal antibody did stain cells in bovine 
Peyer's patch tissues (see Figure 3.8). 
Lymphocytes expressing CD62L (L-selectin) were detected in the SMLN (see Figure 
3.9) and expression did not appear to vary with the different physiological stages of 
the mammary gland. Difficulties were encountered assessing L-selectin positive 
staining in alveolar and cisternal mammary gland tissues due to non-specific staining 
encountered with this monoclonal antibody in these tissues. 
3.5.3 MAdCAM-1 mRNA expression in the untreated mammary 
gland 
3.5.3.1 Detection of MAdCAM-1 mRNA in the untreated mammary gland using 
RT-PCR 
A purified DNA product, amplified by RT-PCR using the primers designed from the 
TIGR EST DNA sequence of bovine MAdCAM-1 and mRNA extracted from bovine 
Peyer's patch tissue, was sequenced. A perfect match was achieved between this 
DNA sequence and the TIGR EST DNA sequence, establishing that the primers were 
amplifying the correct sequence. 
Initially, when expression of MAdCAM-1 mRNA was assessed in alveolar mammary 
tissue samples from four cows at each of four different physiological stages of the 
mammary gland, results showed significant levels of MAdCAM-1 mRNA in pregnant 
and colostral phase tissue samples, with lower levels of mRNA in tissue samples 
from the lactation and involution phase. However, expression was also detected in 
control samples that lacked the reverse transcriptase and thus had no cDNA formed 
from mRNA. This result suggested that the mRNA samples were contaminated with 
genomic DNA. To eliminate this contamination, samples were treated with DNase 
and re-purified. Following this treatment, weak but discernible levels of MAdCAM-1 
mRNA were still detectable in some samples for mammary alveolar tissue samples 
from all physiological stages. 
3.5.3.2 Quantitative analysis of MAdCAM-1 mRNA in the untreated mammary 
gland 
The efficiencies of the real-time PCR reactions for MAdCAM-1 and J3-actin were 
calculated by the Lightcycler software (Roche) to be 1.848 and 1.814, respectively 
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(Figures 3.10 and 3.11 ). To assess the accuracy and reproducibility of the real-time 
PCR intra-assay precision was determined in five repeats of one sample within a 
Lightcycler run and inter-assay variation was determined using one sample in five 
different experimental runs performed on five days. The coefficient of variation for the 
cycle number value within assay was 0.61 % and between assays was 1.60%. 
Levels of MAdCAM-1 mRNA in the alveolar mammary tissue samples from four cows 
at each of four different physiological stages of the mammary gland were compared 
with levels of mRNA in four different samples of Peyer's patch tissue. Data reported 
as the level of MAdCAM-1 mRNA relative to the level of p-actin mRNA are shown in 
Table 3.8. The average value for the mammary tissues at each of the four 
physiological stages was divided by the average value for the Peyer's patch tissues 
to obtain a gene expression level of MAdCAM-1 for mammary gland tissues relative 
to Peyer's patch tissues. The results obtained indicate that alveolar mammary gland 
tissue contained 4.7 - 9.1 x 103-fold lower MAdCAM-1 mRNA than Peyer's patch 
tissues (Table 3.8). This difference was highly significant (p < 0.001 ). There was no 
significant difference for levels of MAdCAM-1 mRNA between any of the different 
physiological stages of the mammary gland. 
Table 3.8 MAdCAM-1 gene expression in the mammary gland of untreated cows 
compared with that in bovine Peyer's patch tissues 
Level of MAdCAM-1 mRNA (relative to p-actin) in bovine Peyer's patch tissue 
compared with alveolar tissue samples from the bovine mammary gland of pregnant, 
colostral, lactation, and involution phases (n = 4). 
Tissue MAdCAM-1 mRNA relative Mammary gland compared 
to ~-actin mRNA8 to Peyer's patchesb 
Peyer's patch 70.380 ± 8.022 100.00 
Mammary gland* 
Pregnant 0.008 ± 0.001 0.011 
Colostral 0.012 ± 0.008 0.017 
Lactation 0.018 ± 0.006 0.026 
Involution 0.015 ± 0.003 0.021 
a. The level of MAdCAM-1 mRNA is relative to the level of P-actin mRNA. The results are reported as 
the group average ± SEM. 
b. The comparison of the expression of MAdCAM-1 mRNA in the mammary gland compared with Peyer's 
patch is obtained by dividing the group average relative level of MAdCAM-1 mRNA in the mammary gland 
by the average relative level of MAdCAM-1 mRNA in the Peyer's patch samples. 
* alveolar tissue from the mammary gland 
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Figure 3.10 Amplification curves and standard curve for MAdCAM-1 real-time 
PCR 
A, Real-time PCR amplification curves for five 10-fold serial dilutions of MAdCAM-1 
cDNA; cycle number plotted against fluorescence (530 nm) B, Representative 
standard curve of MAdCAM-1 used to determine the efficiency of the real-time PCR 
reaction required for the relative quantification of mRNA in unknown samples. Log 
concentration of the dilution of MAdCAM-1 cDNA is plotted against the cycle 
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Figure 3.11 Amplification curves and standard curve for J3-actin real-time PCR 
A, Real-time PCR amplification curves for five 10-fold serial dilutions of J3-actin 
cDNA, cycle number plotted against fluorescence (530 nm}; B, Representative 
standard curve of J3-actin used to determine the efficiency of the real-time PCR 
reaction required for the relative quantification of mRNA in unknown samples. Log 
concentration of the dilution of J3-actin cDNA is plotted against the cycle number at 
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The results presented in this chapter indicate that the vascular addressins involved in 
trafficking lymphocytes into the bovine mammary gland may differ from those 
described in the literature for the mouse. In contrast to the studies in the mouse 
where MAdCAM-1 expression was reported in the pregnant and lactating mammary 
gland (Tanneau et al., 1999; Van der Feltz et al., 2001), in the present study no 
MAdCAM-1 was detected in bovine mammary gland tissues by immunohistochemical 
analysis. This finding was substantiated by quantitative real-time PCR analysis. 
Although levels of MAdCAM-1 mRNA were detectable in the bovine mammary gland 
tissues, these levels were very low especially when compared with mRNA levels 
detected in bovine Peyer's patch tissues. 
There may be several explanations as to why no MAdCAM-1 protein was detected in 
the bovine mammary gland tissues. The simple explanation is that there may be no 
MAdCAM-1 protein expressed in the bovine mammary gland. Although the ruminant 
vascular addressin profile is similar in most respects to other species (Abitorabi et al., 
1996; Rebelatto et al., 2000), the mammary gland may diverge from this pattern. 
The ruminant mammary gland is unique in that lgG1 is the predominant 
immunoglobulin in mammary secretions and lgA levels are low, whereas in other 
species, lgA is a predominant immunoglobulin in early milk (Butler, 1974). Therefore, 
it is feasible that the low levels of lgA observed in bovine mammary secretions may 
be because the cow does not have, or does not activate, the homing mechanisms, 
including the mucosal addressin MAdCAM-1, required to attract lymphocytes of 
mucosal origin to the gland. 
Although MAdCAM-1 protein expression has been found in the mouse mammary 
gland in several studies (Streeter et al., 1988a; Tanneau et al., 1999; Van der Feltz et 
al., 2001) another study failed to detect this addressin (Finke and Acha-Orbea, 
2001 ). The Finke and Acha-Orbea study also investigated lymphocyte homing, 
however, there were major differences compared with the other murine studies: 
lymphocytes were isolated from the draining mammary lymph nodes of one animal 
and adoptively transferred to na"ive recipients and their progress tracked. No 
reference was made to the physiological phase of the mammary gland in the 
recipients, although the histology shown suggests that the animals were in the 
lactation phase. In two of the other studies (Tanneau et al., 1999; Van der Feltz et 
al., 2001), it was noted that the MAdCAM-1 expression in the mammary gland 
decreased as lactation advanced, although it was still detectable, so this would not 
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fully explain the lack of detection in the Finke and Acha-Orbea study. One 
explanation for the differences observed for MAdCAM-1 expression between the 
murine studies may be due to the different primary antibodies the authors used to 
detect MAdCAM-1. MECA- 367, the monoclonal antibody used in the Tanneau et al. 
(1999) and Van der Feltz et al. (2001) studies is reported to bind the first domain of 
MAdCAM-1 and block MAdCAM-1-dependent binding in vitro (Streeter et al., 1988a). 
MECA-89, the monoclonal antibody used in the Finke and Acha-Orbea (2001) study 
is reported to bind the second domain of MAdCAM-1 and does not block MAdCAM-1 
dependent binding in vitro (Streeter et al., 1988a). 
In the experiments described in this chapter, the primary antibody chosen to detect 
MAdCAM-1 was shown to be very important. No positive binding to bovine Peyer's 
patch endothelial cells was observed using the monoclonal antibody specific for 
mouse MAdCAM-1 (MECA-367) and MECA-367 was shown subsequently to not 
cross-react with bovine MAdCAM-1. The monoclonal antibody for human MAdCAM-
1 (7G11) positively stained endothelial cells in bovine Peyer's patches and 
mesenteric lymph nodes, but not in bovine mammary gland tissues. In humans, 
MAdCAM-1 has several isoforms (Leung et al., 1997; Leung et al., 1996; Sampaio et 
al., 1995; Schiffer et al., 1995) and this may also be the case in the cow. An antibody 
that recognises MAdCAM-1 in Peyer's patches and mesenteric lymph nodes may not 
necessarily detect MAdCAM-1 in the mammary gland if the proteins are expressed 
as different variants in the different tissues. On the other hand, in the mouse, MECA-
367 was used to detect MAdCAM-1 in both the Peyer's patch and the mammary 
gland (Abitorabi et al., 1996). In a bovine study, the human MAdCAM-1 monoclonal 
antibody 7G11 positively detected MAdCAM-1 in Peyer's patches, mesenteric lymph 
nodes and nasal/pharyngeal regions (Rebelatto et al., 2000). Therefore, overall it 
would seem reasonable to assume that 7G11 would detect MAdCAM-1 in the bovine 
mammary gland if it were present. 
Timing at which the tissue samples were taken from the bovine mammary gland is 
one possible explanation for the failure to detect MAdCAM-1. The cows were 33 -
34 weeks pregnant when sampled for the pregnant phase, which is during the last 
quarter of gestation. However, in comparison, mice sampled on Day 12 
approximately half way through their pregnancy had significant MAdCAM-1 
expression in the mammary gland (Tanneau et al., 1999; Van der Feltz et al., 2001 ). 
Peak MAdCAM-1 expression in the murine mammary gland was just prior to 
parturition and declined as lactation progressed. Therefore, it could be expected that 
if MAdCAM-1 was expressed in bovine mammary tissues, it would be apparent in 
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colostral phase tissues collected two days post-partum. However, no MAdCAM-1 
was detected in these tissues. 
To verify the finding that MAdCAM-1 was absent from the bovine mammary gland, 
RT-PCR studies were used to look at mRNA expression in these tissues. The 
methodology was difficult to establish because the DNA sequence for bovine 
MAdCAM-1 is unknown. The failure of initial primer sets was probably due to species 
differences in the MAdCAM-1 sequence. MAdCAM-1 homologues are very 
divergent, although sequence comparisons demonstrate that the first two 
immunoglobulin-like domains, at 57%, are the most highly conserved regions of 
these receptors (Briskin et al., 1993). The mucin regions are the most highly 
divergent of the MAdCAM-1 homologues (Shyjan et al., 1996). Because the 
monoclonal antibody for human MAdCAM-1 was more successful at recognising 
bovine MAdCAM-1, the sequence for human MAdCAM-1 was used initially for design 
of primer sets. These primers did not work, probably due to different species 
encoding proteins using different DNA bases. A successful primer set was finally 
designed from an EST DNA sequence located in the TIGR cattle database by 
blasting the database with the human MAdCAM-1 sequence. However, as these 
primers did not span intron-exon regions of the DNA sequence, there remained the 
potential to amplify contaminating genomic DNA in the mRNA samples. 
MAdCAM-1 mRNA expression was detected in mammary gland alveolar tissues, 
although the resulting RT-PCR products only showed weak bands on agarose gel 
electrophoresis. Quantification by real-time PCR demonstrated that the level of 
MAdCAM-1 mRNA was 4.7 - 9.1 x 103- fold less in bovine mammary gland tissues 
than in bovine Peyer's patch tissues. 
Together the failure to detect MAdCAM-1 in bovine mammary gland tissues by 
immunohistochemistry and the very low apparent expression of MAdCAM-1 mRNA in 
these tissues, strongly suggests that MAdCAM-1 is present at only low levels and is 
not involved in recruitment of lymphocytes to the bovine mammary gland. 
In contrast to MAdCAM-1, the vascular addressin VCAM-1 was detected in mammary 
tissues, staining both larger venules that also stained positively for vWF and also the 
perimeter of alveoli, an area which did not stain positively for vWF. This finding was 
similar to that observed in the mouse by Finke and Acha-Orbea (2001 ). Tanneau et 
al. (1999) also observed staining of larger venules in mammary gland tissues by 
VCAM-1 but noted its absence on mammary gland capillaries (where extravasation 
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of lymphocytes occurs) and concluded that VCAM-1 was not involved in lymphocyte 
recruitment into the mammary gland. The same conclusion must be drawn for the 
VCAM-1 expression on the larger venules in the bovine mammary gland, that it is not 
involved in lymphocyte recruitment. 
Of interest is the VCAM-1 staining observed on the periphery of the alveoli. This was 
not seen by Tanneau et al. (1999) but a similar observation was reported by Finke 
and Acha-Orbea (2001 ). This result suggests that VCAM-1 was expressed on either 
the epithelial cells or alveoli capillaries. However, no conclusion can be drawn either 
way from data to hand. The expression of VCAM-1 in these areas was phase 
dependent. It was evident in colostral tissues where all four individual animals gave 
positive results, whereas it was absent in the pregnant, lactation and involution 
phases. The pronounced expression in the colostral phase may suggest that VCAM-
1 has a role in the active migration of cells into colostrum and thereby cells are 
transferred to the neonate for uptake prior to gut closure (Liebler-Tenorio et al., 
2002). Overall, the pattern of VCAM-1 expression suggests that the VCAM-1 is not 
constitutive to the mammary gland but activated by physiological events. 
PNAd was not detected in the alveolar or cisternal mammary tissues but was present 
in the SMLN. This finding is similar to reports in literature reviews (Butcher et al., 
1999; Picker, 1994 ), that PNAd is largely expressed in peripheral lymph nodes, 
indicative that the role of PNAd recruiting na·1ve lymphocytes to inductive sites is 
similar in the ruminant to that of other species. In addition to PNAd, VCAM-1 
expression was also found in the SMLN. This was not only on large venules similar 
to the VCAM-1 expression found in mammary tissues and also on small venules. 
This suggests that VCAM-1 may have a role in recruiting lymphocytes to the bovine 
SMLN. Dual expression of cell-adhesion molecules in lymph nodes has been 
reported by others (Csencsits et al., 2002; Rebelatto et al., 2000). 
Analysis of the expression of lymphocyte cell-adhesion molecule receptors was 
limited to 137 integrin and L-selectin due to reagent availability. The absence of 
lymphocytes expressing 137 in any of the mammary tissues suggested that there were 
no lymphocytes present that would bind to MAdCAM-1. This finding was in direct 
contrast to the paper reporting high levels of this cell-adhesion molecule receptor on 
milk lymphocytes from dairy cows infected with Johnes disease (Harp et al., 2004). 
Although this paper claimed to detect a4137, the monoclonal antibody they used was 
only directed against the 137 chain of the molecule, similar to the monoclonal antibody 
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used in the studies in this thesis. Therefore, the lymphocytes in the milk could have 
been expressing either a4P7 or aEp7, as a4 and aE alpha chains both associate 
with p7. The aEp7 integrin mediates binding of T cells to epithelial cells via the cell-
adhesion molecule, E-cadherin (Cepek et al., 1993). T lymphocytes infiltrating 
inflamed epithelium, including salivary and mammary glands, express aEP7 (Cerf-
Bensussan et al., 1988; Kruschwitz et al., 1991). In the mouse study by Tanneau et 
al. (1999), 60% of the T lymphocytes in the mammary gland were characterised as 
aEP7 positive and these were situated in the epithelium. It is very possible that the 
p7-positive lymphocytes detected in the milk of the chronically diseased cows were 
actually aEp7, not a4p7 as reported. 
The cow does not naturally secrete high levels of lgA in mammary secretions. As 
discussed above, the cow may not express MAdCAM-1 under normal conditions, but 
if a mucosa! lgA response is induced, then MAdCAM-1 may be detected in mammary 
gland tissues. The testing of the hypothesis that differences between the cow and 
other species for lymphocyte homing to the mammary gland may be due to 
differences in lgA secretion is described in Chapter Four, using animals immunised 
with our lgA protocol. 
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Chapter 4 
Effects of intra-mammary immunisation on 
vascular addressins and lymphocytes in the 
bovine mammary gland 
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4.1 Introduction 
The work in Chapter Four examines the cellular changes that are induced in 
mammary gland tissues by our multi-site immunisation regimen. For the induction of 
lgA production in bovine mammary secretions using our procedure, pregnant animals 
are initially primed with antigen by intra-peritoneal (IP) and intra-muscular (IM) 
immunisation. Subsequently a booster dose is given four weeks later at the IP/IM 
sites, along with antigenic challenge to the mammary gland via intra-mammary (IMM) 
immunisation. A second IMM immunisation is given two weeks later. Based on 
published literature and our own studies, I hypothesised in the proposed mechanism 
of lgA production (Section 1.5.3.3) that IMM immunisation stimulates the mammary 
gland to recruit lymphocytes of gut-associated lymphoid tissue (mucosal) origin, 
generated by the IP/IM priming. 
In the ruminant mammary gland the gut-mammary axis, where lymphocytes traffic 
between mucosal inductor and effector sites, appears to be under-developed 
(Watson and Kennedy, 1981 ). This is also indicated by the observation that lgA is a 
minor immunoglobulin in ruminant mammary secretions. lmmunoglobulin secreted 
by the mammary gland into colostrum and milk can be derived from two sources: 
either it is transported into the mammary gland via the blood, or the immunoglobulin 
is locally produced in the gland. For example, in the untreated cow, lgG1 is derived 
directly from the blood into the mammary gland by active transport (Dixon et al., 
1961 ). Earlier studies have indicated that the lgA antibody induced by our 
immunisation regimen is locally produced (Hodgkinson and Hodgkinson, 2003). 
When one side of the udder was immunised and not the other side, then increased 
levels of lgA were only found in the colostrum and milk from the immunised gland. 
This strongly suggests that IMM immunisation activates local mechanisms in the 
immunised gland to induce this response, for example, by recruitment of lymphocytes 
to the gland, because to have local lgA production in the mammary gland it is 
essential to have immune cells in the same locality. 
In the mouse mammary gland, there is no requirement for antigenic stimulation to 
recruit lymphocytes. T-cell migration to the mammary gland has been shown to rise 
during late pregnancy and fall during lactation while plasma-cell numbers increase 
during late pregnancy and the rise continues to mid-lactation when it falls (Tanneau 
et al., 1999; Weisz-Carrington et al., 1977). These plasma cells are predominantly 
lgA. In the ruminant, studies investigating the lymphocyte populations in non-
immunised mammary tissues have shown a variety of findings. The predominant 
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lymphocytes in the ruminant mammary gland are T cells and these are largely CD8 
(Lee et al., 1989). Some authors report low numbers of plasma cells in the ruminant 
mammary gland (Lee and Lascelles, 1970; Yurchak et al., 1971 ). Some researchers 
found numerous plasma cells that increased gradually following involution to peak 
two weeks prior to parturition (Sordillo and Nickerson, 1988b). Cells positive for the 
three immunoglobulin isotypes, lgG, lgA and lgM, are all represented in the bovine 
mammary gland although lgG is the principal isotype (Sordillo and Nickerson, 1988b; 
Yurchak et al., 1971 ). 
When the ruminant mammary gland is infected by mastitis-inducing microorganisms 
or challenged with antigen, numbers of plasma cells in mammary tissues change. In 
infected quarters, plasma-cell numbers tend to be raised compared with non-infected 
quarters although the differences have only been found to be statistically significant 
for plasma-cells of the lgM isotype (Doymaz et al., 1988; Sordillo and Nickerson, 
1988b). Studies that infused antigen into the mammary gland of sheep 
demonstrated an increased number of plasma cells in the infused gland compared 
with the non-infused gland (Lee and Lascelles, 1970; Lee et al., 1992). It was noted 
that CD8 cells were less numerous in the infused gland and there was an increase in 
CD4 cells that were closely associated with B cells (Lee et al., 1992). In one study in 
ovine mammary glands, differential migration of T and B cells was observed in an 
acute inflammatory response and attributed to different regulation of the lymphocytes 
recruitment mechanisms (Meeusen et al., 1991 ). 
In the mouse, the recruitment of circulating lymphocytes into the mammary gland has 
been shown to involve adhesion molecules expressed on vascular endothelium 
(Tanneau et al., 1999; Van der Feltz et al., 2001 ). As described in the introduction to 
Chapter Three, a few studies have examined adhesion molecule receptor expression 
on bovine milk lymphocytes while expression of vascular addressins in the ruminant 
mammary gland has not been described. In Chapter Three, lymphocyte homing 
mechanisms in the bovine mammary gland of untreated animals were investigated. 
Although there was evidence of VCAM-1 and PNAd protein expression similar to that 
seen in other species, significantly no MAdCAM-1 protein expression was observed, 
in marked contrast to findings in the mouse. The work in this chapter builds on that 
observation and investigates whether there are changes to the protein expression of 
the vascular adhesion molecules in the bovine mammary gland when an lgA 
response is induced in the gland using our multi-site immunisation procedure. 
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4.2 Aim and approach 
The aim of the work in this chapter was to characterise the effects induced in the 
mammary gland by our multi-site immunisation regimen and in particular the intra-
mammary (IMM) immunisations. To achieve this, pregnant cows were immunised 
with only one side of the udder receiving the IMM immunisations. Both short-term 
and long-term effects in the mammary gland were investigated. The short-term 
effects being those observed seven days after the 2nd IMM immunisation in the 
pregnant animal and the long-term effects being those observed approximately 12 
weeks after the 2nd IMM immunisation, in the lactating animal. The long-term effects 
were studied because it had been noted that cows immunised using our regimen 
continued to secrete elevated levels of lgA for an extended time into lactation 
(unpublished data}, many months after they had received the last immunisation. 
The two main areas of investigation were: 
• to identify the effects of the IMM immunisation on the expression of the 
vascular addressins, MAdCAM-1, VCAM-1 and PNAd 
• to identify the effects of IMM immunisation on T and B cell populations 
The first objective of this work was to immunise eight pregnant cows using our 
immunisation regimen and collect mammary tissue samples. In these studies only 
one side of the udder was immunised, with the other non-immunised side acting as a 
control. Alveolar and cisternal tissues and supramammary lymph nodes (SMLN) 
were collected at two different time points following the immunisation schedule: 
• seven days following the 2nd IMM immunisation, in pregnant cows 
• approximately 12 weeks after the 2nd IMM immunisation, in lactating cows 
from both the immunised and control sides of the udder. To test the response to 
immunisation, samples of mammary secretion were also collected from the 
immunised animals and analysed for titres of antigen-specific antibody. 
The second objective of this work was to develop immunohistochemical methodology 





The third objective of this work was to use immunohistochemical methodologies to 
analyse the collected tissue samples for: 
• vascular addressin expression on endothelial cells 
• vascular addressin receptor expression on lymphocytes 
• numbers of T cells 
• numbers of isotype-specific plasma cells 
In addition, to verify and quantify the expression of MAdCAM-1 mRNA in the 
mammary glands, alveolar tissue samples were further analysed by real-time PCR, 




Primary antibodies used in immunohistochemical methods are listed in Table 3.1 and 
Table 4.1. 
Table 4.1 Primary antibodies for immunohistochemistry 
Target Host Cellular expression Product code Supplier 
antigen 
Bovine lgA Rabbit lgA-positive cells A10-108A Bethyl 
Bovine lgG Sheep lgG-positive cells A10-118P Bethyl 
Bovine lgM Rabbit lgM-positive cells A10-100A7 Bethyl 
Reagents used for the detection of the primary antibodies are listed in Table 3.2. 
The antibody specific for bovine lgG was directly conjugated to horse-radish 
peroxidase and did not require a secondary antibody. 
4.4 Methods 
4.4.1 Immunisation procedure 
Eight healthy multiparous pregnant cows of mixed Friesian and Jersey breeds were 
immunised using our multi-site regimen (Hodgkinson and Hodgkinson, 2003) as 
outlined in Section 2.2.1. The immunisation schedule is outlined in Table 4.2. 





IP - intra-peritoneal 
IM - intra-muscular 












The initial immunisation was 13 weeks before the group's averaged estimated 
calving date. For these studies, both quarters of the right side of the udder were 
immunised. The two quarters on the left side of the udder were not immunised and 
acted as a control for each individual animal. 
4.4.2 Sample collection and preparation 
Four pregnant cows were sacrificed seven days following the 2nd IMM immunisation, 
approximately five weeks prior to calving. The four lactating cows were sacrificed 
approximately 12 weeks after the 2nd IMM immunisation, five weeks following calving. 
Cows were slaughtered at the Ruakura abattoir and mammary glands excised for 
dissection. Tissue samples were collected from the immunised side of the udder and 
the control (non-immunised) side. The tissues were sampled from alveolar and 
cisternal areas, and the supramammary lymph nodes (SMLN). 
Tissue samples for immunohistochemical analysis were processed and frozen as per 
the protocol outlined in Section 2.2.2.1 and serial sections were cut from these tissue 
samples as described in Section 2.2.3.1 and Section 2.2.3.2. Alveolar tissue 
samples for plasma-cell analysis were processed differently, as described in Section 
4.4.3.1 below. Tissues samples for real-time PCR were processed as per the 
protocol outlined in Section 2.2.2.1. 
Samples of (dry) mammary secretions were collected from the immunised and 
control glands of the pregnant cows on the day prior to slaughter, six days after the 
2nd IMM immunisation. For the lactating cows, mammary secretions were collected 
from the whole udder on the first and seventh day after calving. In addition, during 
established lactation, milk samples were collected separately from the immunised 
and control quarters of these cows on two occasions, three and five weeks after 
calving. Samples were processed as per the protocol outlined in Section 2.2.2.2 and 
stored at -20°C. 
4.4.3 lmmunohistochemistry 
4.4.3.1 Development of immunohistochemical protocol for plasma cells 
In the Chapter Three the development of protocols for the measurement of plasma 
cells in frozen tissue sections had been unsuccessful. This was due to the binding of 
the primary antibody reagent to soluble immunoglobulin present in the extra-cellular 
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regions of the tissues. This produced a high non-specific background effect. To 
counteract this problem, alveolar tissue collected from the immunised animals was 
processed in two different ways and compared by immunohistochemistry to 
determine the method that produced the lowest non-specific binding effects. 
Method one: Tissue samples were cut into 10 x 10 x 2-3 mm pieces, placed into 
Tissue-Tek Unicassettes (Bayer Diagnostics) and submerged in 95% (v/v) ethanol for 
24 hat 4°C. 
Method two (Brandtzaeg P, personal communication): Tissue samples were cut into 
10 x 10 x 2-3 mm pieces, placed into Tissue-Tek Unicassettes (Bayer Diagnostics) 
and submerged in phosphate buffered saline (PBS) containing 0.01 % (w/v) sodium 
azide for 24 h at 4°C, with gentle mixing. Cassettes were then transferred to a 
solution of 95% (v/v) ethanol for 24 h at 4°C. 
The fixed tissues from both methods were processed overnight in a Leica 
JungTP1050 fully enclosed vacuum tissue processor (Cambridge Instruments) 
following the protocol in Table 2.3. The tissues were then embedded in paraffin 
blocks, as described in Section 2.2.2.1. 
Paraffin-embedded tissues were sectioned and mounted on slides, as described in 
Section 2.2.3.2. Prior to immunostaining, the slides were deparaffinised and 
rehydrated, as outlined in Table 2.4. Tissue sections were immunostained according 
to the general protocol described in Section 2.2.3.3. Primary antibodies specific for 
bovine lgA, lgG and lgM were titrated to determine the optimal concentration for use, 
using a dilution series of 1:100, 1:500, 1:1 000, 1:5 000, and 1:10 000. The optimal 
concentration for lgA- and lgM-specific antibodies was found to be 1 :500 and for lgG 
it was 1 :5 000. 
A comparison between the two different processing methods determined that the 
method that washed the alveolar tissue samples in PBS for 24 h prior to fixing in 
ethanol gave the cleanest result with very little non-specific binding apparent. Tissue 
samples processed by this method were used for immunohistochemical analysis. 
4.4.3.2 lmmunohistochemical analysis 
lmmunostaining was performed on serial sections of frozen alveolar, cisternal and 
SMLN tissues collected from the immunised and control mammary glands of the four 
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pregnant cows seven days following the 2nd IMM immunisation and the four lactating 
cows five weeks after calving. Antibodies specific for the vascular addressins 
MAdCAM-1, VCAM-1 and PNAd were used to identify their presence and distribution 
in the mammary gland. Vascular endothelial cells were identified by immunostaining 
with an antibody specific for von Willebrand factor (vWf), an antigen expressed on 
vascular endothelium. 
A semi-quantitative subjective measure of vascular addressin expression was made 
by a visual comparison of the vascular endothelium stained by the addressins and 
the vascular endothelium stained for vWf. The level of expression of vascular 
addressins was expressed as a proportion of venules stained for vWf that also 
stained for addressins. Expression was graded from O - 4: 0 = no addressin 
expression; 1 = 1 - 25% venules stained with addressin that stained with vWf; 2 = 25 
- 50%; 3 = 50 - 75%; 4 = 75 - 100%. 
Serial sections of the alveolar and cisternal frozen tissues analysed for vascular 
addressins were also immunostained with the following antibodies to identify the 
lymphocyte subsets present in the mammary gland: 
• CD3, CD8 - T-cell subsets 
• 882 - pan B-cell population 
• CD62L - counter receptor expressed on lymphocytes for PNAd 
• p7 - counter receptor expressed on lymphocytes for MAdCAM-1 
(NB: p7 detection does not distinguish between a4p7 and aEP7) 
• There was no analysis for CD4 because the assay could not be validated 
Serial sections of ethanol-fixed paraffin-embedded alveolar tissues collected at both 
time points from the immunised and control mammary glands of the experimental 
animals were immunostained with the following antibodies to identify the isotype-




Data are expressed as the average number of cells (± SEM) counted in ten random 
microscope fields at 200 times magnification. 
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4.4.4 Analysis for specific anti-C. albicans lgA in secretions 
Samples of mammary secretions collected from both the pregnant and lactating 
animals were assayed by ELISA to determine the titres of specific anti-C. albicans 
lgA, as per the protocol outlined in Section 2.2.6.1. Results were reported as titre 
units x 103 (kTU) of antibody. 
4.4.5 MAdCAM-1 quantitative real-time PCR 
The mRNA was extracted and purified from the alveolar tissues of the immunised 
and control sides of the udder of the four pregnant cows and the four lactating cows 
following the protocol outlined in Section 2.2.4.1. In addition, four samples of bovine 
Peyer's patch tissues were similarly treated. First strand synthesis of cDNA from the 
purified mRNA was performed using the protocol outlined in Section 2.2.4.2. 
To quantify the mRNA levels of MAdCAM-1 and p-actin in unknown samples, real-
time PCR was then performed using the protocol outlined in Section 2.2.4.6 with the 
primers listed in Table 3.3 and annealing temperatures of 65°C and 60°C for 
MAdCAM-1 and p-actin, respectively. Five 10-fold serial dilutions of PCR products 
for MAdCAM-1 and p-actin (see Section 3.4.4.1) were also analysed by real-time 
PCR to determine the efficiency of the reaction and to calculate the relative quantity 
of mRNA in unknown samples, as described in Section 2.2.4.6. The mRNA levels of 
MAdCAM-1 in unknown samples were reported relative to the mRNA levels of P-
actin. This adjusted for any variation in the quantity of total mRNA used for each 
reaction. The relative expression levels of MAdCAM-1 in the different alveolar 
mammary tissue samples and Peyer's patch tissues were compared. 
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4.5 Results 
4.5.1 lmmunohistochemical characterisation of vascular addressin 
expression in the immunised mammary gland 
The immunohistochemical characterisation of MAdCAM-1, VCAM-1 and PNAd 
protein expression in immunised mammary gland samples is described in the 
sections below. Alveolar, cisternal and SMLN tissues were sampled from immunised 
and control sides of the udder of the four pregnant cows (seven days following the 
2nd IMM immunisation) and the four lactating cows (five weeks post-parlum). 
4.5.1.1 MAdCAM-1 
No MAdCAM-1 expression was detected on the vascular endothelium in any of the 
mammary tissue samples tested. No difference was observed between the 
immunised and control mammary glands in the samples from either the pregnant or 
the lactating animals. Bovine Peyer's patch tissue, included as positive control 
tissue, always immunostained positively for MAdCAM-1. 
4.5.1.2 VCAM-1 
There was a variation in the numbers of animals in each of the groups that expressed 
VCAM-1 in mammary tissues and this ranged from 2/4 - 4/4 (see Table 4.3). 
However, there was no significant difference between the different types of tissues 
for the number of animals that expressed VCAM-1. 
Table 4.3 VCAM-1 expression in the mammary gland of immunised cows 
The number of immunised cows expressing VCAM-1 in alveolar, cisternal and 
supramammary lymph node tissues: comparison of immunised and control tissues 
collected at two time points following the 2"d intra-mammary immunisation. 
Interval after 2nd Mammary gland Proportion of animals per group 
IMM immunisation treatment expressing VCAM-1 
Alveolar Cistemal SMLN 
7days Immunised 4/4 3/4 4/4 
7days Control 3/4 3/4 3/4 
- 12 weeks Immunised 4/4 4/4 2/4 
- 12 weeks Control 2/4 2/4 2/4 
SMLN - supramammary lymph node 
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The proportion of VCAM-1 staining compared with vWf staining is shown in Figure 
4.1 for all tissues collected seven days after the 2nd IMM immunisation from the 
pregnant group and five weeks after calving from the lactating group. Expression 
was graded as described in Section 4.4.3.2. 
Positive staining for VCAM-1 in the alveolar and cisternal mammary tissue samples 
was on larger venules that were also positively stained for vWf. In these samples, 
VCAM-1 was expressed on 25 - 100% of the vascular endothelium that also stained 
positive for vWf. The positive staining for VCAM-1 around alveoli, reported in 
Chapter Three in the colostral phase group of the untreated cows, was not apparent 
in any of the tissues samples collected from the immunised pregnant cows seven 
days or the immunised lactating cows, approximately 12 weeks following the 2nd IMM 
immunisation. 
VCAM-1 expression was detected in SMLN tissue samples on both large and small 
venules that also stained positively for vWf. In SMLN tissue samples, VCAM-1 was 
expressed on 25 - 75% of the vascular endothelium that also stained positive for 
vWf. 
There was no significant statistical difference in the expression of VCAM-1 for any of 
the tissue types when the immunised and control mammary glands were compared. 
4.5.1.3 PNAd 
No PNAd was detectable in alveolar or cisternal tissue samples collected seven days 
after the 2nd IMM immunisation from the pregnant group and five weeks post-partum 
later from the lactating group, irrespective of whether or not the gland was 
immunised. This result was similar to that found for the untreated cows at different 
physiological stages of the mammary gland, in Chapter Three. 
Positive staining was seen in the SMLN samples of all the cows from both the 
immunised and control sides of the udder collected at the two time points. PNAd 
expression ranged from 25 - 75% of the endothelial venules that were also positively 
stained for vWf. The proportion of PNAd staining compared with vWf staining is 
shown in Figure 4.2 for the different groups. Expression was graded as described in 
Section 4.4.3.2. There was no significant difference for PNAd staining in SMLN 
tissues between the immunised and control sides of the udder or between the 
pregnant and lactating groups. 
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Figure 4.1 Proportion of endothelial venules in the mammary gland tissues of 
immunised cows that stained positive for both VCAM-1 and vWf 
Tissues were collected from the immunised and control mammary glands seven days 
after the 2nd IMM immunisation from the pregnant animals and five weeks post-
partum from the lactating animals. Expression was graded from O - 4: 0 = no VCAM-
1 staining; 1 = 1 - 25'Yo venules stained with VCAM-1 that stained with vWf; 2 = 25 -










Pregnant Pregnant Pregnant Lactating Lactating Lactating 
alveolar cisternal SMLN alveolar cisternal SMLN 
• Immunised 
D Control 
SMLN - supramammary lymph node 
Figure 4.2 Proportion of endothelial venules in the supramammary lymph node of 
immunised cows that stained positive for both PNAd and vWf 
Tissues were collected from the immunised and control mammary glands seven days 
after the 2nd IMM immunisation from the pregnant animals and five weeks post-
partum from the lactating animals. Expression was graded from O - 4: 0 = no PNAd 
staining; 1 = 1 - 25'Yo venules stained with PNAd that stained with vWf; 2 = 25 - 50%; 
3 = 50 - 75'Yo; 4 = 75 - lOO'Yo. (Group average± SEM, n = 4) 
4 
~ 












4.5.2 lmmunohistochemical characterisation of lymphocytes in the 
immunised mammary gland 
Alveolar and cisternal tissue samples of the immunised and control mammary glands 
of the four pregnant cows and the four lactating cows were also analysed by 
immunohistochemistry for the lymphocytes subsets: CD3, COB, 882, CD62L and p7. 
Data are expressed as the average number of cells (± SEM) counted in ten random 
microscope fields at 200 times magnification. 
4.5.2.1 CD3- and CDS-positive cells 
T lymphocytes were found predominantly in the interstitial spaces between the 
alveoli. Illustrations of the staining of T-lymphocyte subsets CD3 and COB, in frozen 
alveolar tissue sections sampled from immunised and control mammary glands of 
pregnant animals seven days after the 2nd IMM immunisation, are shown in Figure 
4.3. 
The average numbers of CD3- and COB-positive cells in the alveolar and cisternal 
tissues from the immunised and control mammary glands, collected seven days after 
the 2nd IMM immunisation, are shown in Table 4.4. Group average numbers of both 
CD3- and COB-positive cells were higher in the immunised mammary tissues 
compared with the control tissues except in the cisternal tissues where COB-positive 
cell numbers for the control and immunised tissues were similar. 
Table 4.4 Comparison of T-cell numbers in immunised and control mammary 
glands, seven days after the 2"d intra-mammary immunisation 
Group T-cell numbers (average :!: SEM, n = 4): cell counts from 10 random 
microscope fields of tissue section from each sample, at x 200 magnification. 
Significant statistical differences between immunised and control tissues are 





12. 7 ± 2. 1 *** 
9.8 ± 2.5** 
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2.7 ± 0.8 




8.9 ± 2.1* 
2.6 ± 0.7 
Control 
3.7±1.1 
3.8 ± 0.9 
Figure 4.3 Representative illustration of immunohistochemical staining of CD3-
and CDS-positive cells in frozen alveolar bovine mammary gland 
tissues, seven days after the 2"d intra-mammary immunisation 
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T-cell data for the alveolar mammary tissue samples from individual pregnant 
animals are shown in Figure 4.4. There were higher numbers of C03-positive cell 
numbers observed in the immunised mammary glands compared with the control 
mammary glands for all four pregnant animals and this was statistically significant (p 
< 0.001 ). Only two of the four animals had higher numbers of COB-positive cells in 
immunised mammary glands compared with control mammary glands (p < 0.01 ). 
One animal (2907) had three-fold higher T-cell numbers in immunised tissue 
compared with the other animals in the group and the numbers of T cells in control 
tissues of 2907 were similar to the numbers in immunised tissues for the other 
animals. This difference was observed for both C03- and COB-positive cells. 
Figure 4.4 Analysis of immunohistochemical staining of CD3- and CDS-positive 
cells in frozen alveolar bovine mammary tissues, seven days after the 
2"d intra-mammary immunisation 
Cell counts from random microscope fields of tissue sections from individual animals 
(Average ± SEM; n = 10; x 200 magnification). Significant statistical differences 
between the immunised and control glands are marked (** p < 0.01; *** p < 0.001). 
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The numbers of CD3- and CDS-positive cells in the tissues collected from the 
lactation group (five weeks post-partum) tended to be lower than that found in the 
pregnant animals. The average was 1 - 2 cells per microscope field in the alveolar 
and cisternal tissue sections for three of the animals. Similar to the finding in the 
pregnant group, one animal (2902) in the lactation group had higher T-cell counts 
than the other animals but this was only in the immunised alveolar tissue sample. 
For this animal, the average number of cells per microscope field was 13.0 ± 2.1 and 
10.6 ± 2.2 for CD3 and CD8, respectively. In this animal, comparison of the 
immunised and control alveolar tissue sample for CD3 and CD8 showed a significant 
difference (p < 0.001 ). There was no significant difference between the immunised 
and control tissue samples for the other animals in the lactation group (data not 
shown). 
4.5.2.2 CD62L-positive cells 
Table 4.5 shows a comparison of the group average numbers of CD62L-positive cells 
(± SEM) in immunised and control mammary glands collected from the pregnant 
cows seven days after the 2nd IMM immunisation and the lactating cows five weeks 
after calving. 
Table 4.5 Comparison of CD62L-cell numbers in immunised and control mammary 
glands at intervals following the 2"d intra-mammary immunisation 
Group CD62L-cell numbers (average ± SEM, n = 4): cell counts from 10 random 
microscope fields of tissue section from each sample, at x 200 magnification. 
Interval after Alveolar tissue Cistemal tissue 
2"d IMM 
immunisation 
Immunised Control Immunised Control 
7days 1.03 ± 0.37 0.13 ± 0.05 0.60 ± 0.17 0.65 ± 0.38 
- 12 weeks 2.25±0.18 0.83 ± 0.95 0.13±0.20 0.40 ± 0.07 
Low numbers of CD62L-positive cells were detected in all alveolar and cisternal 
mammary gland tissues and there was no significant difference between immunised 
and control tissues at the two time points sampled. 
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4.5.2.3 P7-positive cells 
There was no evidence of cells staining for p7 in any of the alveolar and cisternal 
mammary tissue sections at the two different time points, irrespective of whether or 
not the gland had been immunised. There was positive staining of cells with p7 
antibody in all samples of Peyer's patch tissues, used as an assay positive control. 
4.5.2.4 882-positive cells 
There was no observation of cells that stained positively for BB2 in any of the 
alveolar and cisternal mammary tissue sections at the two different time points, 
irrespective of whether or not the gland had been immunised. Cells in Peyer's patch 
tissues, used as an assay positive control, always stained positive with BB2 antibody. 
4.5.3 lmmunohistochemical characterisation of plasma cells in the 
immunised mammary gland 
Alveolar tissue samples collected from immunised and control mammary glands of 
the four pregnant cows seven days after the 2nd IMM immunisation and the four 
lactating cows five weeks post-partum were analysed by immunohistochemical 
methods for the plasma-cell isotypes: lgA, lgM and lgG. Plasma cells tended to be 
located in the interstitial spaces between alveoli although many were also located in 
the alveolar or ductal lumen. Positively staining cells were also detected in the 
alveoli or ductal epithelium wall. 
A small number of the plasma cells were observed to have double nuclei. These 
cells with double nuclei stained predominantly for lgA and lgM. Illustrations of lgA-
positive cells in different locations in alveolar tissue of the immunised mammary 
gland seven days after the 2nd IMM immunisation are shown in Figure 4.5. 
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Figure 4.5 Representative illustration of immunohistochemical staining of IgA-
positive cells (in various locations) in ethanol-fixed paraffin-
embedded alveolar bovine mammary gland tissues, seven days after 
the 2nd intra-mammary immunisation 
Plasma cells in interstitial spaces Plasma cells in the lumen 
• 
Plasma cells in the epithelial wall Plasma cells with double nuclei 
• • 
Red solid bar is lOµm 
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4.5.3.1 lgA-positive plasma cells 
lgA-positive cells were detected in the tissues of the immunised mammary glands of 
the pregnant animals. Illustrations of ethanol-fixed paraffin-embedded alveolar tissue 
sections from immunised and control mammary glands, stained with specific bovine 
lgA antibody, are shown are Figure 4.6. The group average for lgA-positive cells per 
random microscope field (200 x magnification) was 5.2 ± 0.8 in the immunised glands 
compared with 1.3 ± 0.3 lgA-positive cells in the control glands. The variation for the 
numbers of lgA-positive cells between the individual animals can be seen in Figure 
4.7. The average number of lgA-positive cells in the immunised glands was 
significantly higher compared with the control glands for three of the four animals in 
the pregnant group (2907, p < 0.01; 2904 and 2905, p < 0.001 ). 
Figure 4.6 Representative illustration of immunohistochemical staining of IgA-
positive cells in ethanol-fixed paraffin-embedded alveolar bovine 
tissues from immunised and control mammary glands, seven days 
after the 2"d intra-mammary immunisation 
lgA/immunised tissue lgA/control tissue 
Black solid bar is lOOµm 
lgA-positive cells in ethanol-fixed paraffin-embedded alveolar tissue sections of the 
lactation group, collected five weeks post-partum, were undetectable in both 
immunised and control glands. 
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Figure 4.7 Analysis of immunohistochemical staining of IgA-, IgM- and IgG-
positive cells in ethanol-fixed paraffin-embedded alveolar bovine 
mammary gland tissue, seven days after the 2"d intra-mammary 
immunisation 
Cell counts from random microscope fields for individual animals (Average:!: SEM: n = 
10; magnification x 200). Statistically significant differences between the 
immunised and control glands are marked (* p < 0.05; ** p < 0.01; *** p < 0.001) 
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4.5.3.2 lgM-positive plasma cells 
Illustrations of ethanol-fixed paraffin-embedded alveolar tissue sections from 
immunised and control mammary glands of the pregnant animals, stained with 
specific bovine lgM antibody, are shown in Figure 4.8. In alveolar tissues collected 
from the four pregnant animals seven days after the 2nd IMM immunisation, the group 
average lgM-positive cells per random microscope field (200 x magnification) was 3.4 
± 0.4 in the immunised glands and 1.3 ± 0.3 in the control glands. The variation for 
the individual animals showed a similar pattern to that observed for the lgA-positive 
cells (Figure 4.7). The average numbers of lgM-positive cells in the immunised 
glands were significantly higher than control glands for three animals (2904, 2905 
and 2907) in the pregnant group (p < 0.01 ). 
Figure 4.8 Representative illustration of immunohistochemical staining of IgM-
positive cells in ethanol-fixed paraffin-embedded alveolar bovine 
tissues from immunised and control mammary glands, seven days 
after the 2"d intra-mammary immunisation 
lgM/immunised tissue lgM/control tissue 
• 
• 
Black solid bar is lOOµm 
Few lgM-positive cells were observed in the alveolar mammary tissues collected from 
the lactation group five weeks post-partum. One or two cells were detectable in a 
few of the microscope fields, but generally no lgM-positive cells were visible. There 
was no apparent difference in the average numbers of lgM-positive cells between the 
immunised and control glands in the lactation group. 
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4.5.3.3 lgG-positive plasma cells 
In the alveolar tissues collected from the four pregnant animals seven days after the 
2nd IMM immunisation, the group average lgG-positive cells per random microscope 
field (200 x magnification) was 8.6 ± 0.7 for the immunised glands and 2.8 ± 0.7 for 
the control glands. Illustrations of ethanol-fixed paraffin-embedded alveolar tissue 
sections from immunised and control mammary glands, stained with specific bovine 
lgG antibody, are shown in Figure 4.9. There was less variation for the average 
number of lgG-positive cells between individual animals for the immunised glands, 
compared with lgA- and lgM-positive cells (Figure 4.7). The average numbers of 
lgG-positive cells in the immunised glands were significantly higher than control 
glands for three of the four animals in the pregnant group (2904 and 2907, p < 0.01; 
2905, p < 0.001 ). 
Figure 4.9 Representative illustration of immunohistochemical staining of IgG-
positive cells in ethanol-fixed paraffin-embedded alveolar bovine 
tissues from immunised and control mammary glands, seven days 
after the 2"d intra-mammary immunisation 
lgG/immunised tissue lgG/control tissue 
Black solid bar is lOOµm 
Similar to the other isotypes, there were very few lgG-positive cells detected in the 
tissues of the lactation group collected five weeks post-partum, and there was no 
apparent difference between immunised and control glands. 
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4.5.3.4 Other cell types 
Macrophages and neutrophils that positively stained with isotype-specific antibody 
were also detected in the ethanol-fixed paraffin-embedded alveolar tissue sections of 
the pregnant immunised animals. These cells were generally located in the alveolar 
or ductal lumen. These cells were most prevalent in the immunised tissue samples 
and animal 2907 had the highest number compared with all the other animals. 
These cells stained positively both for lgA and lgG. 
4.5.4 Antigen-specific lgA levels in mammary secretions 
Collecting secretion samples from the control gland of pregnant animals proved to be 
difficult. Secretion volumes from these glands were low and samples very viscous. 
In contrast, samples from the immunised glands of the pregnant group were copious 
and watery. No secretions could be collected from either the control or immunised 
glands of Cow 2906. 
Assays for specific anti-C. albicans lgA in samples of mammary secretions found 
Cow 2904 and 2905 had higher titres of antigen-specific antibody compared with 
Cow 2907 (0.9, 1.6 and 0.01 kTU, respectively). Samples from the control glands of 
the pregnant animals were not suitable for assay. 
Titres of specific anti-C. albicans lgA for colostrum and milk samples collected from 
the lactation group are shown in Table 4.6. Samples for the first and seventh day 
after calving were collected from the whole udder, although only the one side of the 
udder had been immunised. Three animals responded to the immunisation regimen 
with high titres of antigen-specific lgA. One animal (2903) responded poorly to the 
immunisation process and had low titres of antibody, even on the first day after 
calving. The milk samples for Week 3 and Week 5 were collected separately for the 
immunised side of the udder and the control side. Milk collected from the immunised 
side of the udder had very high titres of antigen-specific antibody compared with the 
control side and this difference was statistically significant (p < 0.01 ). 
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Table 4.6 Titres of specific anti-C. a/bicansigA (kTU) in colostrum/milk 
samples for individual cows in the lactation group 
Samples were collected from the whole udder on days one and seven after calving. 
In established lactation, samples were collected separately from the immunised and 
control sides of the udder three and five weeks post-partum. 
Cow Day 1 Day7 Week3 Week& 
Whole udder Whole udder Immunised Control Immunised Control 
side side side side 
2901 8.20 3.60 3.70 0.01 4.70 0.01 
2902 19.60 0.90 1.20 0.01 1.40 0.10 
2903 0.70 0.20 0.50 0.01 0.04 0.01 
2908 13.90 1.90 3.00 0.10 3.00 0.10 
kTU - titre units x 103 
4.5.5 Quantitative analysis of MAdCAM-1 mRNA in the immunised 
mammary gland 
The results of the quantitative analysis of mRNA levels of MAdCAM-1 and p-actin by 
real-time PCR, for alveolar tissues collected from the immunised and control 
mammary glands of the four pregnant cows seven days after the 2nd IMM 
immunisation and the four lactating cows five weeks after calving, are described in 
the sections below. 
The efficiency of the real-time PCR reaction for MAdCAM-1 and p-actin was 
calculated by the Lightcycler software (Roche) to be 1.848 and 1.814, respectively. 
The level of MAdCAM-1 mRNA in the alveolar tissues sampled from the immunised 
and control glands of the pregnant and lactation groups were compared with levels of 
mRNA in four different samples of bovine Peyer's patch tissue. Data reported as the 
level of mRNA of MAdCAM-1 relative to the mRNA level of p-actin are shown in 
Table 4.6. The group average value for the mammary gland tissues was divided by 
the average value for Peyer's patch tissues to obtain an expression level of 
MAdCAM-1 mRNA for mammary gland tissues relative to Peyer's patch tissues. 
These results indicate that expression of MAdCAM-1 in these bovine mammary 
alveolar tissues was very low compared with that in bovine Peyer's patch tissues. 
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The level of MAdCAM-1 mRNA in immunised tissue was approximately four-fold 
higher when compared with the level in control tissue, for both pregnant and lactation 
animals. The immunised tissues contained 0.6 x 103 - 0.7 x 103 fold lower 
MAdCAM-1 mRNA than Peyer's patch tissues (see Table 4.7), and the alveolar 
mammary gland control tissue contained 2.7 x 103 - 4.3 x 103 fold lower MAdCAM-1 
mRNA than Peyer's patch tissues (see Table 4.6). The differences between 
mammary tissues and Peyer's patch tissues were highly significant (p < 0.001 ). 
Table 4.7 MAdCAM-1 gene expression in immunised and control mammary glands 
compared with that in Peyer's patch tissues 
Level of MAdCAM-1 mRNA (relative to p-actin) in bovine Peyer's patch tissue 
compared with immunised and control (non-immunised) alveolar mammary tissue 
samples collected from pregnant animals seven days after the 2nd intra-mammary 
immunisation and from lactating animals five weeks post-partum (n = 4). 







to p-actin mRNA1 
70.380 ± 8.022 
0.166±0.030 
0.037 ± 0.027 
0.101 ± 0.049 
0.023 ± 0.014 






a. The level of MAdCAM-1 mRNA is relative to the level of p-actin mRNA in individual samples. The 
results are reported as the group average:!: SEM (n = 4). 
b. The comparison of the expression of MAdCAM-1 in the mammary gland compared with Peyer's patches 
is obtained by dividing the group average relative level of MAdCAM-1 mRNA in the mammary gland by the 
average relative level of MAdCAM-1 mRNA in the Peyer's patch samples 
* Alveolar tissue from the mammary gland 
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4.6 Discussion 
In this chapter the cellular effects induced in the bovine mammary gland by our multi-
site immunisation regimen were investigated to gain an understanding of the types of 
immune responses being activated. Introduction of antigen by infection with 
pathogenic microorganisms or by vaccination provokes an immune response in the 
body. This first line of defence is the innate-immune response, with macrophages 
producing cytokines and chemokines that induce an inflammatory response and 
infiltration of neutrophils. In addition, the innate-immune response contributes to the 
activation of adaptive-immunity where the principal cells are lymphocytes (Fearon 
and Locksley, 1996). Dependant on dendritic cell signalling (Banchereau and 
Steinman, 1998; Iwasaki and Kelsall, 1999), either a cell-mediated type response is 
initiated, where CD8 and Th1 CD4 cells have the main role, or a humoral antibody 
type response is induced where B cells and Th2 CD4 cells predominate. These two 
immune responses are not exclusive to one another and many infections stimulate 
both types of responses. 
In this study, cows received IMM immunisation only on one side of the udder so that 
differences between lymphocyte populations of immunised and control glands could 
be compared. The data indicate that the intra-mammary (IMM) immunisations 
induced an increase in T cells in the immunised mammary glands. For example, in 
the pregnant group seven days after the 2nd IMM immunisation, there was a 
significant increase in CD3-cell numbers in the immunised glands compared with 
control glands (Group average± SEM; 12.7 ± 2.1 compared with 2.7 ± 0.8). CD4-
positive cells were not directly measured, however, others have reported that the 
total numbers of T lymphocytes in the mammary gland equate to the sum of CD4 and 
CD8 cells (Yamaguchi et al., 1999). Therefore, the observation of a similar number 
of CD3- and CDS-positive cells in control alveolar tissues suggests that the majority 
of the T cells were CD8. Conversely, in the immunised alveolar tissue a lower 
number of CDS-positive cells found compared with numbers of CD3-positive cells 
suggests a greater proportion of CD4-positive cells in the immunised side compared 
with the control side of the udder. Overall, both CD4- and CDS-cell numbers were 
increased in the immunised mammary glands seven days following the IMM 
immunisations, signifying a complex immune response was induced in the glands. 
It is of interest to note that the pregnant animal which gave the poorest lgA response 
(Cow 2907), had a different T-lymphocyte profile from the other animals in that group. 
Cow 2907 had three-fold higher numbers of CD3- and CDS-positive cells in both the 
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immunised and control alveolar tissue samples compared with the other animals. 
This animal also had T-cell numbers in the non-immunised side of the udder 
equivalent to the T-cell numbers in the immunised side of the other animals in the 
pregnant group. These T cells were predominantly CDS- not CD4-positive cells, as 
CDS numbers were similar to CD3 numbers. The reason for these elevated CDS-
positive cells in this animal is unclear but may be indicative of a sub-clinical chronic 
infection in the udder. Studies investigating mammary glands chronically infected 
with S. aureus have shown an increased number of CDS cells compared with CD4 
(Riollet et al., 2001 ). Cow 2907 also had increased numbers of macrophages and 
neutrophils compared with the other animals, which may also be indicative of an 
infectious state in the gland. 
In the lactation group low numbers of T lymphocytes were found in the mammary 
gland, irrespective of whether or not the glands had been immunised. These animals 
were sampled 12 weeks after the 2nd IMM immunisation, five weeks after calving, 
suggesting that the immune response induced by the IMM immunisation had 
subsided by the time full lactation was established, when these tissue samples were 
collected. 
In addition to the comparison of T-lymphocyte populations in immunised and control 
mammary tissue samples, plasma-cell populations were also characterised. In 
agreement with other ruminant studies (Lee and Lascelles, 1970; Yurchak et al., 
1971 ), low numbers of plasma cells were detected in the control mammary gland. In 
contrast, numbers of plasma cells were generally higher in the immunised mammary 
gland compared with the control gland, a finding similar to studies in the sheep (Lee 
and Lascelles, 1970; Lee et al., 1992). Comparison of the different isotypes of 
plasma cells in immunised tissues of the pregnant group indicated that lgA and lgM 
plasma-cell numbers varied more for individual animals, whereas the lgG plasma 
cells showed a more uniform response. This would imply that animal-to-animal 
variation in lgA response to the multi-site immunisation does not hold true for an lgG 
response, and therefore suggests that the lgA and lgG responses are activated by 
different pathways. 
In the pregnant group, the two individual cows (2904 and 2905) that had the highest 
number of lgA-positive plasma cells in their immunised alveolar tissue samples also 
had the highest titres of antigen-specific lgA. This observation suggests that there is 
a direct correlation between the number of plasma cells and the resultant lgA 
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antibody levels in mammary secretions, and warrants further analysis using a larger 
sample size. 
One cow (2906) had a greater number of lgA-positive plasma cells in the control 
alveolar tissue (2.1 ± 0.2) compared with immunised tissue (0.4 ± 0.5). This cannot 
be explained. This animal also had a higher count of lgG-positive plasma cells in the 
control mammary gland when compared with the other animals in the group. 
Unfortunately, no secretion sample was obtained from this animal for antigen-specific 
antibody analysis; and therefore, no conclusion could be made about the disparity of 
the plasma-cell response observed in this animal. The T-lymphocyte profile for this 
animal (2906) was similar to the two animals that had produced a high antigen-
specific antibody response in secretions. However, this does not necessarily indicate 
that the antibody response was high in this animal. This may simply indicate that T-
cell numbers do not necessarily correlate to lgA plasma-cell numbers. 
There were low or undetectable numbers of lgA-, lgM- and lgG-positive plasma cells 
in the mammary gland of the lactation group with no discernible difference between 
the immunised and control glands. Although the immunised glands maintained a 
persistent level of lgA secretion into milk during the lactation phase, numbers of lgA-
positive plasma cells detected in tissues cannot account for this maintenance of lgA 
antibody secretion. This is in contrast to the correlation between plasma-cell 
numbers and antibody responses seen in the pregnant group. One explanation 
could be that the individual lgA-positive plasma cells remaining in the lactating 
immunised mammary gland are more efficient and may produce greater amounts of 
antibody or antibody at an increased rate of production. 
In the study in this chapter, the effects of IMM immunisation on vascular addressin 
expression in the bovine mammary gland were also investigated. Similar to the 
findings in Chapter Three, VCAM-1 detection in the mammary gland tissues of these 
experimental animals was on larger venules that also stained positively for vWf. 
Expression of VCAM-1 was detected in more pregnant animals in the immunised 
group compared with the untreated pregnant cows analysed in Chapter Three. The 
increase in VCAM-1 expression was observed in alveolar and cisternal tissue 
samples as well as the SMLN tissues, although there was no significant difference 
between the immunised and control glands. The increase in the numbers of 
immunised pregnant animals expressing VCAM-1, compared with untreated pregnant 
animals, may reflect changes induced by the immunisation regimen, but a role for 
this increased VCAM-1 expression could not be elucidated from these experiments. 
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Another study that investigated effects of antigen challenge to regional lymph nodes 
and skin reported the presence of VCAM-1 on small venules at these sites and 
suggested that the role of VCAM-1 was recruiting memory T cells (Mackay et al., 
1992). However, no VCAM-1 expression was observed on small venules in the 
mammary gland in this study, suggesting VCAM-1 does not have a role in 
lymphocyte extravasation in the mammary gland. 
It is possible that the non-detection of VCAM-1 on smaller venules in the immunised 
mammary gland may be due to the timing of collection of tissue samples from 
pregnant cows, which occurred seven days after the 2nd IMM immunisation. If the 
trafficking of lymphocytes to the mammary gland was transient then the expression of 
VCAM-1 may also have been transient. However, a cellular immune response to 
immunisation takes time to develop. In the literature, one study in mice 
demonstrated that an initial plasma-cell response peaked at eight days after 
immunisation (Slifka et al., 1998). In another study, mice responding to a booster 
immunisation had peak levels of circulating plasma cells six to eight days after the 
immunisation (Bernasconi et al., 2002). Therefore, it would seem reasonable to 
conclude that sampling tissues in the mammary gland seven days after the 2nd IMM 
immunisation would be an ideal time. 
PNAd was not detected in the alveolar or cisternal tissues of the immunised cows, 
only in the SMLN, similar to the findings in the untreated animals in Chapter Three. 
Levels of expression of PNAd were similar for immunised and untreated cows with 
slightly lower levels in the pregnant cows compared with the lactating cows in both 
cases. There was no significant difference in PNAd expression between the SMLN 
draining the immunised and control glands. Therefore, immunising cows to induce 
an lgA response does not appear to change PNAd expression in the mammary 
gland. This would suggest that the SMLN is not activated to recruit na"ive 
lymphocytes in response to antigen challenge to the mammary gland via the IMM 
immunisation. However, this observation may also be influenced by the timing of the 
sample collection. 
In the study in Chapter Three, the key result was the absence of MAdCAM-1 
expression in mammary gland tissue samples of untreated animals. This is in direct 
contrast to findings in the mouse (Tanneau et al., 1999; Van der Feltz et al., 2001) 
but may be explained by the fact that there are major differences between the mouse 
and the cow in the expression of immunoglobulin isotypes in mammary secretions. 
The work in this chapter tested whether inducing a local lgA response in the bovine 
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mammary gland by immunisation would induce MAdCAM-1 expression in the 
mammary gland. The results presented in this chapter would suggest that MAdCAM-
1 is not involved in the trafficking of lymphocytes to the bovine mammary gland. 
Even when the mammary gland was immunised to induce lgA production, no 
mammary tissue samples from the immunised animals were found to express 
MAdCAM-1. Similar to the outcome in Chapter Three, there are several explanations 
as to why MAdCAM-1 was not detected in this study. The simple explanation is that 
there is no MAdCAM-1 expressed by the bovine mammary gland and that mucosal 
lymphocytes are recruited to the gland by other vascular addressins and/or 
chemokines. The possibility that the absence of MAdCAM-1 in tissues was due to 
timing of the collection of samples cannot be discounted, although the arguments for 
timing of collection and VCAM-1 expression discussed above, also hold true for 
MAdCAM-1. 
The eight immunised animals were na"ive and had not previously undergone the 
immunisation regimen. Our earlier studies have shown that not all cows respond to 
the lgA immunisation protocol and that there is considerable variation in responses 
between individual animals. If the cows in the pregnant group had not responded to 
the immunisation then it would not have been possible to test the hypothesis. In this 
study, secretion samples were collected from the pregnant cows the day preceding 
the tissue collection. Secretion samples analysed for antigen-specific lgA levels 
indicated that at least two of the four cows responded to the immunisation protocol. 
One of the four animals had very low levels of antigen-specific antibody and the 
remaining cow did not give sufficient sample for testing. Therefore, lgA was induced 
in at least two of the animals but there was no evidence of MAdCAM-1 expression in 
their mammary tissues. Thus the accumulating evidence suggests that MAdCAM-1 is 
not involved in lymphocyte homing to the bovine mammary gland even when the 
mammary gland is activated by antigen to induce a local lgA response. 
The immunohistochemical finding of the absence of MAdCAM-1 in mammary gland 
tissues was substantiated by the quantitative analysis of tissue for expression of 
MAdCAM-1 mRNA. Compared with bovine Peyer's patch tissues, levels of mRNA in 
bovine mammary gland tissues of immunised animals were very low. Further to this, 
no lymphocytes expressing 137 were found in any of the mammary gland tissues, 
supporting the evidence of no MAdCAM-1 expression in the immunised mammary 
gland. 
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Overall, it can be seen that the IMM immunisations induced many changes in the 
immunological environment of the mammary gland. The treatment induced marked 
changes in the lymphocyte population in immunised mammary tissues with higher 
numbers of T and differentiated B cells in the pregnant animals observed seven days 
after the 2nd IMM immunisation. These changes were not evident in the long-term 
study as there was no discernible difference between the immunised and control 
mammary tissues in the lactating animals. While the lgA-response to the IMM 
immunisations may be correlated to numbers of lgA-positive plasma cells in the 
recently immunised gland, the same correlation does not hold true for the lactating 
animal that had been immunised many weeks previously. The reason for the 
continued production of lgA in the milk could not be identified from these studies. 
Although there was no evidence of MAdCAM-1 expression, VCAM-1 levels in the 
immunised animals were elevated in comparison to the untreated animals. It must 
be remembered that these findings have been based on a small number of animals. 
Due to the variability between animals, further experiments with larger numbers of 
animals are required before any definitive conclusions may be drawn. 
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Chapter 5 
Comparison of immune responses in the 
mammary gland following immunisation of 
high- and low-responding cows 
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5.1 Introduction 
The work in Chapter Five investigates the rate of immune cells trafficking into the 
bovine mammary gland in response to intra-mammary (IMM) immunisation. The 
work in Chapter Four established that by seven days after treatment with IMM 
immunisation, there is an increase in lymphocyte n.umbers in the mammary gland. In 
this study, bovine mammary secretions are examined for changes in lymphocyte 
populations and antibody levels over an extended time course following IMM 
immunisation. 
Animals immunised with our multi-site immunisation regimen for the induction of lgA 
in mammary secretions have a variable lgA response. Earlier studies have found 
that the variability in antibody response is reproducible for individual animals. An 
animal that produces a high lgA response in its mammary secretions to the 
immunisation regimen in one year will respond in a similar way the following year 
(unpublished data). Similarly, animals that produce a low lgA response in one year 
will produce a low response to the immunisation in subsequent years. Animals that 
have been previously immunised can thus be grouped into high- and low-responding 
animals and thereby provide a unique resource for investigating the differences in 
their immune responses. In this chapter, animals that have been immunised in the 
previous two years were reimmunised and their cellular immune responses in 
mammary secretions compared. 
The differences observed in an animal's immune response to our multi-site 
immunisation regimen may be due to a number of factors, including the priming of 
lymphocytes by the initial intra-peritoneal and intra-muscular immunisation, 
differences in the efficiency of recruitment of immune cells to the mammary gland, 
and/or differences in the proliferation and differentiation of plasmablasts. Earlier 
studies have indicated that lgA antibody is produced locally in the immunised gland 
in response to our immunisation regimen (Hodgkinson and Hodgkinson, 2003). 
Antibody is only produced in the quarter of the udder that has been immunised. For 
the local production of immunoglobulin to occur, it is hypothesised that immune cells 
will be required in situ. In Chapter Four it was demonstrated that antigenic 
stimulation by IMM immunisations activates mechanisms for the recruitment of 
immune cells to the immunised gland. This was shown by increased numbers of 
lymphocytes, both T cells and B cells, in the tissues of the immunised glands 
compared with control (non-immunised) glands. 
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Many studies investigating the cellular response to IMM immunisation in the ruminant 
have utilised sheep; sacrificing the animals to collect tissue samples to characterise 
immune cells (Lee and Lascelles, 1970; Lee et al., 1992; Sheldrake et al., 1985a). 
This approach was also adopted in Chapter Four of this thesis. However, clearly for 
studies in the cow this limits the number of animals that can be used because of the 
value of the animals. Many studies looking at bovine mammary health have utilised 
mammary secretions and flow cytometry methodology to characterise T-cell and 8-
cell populations, for example, Dosogne et al., (2003), Leitner et al., (2000b) and 
Rivas et al., (2001 ). Mammary secretions from unchallenged bovine mammary 
glands show clear differences in the relative proportions of lymphocyte populations 
compared with circulating peripheral blood lymphocytes. It has been suggested that 
this difference may be associated with functional activity in the mammary gland (Park 
et al., 1992). Differences in the ratio of CD4 and CDS cells may reflect the type of 
immune response induced by pathogens in the mammary gland. During the dry 
(non-lactating) period, there is a higher percentage of CD4-positive cells compared 
with CDS-positive cells in mammary secretions. This ratio becomes inverted during 
the lactation phase (Yang et al., 1997), with the majority of CDS cells being activated 
(Park et al., 1992). The percentage of B cells in the mammary secretions is higher 
(25%) in the periparturient stage compared with the lactation phase (where it is< 5%) 
(Leitner et al., 2000b; Park et al., 1992). 
In the lactating mammary gland challenged by pathogenic antigens, the cellular 
profile of mammary secretions changes and milk leukocyte population patterns have 
been reported to be indicative of udder infections of different aetiologies (Leitner et 
al., 2000b). In the mammary gland chronically infected by S. aureus, an overall 
increase in the numbers of cells was found, with the major cell population being 
neutrophils (Riollet et al., 2001; Rivas et al., 2001). The T-lymphocyte percentage 
increased, with a greater percentage of CD8 cells recruited into the mammary gland 
in comparison with the CD4 cells (Riollet et al., 2001 ). In the mammary gland acutely 
infected with E. coli the major cell type in the milk was also neutrophils. However, the 
predominant T lymphocyte was reported to be CD4 cells (Taylor et al., 1997). 
Another study observed low percentages of T lymphocytes in acutely infected 
mammary glands compared with chronically infected mammary glands (Leitner et al., 
2000b). The proportion of B lymphocytes in milk from infected bovine mammary 
glands was low (Leitner et al., 2000b; Riollet et al., 2001 ). 
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5.2 Aim and approach 
The main aim of the work in this chapter was to characterise the change to 
lymphocyte populations in mammary gland secretions following two IMM 
immunisations. In the previous chapter, effects of IMM immunisation had been 
assessed in tissue samples taken at two time points after the 2nd IMM immunisation; 
seven days and 12 weeks. This raised the question of the best time to take samples 
to observe changes induced by the treatment. Using mammary secretions instead of 
tissues to monitor changes following the IMM immunisations allowed for multiple 
samples to be collected over an extended time interval. 
The potential issue of using na"ive animals was also highlighted in Chapter Four. If 
the relative level of response to immunisation is not known, then interpreting cellular 
changes becomes difficult. For example, finding no changes in cell counts could be 
due to there being no induced effects or simply to a poor level of response. The 
animals that were immunised in this chapter had been immunised in the two previous 
years with our multi-site regimen and each could be categorised from earlier results 
as either high- or low-responding animals. Animals were categorised using antigen-
specific antibody titres measured in milks collected seven days after parturition: an 
antigen-specific lgA greater than 2 000 titre units (2.0 kTU) was a high-responding 
animal and less than 2.0 kTU was a low-responding animal. 
The first objective of this work was to collect mammary secretions from pregnant 
(non-lactating) immunised animals before and after the IMM immunisations. To 
achieve this, eight high-responding pregnant animals and six low-responding 
pregnant animals were immunised for a third time using our multi-site immunisation 
regimen. All four quarters received the IMM immunisations. Mammary secretions 
were collected at intervals before and after the IMM immunisations, with secretions 
collected from the left side of the udder only, alternating between the front and back 
quarters. 
The second objective of this work was to analyse cells isolated from mammary 
secretions by flow cytometry to determine the percentages of lymphocyte sub-
populations: 
• T-cell sub-populations: CD4, CD8 
• Pan 8 cell: 882 
• lmmunoglobulin isotype-specific cells: lgA, lgG, lgM 
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The third objective was to test the level of antibody response of each animal. To do 
this, the mammary secretions were analysed for levels of antigen-specific and total 
lgA antibody. In addition, to assess the effects of multiple sampling of secretions 
from the left side of the udder, a comparison was made of the levels of antigen-
specific lgA antibody in colostrum samples collected from both the left and right 
quarters of the udder. Milk samples collected seven days post-partum were also 





Primary antibodies used for flow cytometry methods are listed in Table 5.1. All 
primary antibodies were used at a dilution of 1 :400. 
Table 5.1 Primary antibodies used for flow cytometry analysis 
Clone Target Cellular Expression lsotype Supplier 
antigen 
ILA-11A bovine CD4 MHC class II lgG2a wsu 
T-cell subset 
CACT80C bovine coa MHC class I lgM VMRD 
T-cell subset 
CACT116A bovine CD25 IL-2 receptor lgG1 VMRD 
alpha chain 
8AQ44A bovine 882 8 cells lgM VMRD 
(non lg marker) 
Rabbit bovine lgA lgA-positive cells 8ethyl 
polyclonal* 
Rabbit bovine lgM lgM-positive cells 8ethyl 
polyclonal* 
Sheep bovine lgG lgG-positive cells 8ethyl 
polyclonal* 
Ci4 neg. control lgG1 Chemicon 
GC270 neg. control lgG2a Chemicon 
GC323 neg. control lgM Chemicon 
* Directly conjugated to fluorescein isothiocyanate 
Ig - immunoglobulin 
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Secondary antibodies used for flow cytometry methods are listed in Table 5.2. 













5.4.1 Immunisation procedure 
Dilution Source 
1:50 Jackson 
1 :1000 Pharmingen 
1:400 Pharmingen 
1:400 Jackson 
Fourteen healthy multiparous pregnant cows of mixed Friesian and Jersey breeds 
were selected from a group that had been previously immunised using our multi-site 
immunisation regimen (Hodgkinson and Hodgkinson, 2003). The selection was 
made on the basis of the titres of the specific anti-C. albicans lgA in the previous two 
years, in milk collected seven days post-partum. Eight animals that had antibody 
titres greater than 2.0 kTU were assigned to the High group. Six animals that had 
antibody titres less than 2.0 kTU were assigned to the Low group. All animals were 
then re-immunised with C. albicans using our multi-site immunisation regimen as 
outlined in Section 2.2.1. All four mammary gland quarters were immunised. The 
immunisation schedule is outlined in Table 5.3. The initial immunisation at Week 0 
was 14 weeks before the group's average estimated calving date. 





IP - intra-peritoneal 
IM - intra-muscular 












5.4.2 Sample collection and preparation 
Mammary secretions were collected only from the left side of the udder. The 
collection was alternated between the front and back quarters to minimise any effects 
sampling may have had on the general mammary secretion parameters. Mammary 
secretions were collected according to the protocol outlined in Section 2.2.2.3. The 
schedule for the collection is outlined in Table 5.4. The first sample on Day O was 
collected just prior to the administration of the 151 IMM immunisation. The fifth 
sample of Day 12 was collected just prior to the administration of the 2nd IMM 
immunisation. 
Table 5.4 Schedule for the collection of mammary secretions from animals 
















IMM - intra-mammary 
















(seven days post-partum) 









Mammary secretions were processed to isolate the immune cells according to the 
protocol outlined in Section 2.2.2.3. Cells required for flow cytometry were assayed 
immediately. An aliquot of each secretion was stored at -20°C for antibody and 
protein concentration analysis. 
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Two colostrum samples were collected from each animal as per the protocol outlined 
in Section 2.2.2.2, one sample from the right quarters and one sample from the left 
quarters of the udder. These were collected for comparative purposes, to establish 
any effects that were caused by the removal of multiple samples of mammary 
secretions from the left side of the udder. Finally, a milk sample was collected seven 
days after parturition using the protocol outlined in Section 2.2.2.2. Colostrum and 
milk samples were processed as per the protocol outlined in Section 2.2.2.2. 
5.4.3 Flow cytometry 
Cells from six animals from the High group and six animals from the Low group were 
analysed at each time point. Cells isolated from mammary secretions were 
immunostained for flow cytometry using the protocol outlined in Section 2.2.5. The 
cells were incubated with antibodies specific for the lymphocyte cell-surface antigens 
listed in Table 5.1. Aliquots of cells were first double-labelled with pairs of primary 
antibodies with different isotypes, or singly, as shown in Table 5.5. Following this, 
the cells were incubated with two secondary antibodies that were coupled to either 
fluorescein isothiocyanate (FITC) or phycoerythrin (PE) fluorescent dyes. The anti-
bovine isotype-specific antibodies (lgA, lgM and lgG) were directly conjugated to 
FITC and did not require a secondary antibody. Measurement was made using a 
flow cytometer and populations of lymphocytes and neutrophils were gated using 
SSC and FSC parameters. The percentage of lymphocytes and neutrophils in the 
total population and the percentage of T and 8 cells in the lymphocyte population 
stained by each antibody were calculated using Cellquest™ software (80). 
Table 5.5 Combinations of primary and secondary antibodies used for double 
staining of cells for flow cytometry analysis 
1° MAb -A 1° MAb- B 
CD4 (lgG2a) CD25 (lgG1) 




The monoclonal antibody isotype is shown in brackets 
FITC - fluorescein isothiocyanate 
PE - phycoerythrin 
Mu - mouse 
Bov - bovine 
2° Ab-A 
a-Mu lgG2a- FITC 
a-Mu lgG- FITC 
a-8ov lgA - FITC 
a-8ov lgM - FITC 
a-8ov lgG - FITC 
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2° Ab -B 
a-Mu lgG1 - PE 
a-Mu lgM - PE 
a-Mu lgM - PE 
a-Mu lgM - PE 
a-Mu lgM - PE 
Non-specific binding of antibodies to cells was determined by the addition of RPMl-
medium only or negative isotype control serum in place of the primary antibody. This 
percentage of non-specific binding was subtracted from the total percentage to give a 
corrected value for each analysis. 
5.4.4 ELISA 
5.4.4.1 Specific anti-C. albicans lgA 
Mammary secretions collected from the High and Low groups, plus the colostrum 
and milk samples, were assayed by ELISA to determine the titre of the specific anti-
c. albicans lgA, as per the protocol outlined in Section 2.2.6.1. Results were 
reported as kTU of antibody. 
5.4.4.2 Total lgA 
Total lgA concentrations were determined by the ELISA protocol, outlined in Section 
2.2.6.2, for mammary secretions collected from the High and Low groups on Days 0, 
5, 12, 15, 19 and 35, plus milk samples collected seven days post-partum. Results 
were reported as mg/ml lgA. 
The titres of specific anti-C. albicans lgA and total lgA concentrations measured in 
the mammary secretions were both adjusted for protein concentration. This allowed 
for differences in collection procedure; whether or not a saline infusion was required 
for sample collection. Protein concentrations were determined by the protocol 
outlined in Section 2.2.7. 
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5.5 Results 
5.5.1 Characterisation of lymphocytes in mammary secretions 
following intra-mammary immunisation 
Mammary secretion samples collected before and after IMM immunisations varied 
considerably in their consistency. There was no visual evidence of the oil adjuvant 
(FICA) in the samples collected two days after IMM immunisation. Secretions 
collected prior to IMM immunisation required a saline infusion to produce a sample. 
Two to four days following IMM immunisation, the gland did not usually require the 
saline infusion as the gland cistern contained sufficient fluid for sampling. On these 
days secretions often contained a gelatinous precipitate whereas pre-lMM 
immunisation samples were relatively clear. Four to five days following IMM 
immunisation, secretions were clear, similar to that collected prior to IMM 
immunisation. 
Cells were isolated from mammary secretions for analysis by flow cytometry to 
determine profiles of cells found in the mammary gland cistern following IMM 
immunisation. Numbers of cells isolated from the 25 ml secretion samples varied 
amongst animals and from day-to-day, with values ranging from 1 x 106 to 5 x 108 
cells. However, total cells could not be isolated from samples containing the 
gelatinous precipitate described above. 
5.5.1.1 Lymphocytes, neutrophils and other cells 
Overall comparison of cells isolated from mammary secretions showed that the 
lymphocyte population (15 - 50%) was greater than the neutrophil population (7 -
33%), with the other cell types accounting for 25 - 60% of the total cells. Few 
differences were observed between the High and Low groups for cell types across 
the time points sampled. However, marked response to immunisation was observed 
with changes occurring to the proportions of different cell types following IMM 
immunisations. Average percentages of lymphocytes, neutrophils and other cells in 
the total population of cells isolated from mammary secretions for the High and Low 
groups (± SEM) are shown in Figure 5.1. 
Prior to IMM immunisation, approximately 50% of the total cell population isolated 
from mammary secretions were lymphocytes. In the samples collected up to five 
days following the two IMM immunisations, the percentage of lymphocytes 
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Figure 5.1 Flow cytometry analysis of total cells in mammary secretions for 
lymphocytes, neutrophils and other cells 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Graphs show the average 
percentage of each type of cell for the High and Low groups (± SEM): A, 
Lymphocytes; B, Neutrophils; C, other cells. Days on which there were significant 
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decreased to 15 - 25% of total cells, a two-fold reduction. Values then recovered to 
pre-lMM immunisation levels. No significant difference was observed between the 
percentages of lymphocytes in the high- and low-responding groups. 
The percentage of neutrophils in the total population of cells isolated from mammary 
secretions ranged from 7 to 33%. Average values were similar for the High and Low 
groups except on Day 12 when neutrophils in the Low group were two-fold lower than 
in the High group (p < 0.01 ). Following the 1st IMM immunisation, the percentage of 
neutrophils increased to approximately 20 - 30% of the total cells in the mammary 
secretions, 3 - 4 times higher than the pre-lMM immunisation levels. The 
percentage of neutrophils in the total cell population remained at these higher levels 
until several days after the 2nd IMM immunisation, at which time the percentage of 
neutrophils declined to pre-lMM immunisation values. On Day 21 (nine days after 
the 2nd IMM immunisation) there was another rise in the percentage of neutrophils 
(20 - 30%) which then fell again by Day 35 to approximately pre-lMM immunisation 
values. 
Other cells, not classified, ranged from 30 - 60% of the total population of cells 
isolated from mammary secretion samples collected over the time course. On Days 
0, 2 and 5 (before and up to five days after the 1st IMM immunisation) the percentage 
of these cells was approximately 60% of total cells isolated from mammary 
secretions. On Days 7 and 12 the percentage of these cells decreased to 
approximately 35%. Following the 2nd IMM immunisation, these cells increased 
again to approximately 60% of total cells. By Day 21, levels of these cells had 
decreased to 30% and were still at this level on Day 35. 
5.5.1.2 CD4- and CDS-positive cells 
Prior to the IMM immunisations, the predominant lymphocyte population in mammary 
secretions was the T cell (76% of the total lymphocytes). At the peak of the 
immunisation response (Day 15, three days after the 2nd IMM immunisation), the 
percentage of T cells had fallen to approximately 48% of the total lymphocytes. Five 
weeks after the 1st IMM immunisation (Day 35, 21 days after the 2nd IMM 
immunisation), the percentage of T cells had returned to pre-immunisation levels (-
75%). The combined percentage of T lymphocytes that stained positively for CD4 
and CD8 are shown in Figure 5.2. Data are shown for individual animal responses 
over the time course, grouped as either high- or low-responding animals. Group 
averages (± SEM) are also shown. 
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Figure 5.2 Flow cytometry analysis of lymphocytes from mammary secretions 
for combined CD4- and CDS-positive lymphocytes 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Graphs show the combined 
percentage of lymphocytes that stained positively for CD4 and CDB: A, Individual 
animals in the High group; B, Individual animals in the Low group; C, Average 
response of the High and the Low group (± SEM). Days on which there were 
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Comparison of the T-cell responses for the High and Low groups determined that 
overall there was little difference between the two groups in their response and that 
only on Day 14 (two days after the 2nd IMM immunisation) was the difference 
significant (p < 0.05). On this day, the Low group had a higher percentage of T cells 
than the High group (60% and 51 %, respectively). 
The percentage of lymphocytes that stained positively for CD4 and CDS T-cell 
subpopulations is shown in Figure 5.3 and Figure 5.4, respectively. Data are shown 
for individual animal responses over the time course, grouped as either high- or low-
responding animals. Group averages (± SEM) are also shown. CD4 lymphocytes 
were found to be the predominant T-cell subpopulation in the mammary secretions. 
Prior to the IMM immunisations, the proportion of CD4-positive cells was 47% 
compared with 29% CDS-positive cells. On Day 15 (three days after the 2nd IMM 
immunisation) when the T-lymphocyte percentage was at its lowest point, the value 
for CD4-positive cells was 36% compared with 12% for CDS-positive cells. This 
equated to a 23% drop for CD4-positive cells and a 59% drop for CDS-positive cells. 
There was no significant difference between either the average CD4 or the average 
CDS values for the High and Low groups for any of the days that were sampled. 
T cells were also examined for expression of the IL-2 receptor (R). The proportion of 
activated T cells was calculated by dividing the percentage of cells that expressed 
both the IL-2R and the T-cell marker by the total percentage of cells that expressed 
that T-cell marker. The values obtained for the High and Low groups are shown in 
Table 5.6. 
The majority of CD4-positive cells in mammary secretions collected over the time 
course were activated cells (72 - 90%). The proportion of CD4-activated cells 
increased from approximately 92% of the total CD4-positive cells prior to the IMM 
immunisation to approximately 9S% on the second day following each IMM 
immunisation and this increase was significantly different (p < 0.05). By Day 35, the 
percentage of activated cells had fallen to approximately 73% of the total CD4-
positive cells. There were no significant differences when CD4 values obtained for 
the High and Low groups over the time course were compared. 
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Figure 5.3 Flow cytometry analysis of lymphocytes from mammary secretions 
for CD4-positive lymphocytes 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Graphs show the percentage 
of lymphocytes that stained positively for CD4: A, Individual animals in the High 
group: B, Individual animals in the Low group; C, Average response of the High and 
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Figure 5.4 Flow cytometry analysis of lymphocytes from mammary secretions 
for CDS-positive lymphocytes 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Graphs show the percentage 
of lymphocytes that stained positively for CDS: A, Individual animals in the High 
group; B, Individual animals in the Low group; C, Average response of the High and 
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Table 5.6 Percentage of activated T lymphocytes in mammary secretions 
following intra-mammary immunisation 
The proportion of activated T cells was calculated by dividing the percentage of 
cells that expressed both the IL-2 receptor and the T-cell marker by the total 
percentage of cells that expressed that T-cell marker. 




High Group Low group High Group Low group 
0 91.73 ± 1.17 91.62 ± 1.62 34.06 ± 6.49 44.52 ± 11.13 
2 97.42 ± 0.50 97.42 ± 0.62 44.75 ± 9.00 55.78 ± 4.91 
5 91.04 ± 4.39 96.23 ± 1.52 33.47 ± 7.99 34.18 ± 5.16 
12* 90.52 ± 1.48 92.46 ± 1.48 19.62 ± 6.26 21.49 ± 3.52 
14 96.54 ± 0.78 97.54 ± 0.79 45.00 ± 7.76 41.13 ± 6.43 
15 90.72 ± 1.34 90.65 ± 1.10 25.93 ± 5.57 36.63 ± 3.22 
16 94.46 ± 1.05 93.20 ± 1.16 26.45 ± 6.13 23.74 ± 3.80 
35 72.29 ± 3.74 74.29 ± 4.75 24.71 ± 5.49 28.64 ± 5.49 
IMM- intra-mammary 
* Day of 2"d IMM immunisation 
Over the time course, the proportion of activated CDS-positive cells ranged from 20 
to 55% of the total CDS-positive cells. Similar to CD4-positive cells, the percentage 
of activated CDS-positive cells increased following each IMM immunisation. The 
increase in the percentage of activated CDS cells after the 1st IMM immunisation was 
not significantly different from pre-lMM immunisation values (p = 0.4). 
Following the 2nd IMM immunisation, there was a two-fold increase in activated CDS-
positive cells from approximately 20% on Day 12 to approximately 40% on Day 14 
which was significant (p < 0.05). There were no significant differences when 
activated CDS-positive cell percentages obtained for the High and Low groups over 
the time course were compared. 
5.5.1.3 lgA-positive cells 
Data for lgA-positive cells are shown in Figure 5.5 for individual animal responses 
over the time course, grouped as either high- or low-responding animals. Group 
averages (± SEM) are also shown. 
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Prior to the IMM immunisations, lgA-positive cells represented approximately 8% of 
the total lymphocyte population in mammary secretions. Following the 1st IMM 
immunisation, the High and Low groups responded in a similar way with the 
percentage of lgA-positive cells increasing to approximately 12%, two to five days 
after the IMM immunisation. This increase was significantly different from Day O for 
the High group on Days 2 and 5 (p < 0.05), but not for the Low group. 
After the 2nd IMM immunisation, the lgA-positive cells in the High group increased to 
19% of total lymphocytes by Day 14 compared with the Low group where the lgA-
positive cells increased to only 11 %. The peak response for both groups was on Day 
15 and of the same magnitude (23% lgA-positive cells, a three-fold increase 
compared with Day 0). Compared with the peak response after the 1st IMM 
immunisation, the peak response after the 2nd IMM immunisation was significantly 
higher for the High group (p < 0.05) and very significantly higher for the Low group (p 
< 0.01 ). After Day 15 (three days after the 2nd IMM immunisation) the average 
percentage for the High group remained elevated until Day 19 (- 23% lgA-positive 
cells). For the High group, Days 14, 15 and 19 were very significantly different (p < 
0.01) and Day 16 was highly significantly different (p < 0.001) from the pre-I MM 
immunisation value for lgA-positive cells. By Day 35, the average percentage of lgA-
positive cells for the High group was still higher compared with the pre-lMM 
immunisation level (14% and 7%, respectively), but this was not significantly different 
(p = 0.053). 
In contrast, the average percentage of lgA-positive cells for the Low group declined 
on Day 16 to 15% of the total lymphocytes and had returned to the pre-lMM 
immunisation level (8%) by Day 21. For the Low group, only Day 15 and Day 16 
were significantly different (p < 0.01 and p < 0.05, respectively) from the pre-lMM 
immunisation value for lgA-positive cells. 
Analysis comparing the average lgA-positive cell responses for the High and the Low 
groups over the time course determined that overall the response was higher for the 
High group. Statistical analysis showed that this difference was only significant on 
Days 12, 16, 21 and 35 (p < 0.05) and very significantly different on Days 14 and 19 
(p < 0.01 ). There was no significant difference between the two groups for their peak 
response on Day 15. 
161 
Figure 5.5 Flow cytometry analysis of lymphocytes from mammary secretions 
for IgA-positive lymphocytes 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Graphs show the percentage 
of lymphocytes that stained positively for IgA: A, Individual animals in the High 
group; B, Individual animals in the Low group; C, Average response of the High and 
Low group (± SEM). Days on which there were significant differences between the 
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5.5.1.4 lgM-positive cells 
Similar to lgA-positive cells, a biphasic response was observed for lgM-positive cells 
in mammary secretions following the two IMM immunisations. Data for lgM-positive 
cells are shown in Figure 5.6 for individual animal responses over the time course, 
grouped as either high- or low-responding animals. Group averages (± SEM) are 
also shown. 
Prior to the 1st IMM immunisation, lgM-positive cells represented approximately 16% 
of the total lymphocyte population. There was a large variation for this baseline value 
for the Low group, ranging from 8 to 40%, a five-fold difference. After the 1st IMM 
immunisation, there was an increase for both groups in lgM-positive cells to an 
average of approximately 24% of lymphocytes, which then returned to baseline 
levels. This increase was significantly different from Day O for the High group on 
Days 2, 5 and 7 (p < 0.05). In contrast, there was no significant difference from pre-
immunisation values for the Low group in this phase of the response. 
Similar to the results for the lgA-positive cells, the lgM-positive cells for the High and 
Low groups appeared to have a different pattern of response following the 2nd IMM 
immunisation. Two days after the 2nd IMM immunisation (Day 14), the average 
percentage of lgM-positive cells for the animals in the High group had increased to 
29% whereas the Low group lgM-positive cells only increased to 19%. On the third 
day following the 2nd IMM immunisation (Day 15), both groups reached their peak 
response (- 33% lgM-positive cells). Compared with the 1st IMM immunisation, the 
peak response after the 2nd IMM immunisation was significantly higher for the Low 
group (p < 0.01) but not for the High group (p = 0.09). After Day 15, the average 
percentage of lgM-positive cells for the High group remained elevated at this level 
until Day 19. By Day 35 the average percentage of lgM-positive cells for the High 
group was still higher compared with the pre-I MM immunisation level (21 % and 11 %, 
respectively) and this difference was significant (p< 0.05). In contrast, the average 
percentage of lgM-positive cells for the Low group declined on Day 16 to 23% and 
had returned to pre-lMM immunisation levels (16%) by Day 19. 
Comparison of the average lgM-positive cell responses for the High and the Low 
groups over the time course showed a significant difference between the groups only 
on Days 14 and 19 (p < 0.01 ), and 35 (p < 0.05). 
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Figure 5.6 Flow cytometry analysis of lymphocytes from mammary secretions 
for IgM-positive lymphocytes 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Graphs show the percentage 
of lymphocytes that stained positively for IgM: A, Individual animals in the High 
group; B, Individual animals in the Low group; C, Average response of the High and 
the Low group (± SEM). Days on which there were significant differences between 
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5.5.1.5 lgG-positive cells 
Values for lgG-positive cells in mammary secretions were much lower than those 
found for lgA and lgM. lgG-positive cells represented approximately 2% of the total 
lymphocyte population prior to IMM immunisation. After the 151 IMM immunisation, 
lgG-positive cells increased to around 4% then returned to baseline levels. A peak 
level of 6% of the total lymphocytes was attained three days after the 2nd IMM 
immunisation (Day 15). The percentage of lgG-positive cells then declined, and by 
Day 35 it was at pre-immunisation values (2%). 
Data for lgG-positive cells are shown in Figure 5.7 for individual animal responses 
over the time course, grouped as either high- or low-responding animals. Group 
averages (± SEM) are also shown. There was no significant difference for lgG-
positive cells when values for the High and Low groups were compared, for any of 
the days that were sampled. 
Although the values of lgG-positive cells were low, Days 15 and 19 were significantly 
different from pre-lMM immunisation levels (p < 0.05) for the High group. There was 
no significant difference from pre-lMM immunisation levels for the Low group for any 
of the days following the IMM immunisations. 
5.5.1.6 882-positive cells 
882 antibody has been used in this study as a general 8 cell marker. This antibody 
is thought to recognise a cell-surface antigen, other than immunoglobulin, that is 
common to all mature 8 cells (Pallares et al., 1999). 8 cells isolated from mammary 
secretions that stained positively for 882 represented approximately 3% of the total 
lymphocytes prior to IMM immunisation. Animals in the High group showed a large 
variation in lymphocytes staining positive for 882 whereas animals in the Low group 
showed a more uniform pattern of response. 
Data for 882-positive cells are shown in Figure 5.8 for individual animal responses 
over the time course, grouped as either high- or low-responding animals. Group 
averages(± SEM) are also shown. 
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Figure 5.7 Flow cytometry analysis of lymphocytes from mammary secretions 
for IgG-positive lymphocytes 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Graphs show the percentage 
of lymphocytes that stained positively for IgG: A, Individual animals in the High 
group; B. Individual animals in the Low group; C, Average response of the High and 
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Figure 5.8 Flow cytometry analysis of lymphocytes from mammary secretions 
for BB2-positive lymphocytes 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Graphs show the percentage 
of lymphocytes that stained positively for BB2: A, Individual animals in the High 
group; B, Individual animals in the Low group; C, Average response of the High and 
the Low group (± SEM). Day on which there were significant differences between 
the groups are marked (* p < 0.05). 
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There was only a slight increase in the proportion of the 882-positive cells in the total 
lymphocyte population following the 151 IMM immunisation. Following the 2nd IMM 
immunisation the percentage of 882-positive cells increased from 3% of the total 
lymphocytes to an average peak of 18% for the High group and 12% for the Low 
group on Day 21 (nine days after the 2nd IMM immunisation). However, there were 
large variations in the values for the High group ranging from 5 to 32%, a six-fold 
difference, but only a three-fold variation (6 - 18%) in values for the Low group on 
this day. 
By Day 35, the average percentage of 882-positive cells for the Low group had 
returned to approximately pre-lMM immunisation values (5%). The average value of 
882-positive cells on Day 35 for the High group was still elevated at 12% of total 
lymphocytes compared with the pre-lMM immunisation value of 4% but again there 
was a large spread in values amongst the individual animals (3 - 29%), similar to 
Day 21. 
Comparison of the average 882-positive cell responses of the High versus the Low 
group over the time course determined that there was a significant difference on only 
one of the days sampled, Day 16 (p < 0.05). 
Cells stained for the immunoglobulin isotypes lgA or lgM were double-stained with 
882 antibody to determine the proportion of cells that were positive for both cell-
surface markers. There was no statistical difference between the High and Low 
groups in the relative proportions of cells that stained positively for both 882 and lgA 
and both 882 and lgM (data not shown). Therefore, the data are presented as a 
combined average of the High and Low groups. The percentages of total 
lymphocytes that stained positively for isotype lgA or lgM plus 882, in comparison 
with the percentage of cells that stained positively for the immunoglobulin isotype 
alone are shown in Figure 5.9. 
For all the samples collected over the time course, a larger percentage of the cells 
were positively stained with the immunoglobulin isotype antibody alone than were 
doubled-stained with the immunoglobulin isotype plus 882 antibody. 
For lgA-positive cells, the percentage of cells that stained positively for lgA alone 
ranged from 4.0 to 17.0% and the percentage of cells that double-stained positively 
with both lgA and 882 ranged from 2.8 to 8.0%. For lgM-positive cells, the 
percentage of cells that stained positively for lgM alone ranged from 9.0 to 21.8% 
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and the percentage of cells that double-stained positively for both lgM and 882 
ranged from 4.2 to 13.5%. The peak of cells positively doubled-stained was on Day 
14 (two days following the 2nd IMM immunisation) for both lgA and lgM. In contrast, 
the peak of cells that stained positively only with the immunoglobulin isotype antibody 
was three days following the 2nd IMM immunisation, on Day 15. 
Figure 5.9 Flow cytometry analysis of lymphocytes from mammary secretions 
double stained for immunoglobulin isotypes IgA and IgM, and BB2 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Cells were double-stained 
with immunoglobulin isotype-specific antibody and BB2 antibody. The data are for 
the combined average of the High and Low groups. The graphs show the average 
percentage of total lymphocytes (± SEM) that stained positively with antibody for 




















"' 10 § -0 
B 
0 2 5 7 12 14 15 16 19 21 35 
Days after 1st IMM immunisation 
O 2 5 7 12 14 15 16 19 21 35 
Days after 1st IMM immunisation 
169 
D lgA+ 882-
0 lgA+ 882+ 
D lgM+ 882-
0 lgM+ 882+ 
5.5.2 Analysis of antibody levels in mammary secretions following 
intra-mammary immunisation 
Mammary secretion samples collected from the mammary gland before and after the 
IMM immunisations were analysed by ELISA for specific anti-C. a/bicans lgA and 
total lgA antibody. Animal responses for the High and Low groups were compared. 
A ratio of the protein concentration to the level of antibody for individual mammary 
secretions was calculated. This adjusted for any dilution of the mammary secretion 
sample that may have occurred when saline infusion was used during the sample 
collection process. 
5.5.2.1 Total protein 
Data for total protein concentration in mammary secretions collected over the time 
course are shown in Figure 5.10 for individual animals, grouped as either high- or 
low-responding animals. Group averages (± SEM) are also shown. The initial 
protein concentrations, in samples collected prior to the 1st IMM immunisation, 
tended to be the highest of all times points measured but considerable animal-to-
animal variation was observed, with values ranging from 15 - 185 mg/ml of protein. 
After the 1st IMM immunisation, concentrations decreased and plateaued at a level of 
25 - 30 mg/ml of protein. The between-animal variability also decreased after the 
first sample. Comparison of the High and Low groups determined that there was no 
significant difference between the groups for protein concentrations on any of the 
days sampled. 
5.5.2.2 Specific anti-C. albicans lgA 
Data for the ratio of specific anti-C. albicans lgA titres to protein concentration in 
mammary secretions are shown in Figure 5.11 for individual animals over the time 
course, grouped as either high- or low-responding animals. Group averages (± SEM) 
are also shown. Overall, titres of specific anti-C. albicans lgA in mammary secretions 
were higher prior to the IMM immunisations compared with the days following the two 
IMM immunisations. After the 1st IMM immunisation, titres fell then plateaued prior to 
falling again after the 2nd IMM immunisation. The titres then rose steadily and by Day 
35 had returned to pre-lMM immunisation levels. The patterns of response for the 
High and Low groups were very similar but the antigen-specific lgA titre values in 
mammary gland secretions for the High group were considerably higher than for the 
Low group (3.5 - 13.0 times). This difference between the groups in antigen-specific 
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Figure 5.10 Analysis of the protein concentration in mammary secretions 
Graphs show the protein concentration in mammary secretions collected at intervals 
following intra-mammary immunisation (at times marked with arrows): A, Individual 
animals in the High group; B, Individual animals in the Low group; C, Average 
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Figure 5.11 Analysis of the level of specific anti-C. a/bicans IgA in mammary 
secretions 
Graphs show the ratio of the titre of specific anti-C. albicans IgA and protein 
concentration in mammary secretions collected at intervals following intra-mammary 
immunisation (at times marked with arrows): A, Individual animals in the High group; 
B. Individual animals in the Low group; C, Average response of the High and the Low 
group (± SEM). Days on which there were significant differences between the 
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lgA titre values was significant on all days sampled (p values ranging from < 0.05 to 
< 0.001), except Days 5, 12 and 19. In the High group, pre-lMM immunisation and 
Day 35 values were significantly higher than the other days sampled (p < 0.05). In 
contrast, the Low group showed no significant difference in titre values compared 
with pre-I MM immunisation values on any of the days over the time course. 
5.5.2.3 Total lgA 
Total lgA concentrations in mammary secretions were also adjusted for protein 
concentrations in the samples to allow for differences due to collection procedures, 
i.e. whether or not a saline infusion was required to obtain the mammary secretion 
sample. Data for the ratio of total lgA concentration to protein concentration are 
shown in Figure 5.12 for individual animal responses over the time course, grouped 
as either high- or low-responding animals. Group averages(± SEM) are also shown. 
Similar to results for titres of antigen-specific lgA, levels of total lgA tended to be 
higher in the secretion sample collected prior to IMM immunisation compared with 
secretion samples collected after IMM immunisation. The results showed high 
between-animal variability, ranging from 7 - 50, with an average of 24.6 ± 4.8 for the 
High group and 16.7 ± 4.2 for the Low group. There was no significant difference 
between the groups for Day O total lgA values (p = 0.126). By Day 5 after the 1st IMM 
immunisation, the ratio of total lgA to protein had fallen to 11. 7 ± 1.6 and 10.6 ± 1.4 
for the High and Low groups, respectively. The level of total lgA remained constant 
over most of the time course, and then rose between Day 19 and 35 to 52.4 ± 6.6 for 
the High group and 30.5 ± 3.7 for the Low group. Day 35 was the only time-point 
where there was a significant difference between the two groups for the total lgA to 
protein ratio (p < 0.05). 
Comparison of the titre of specific anti-C. albicans lgA and the total lgA concentration 
(both adjusted for protein concentration) is shown in Figure 5.13. For the High group 
a relationship between the titres of antigen-specific antibody and the total lgA 
concentrations (r2 = 0.7513) was observed. For the Low group no such relationship 
was found (r2 value = 0.1641 ). 
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Figure 5.12 Analysis of the total IgA concentration in mammary secretions 
Graphs show the ratio of the total IgA concentration and protein concentration in 
mammary secretions collected at intervals following intra-mammary immunisation (at 
times marked with arrows): A, Individual animals in the High group; B, Individual 
animals in the Low group; C, Average response of the High and the Low group (± 
SEM). Days on which there were significant differences between the groups are 
marked (* p < 0.05). 
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Figure 5.13 Comparison of concentrations of total IgA and titres of specific 
anti-C. a/bicans IgA in mammary secretions 
Graphs show the correlation of total IgA concentrations and titres of specific anti-
c. albicans IgA (both adjusted for protein) in individual animal mammary secretions 
collected over the time course: A, High group; B, Low group 
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A comparison between the percentage of lgA-positive cells (of the total lymphocytes) 
and the titres of specific anti-C.albicans lgA (adjusted for protein concentration) in 
mammary secretions collected from all individual animals at the end of the time 
course (Day 35) is shown in Figure 5.14 A. A highly positive correlation was 
observed (r2 value = 0.8091 ). 
Comparison of the percentage of lgA-positive cells (of the total lymphocytes) and the 
total lgA concentrations (adjusted for protein concentration) in mammary secretions 
collected from individual animals on Day 35, also showed a positive correlation (r2 = 
0.6078). Data are shown in Figure 5.14 B. 
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Figure 5.14 Comparison between the percentage of IgA-positive cells and IgA 
antibody levels 
Graphs show the correlation of the percentage of IgA-positive cells (of the total 
lymphocytes) and IgA antibody (adjusted for protein concentration) in mammary 
secretions collected on Day 35 following the 1st intra-mammary immunisation: A, 
IgA-positive cells and titres of specific anti-C. a/bi cans IgA: B, IgA-positive cells 
and total IgA concentrations 
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5.5.3 Analysis of antibody levels in colostrum and milk 
~ 
~ 
Colostrum samples collected from the left and right quarters of the udder were 
analysed to determine whether multiple sampling of mammary secretions from the 
left side had influenced the response to immunisation. Titre results for specific anti-
c. albicans lgA (adjusted for protein) are shown in Table 5.7. Comparison of the 
data for the left and right sides revealed that there was no significant difference 
between antibody responses for the two sides of the udder (p = 0.345 and 0.657 for 
the High and Low groups, respectively). 
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Table 5.7 Comparison of antigen-specific IgA titres in colostrum samples from 
the left and right sides of the udder 
The ratio of the average titre of specific anti-C. albicans IgA and protein 
concentration (± SEM) in colostrum samples collected from the left and right sides 




Ratio of antigen-specific antibody titre 
and protein concentration 
High group 
182.77 ± 44.62 
214.66 ± 48.91 
Low group 
38.81 ± 21.07 
34.88 ± 16.07 
Titres of specific anti-C. albicans lgA and concentrations of total lgA in milk samples 
collected seven days after parturition were compared with results of the two previous 
years. Average data for the High and Low groups are shown in Figure 5.15. For the 
titres of specific anti-C. albicans lgA there was a significant difference between the 
High and Low groups in all three years (p < 0.01 in 2001, p < 0.001 in 2002, p< 0.01 
in 2003). There was also a significant difference between the High and Low groups 
in all three years for concentrations of total lgA (p < 0.01 in 2001, p < 0.001 in 2002, 
p < 0.05 in 2003). 
Comparison between titres of specific anti-C. a/bicans lgA (adjusted for protein 
concentration) in mammary secretions collected on different days are shown in 
Figure 5.16. There was no correlation between the antibody titres for Day O and Day 
35 mammary secretion samples (r2 = 0.2821 ). There was a weak correlation 
between the antibody titres for Day 35 mammary secretions and milks collected 
seven days post-partum (r2 = 0.5606). 
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Figure 5.15 Comparison of antibody levels over three years of immunisation, in 
milks collected seven days post-partum 
Graphs show data for average responses of the High and Low group(± SEM) for: A, 
Titres of specific anti-C. a/bicans IgA; B, Total IgA concentration. Years in which 
there were significant differences between the groups are marked (* p < 0.05, ** p < 
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Figure 5.16 Comparison of titres of specific anti-C. albicans IgA in mammary 
secretions collected at different time points 
Graphs show the correlation for: A, mammary secretions collected on Day O and Day 
35 following the i5t intra-mammary immunisation; B, mammary secretions collected 
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5.6 Discussion 
In this chapter the cellular responses in the mammary gland to intra-mammary 
immunisation have been compared in animals that have been classified as high- and 
low-responding animals. The animals had been previously immunised and were 
assigned to their group based on their titre of specific anti-C. albicans lgA in the two 
preceding years, in milks collected seven days after parturition. The two groups were 
re-immunised using our immunisation regimen and the lymphocyte populations and 
the level of antibody were assessed in mammary secretions collected at intervals 
before and after the two IMM immunisations. In the current study, the response of 
the High and Low group to the multi-site immunisation was found to be similar to the 
two previous years in respect to antigen-specific lgA, i.e. animals in the High group 
produced significantly increased antigen-specific lgA titres compared with animals in 
the Low group. 
The overall objective of the immunisation regimen is the production of lgA so the 
lymphocyte population of greatest interest in mammary gland secretions following 
immunisation was the lgA-positive cell type. The pattern of response shown by the 
lgA-positive cells appeared to be a classical immune response to a priming antigen 
dose followed by a booster dose. Data from the experiment showed that the 
percentage of lgA-positive cells increased following both IMM immunisations in a 
biphasic pattern and the increase was greater following the 2nd IMM immunisation. A 
distinct difference was observed in the pattern of response between the High and 
Low groups following the 2nd IMM immunisation, with respect to lgA-positive cells. 
The data suggests that the High group had a faster response to the IMM 
immunisation booster and sustained the response for a longer interval when 
compared with the response of the Low group. It is of interest to note that the 
response of both the High and Low groups peaked on the same day following the 2nd 
IMM immunisation (Day 15) and the peak percentage of lgA-positive cells was the 
same. However, overall it can be seen that animals that produced a high level of 
antibody in response to immunisation had a greater response to the immunisation 
with respect to the percentage of lgA-positive cells in mammary secretions compared 
with animals that produced a low level of antibody in response to immunisation. 
The percentage of lymphocytes that were lgA-positive in Day 35 secretions 
correlated well with the antigen-specific antibody concentration for the same day. 
Previous studies have indicated that the lgA antibody is produced locally by cells in 
the mammary gland (Hodgkinson and Hodgkinson, 2003). Therefore, the observed 
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correlation implies that cells isolated from mammary secretions reflect the cellular 
environment of the mammary gland. This has been demonstrated by other 
researchers working with goat mammary glands. They found that mRNA extracted 
from cells isolated from milk and cells isolated from mammary gland tissue samples 
gave comparable results for gene analyses (8outinaud et al., 2002). The correlation 
between the percentage of lgA-positive cells and titres of antigen-specific lgA, in this 
study, suggests that the higher titres in the mammary secretions are due to an 
increase in the number of cells producing lgA rather than individual cells producing 
more lgA. This relationship also confirms the trend observed in Chapter Four, that 
higher numbers of lgA-positive cells correlate with higher antigen-specific lgA levels 
in secretions. However, the observation does not exclude the possibility that lgA-
positive cells may demonstrate a range of lgA productivity. 
The finding that there was no significant difference between the High and Low groups 
for the 882-positive cell population would suggest that this population of lymphocytes 
was not involved in the cellular response to IMM immunisation. The observation that 
there was no significant increase in the percentage of the 882-positive cell 
population prior to the increase in lgA-positive cells would suggest that the lgA-
positive cells are trafficking to the mammary gland as differentiated plasmablasts 
rather than as 8 cells that are then differentiated in the mammary gland. The reason 
for the increase in the 882 lymphocyte population observed on Day 21, nine days 
after the 2nd IMM immunisation and the similar increase in the percentage of 
neutrophils on this day could not be deduced from the data. 
The very low percentage of lgG-positive cells compared with the percentage of lgA-
positive cells is in contrast to the findings in Chapter Four where numbers of lgG- and 
lgA-positive cells in the tissue of the immunised mammary gland were comparable. 
One explanation is that the antibody used (sheep anti-bovine lgG heavy-chain 
specific) did not detect all of the lgG-positive cells using the flow cytometry cellular 
staining protocol, although this was the same antibody that had been used to 
successfully detect lgG-positive cells in tissues using the immunohistochemical 
staining protocol. 
It should be noted that the flow cytometry method used for measuring lymphocyte 
populations would not have detected the presence of plasma cells in mammary 
secretions, only plasmablasts. This is because the method detects cell surface 
immunoglobulin, not intracellular antibody. Mature plasma cells down-regulate the 8-
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cell receptor and membrane immunoglobulin is low or absent on plasma cells 
(Calame et al., 2003b). 
Prior to IMM immunisations, the predominant lymphocyte population in mammary 
secretions was the T cell (- 75% of total lymphocytes), in agreement with other 
studies for the dry (non-lactating) period of the cow (Park et al., 1992; Yang et al., 
1997). The proportion of CD4-positive cells was higher than COB-positive cells (49% 
and 29% of total lymphocytes, respectively), which is also in agreement with other 
studies (lnchaisri et al., 2000; Yang et al., 1997). As the overall percentage of T cells 
decreased following the IMM immunisation, the relative proportions of CD4- and 
CDS-positive cells changed. Prior to the IMM immunisation, COB-positive cells 
comprised of 40% of the T-cell population. When the T-cell percentage was at its 
lowest point (Day 15, three days after the 2nd IMM immunisation) the CDS-positive 
cells made up only 25% of the T-cell population. This decrease in COB-positive cells 
was the opposite result to that found in bovine mammary glands chronically infected 
with S. aureus, where the proportion of CD8 cells increased relative to CD4 cells 
(Riollet et al., 2001 ). However, the response was similar to the pattern observed in 
mammary glands acutely infected with E. coli where CD4 cells increased relative to 
CD8 cells (Taylor et al., 1997). 
Overall, these findings would suggest that the type of immune response induced by 
our immunisation regimen is somewhat different from the immune response induced 
in a cow with chronic or acute mastitis. The relative decrease in the percentage of T 
lymphocytes with an increase in the percentage of CD4-positive cells compared with 
CDS-positive cells, along with an increase in plasmablasts, could indicate that our 
immunisation regimen induces a T-cell-dependent antibody response involving CD4 
T cells, in contrast to a cell-mediated response involving CD8 T cells. 
The T lymphocytes examined for the expression of the IL-2R, to determine if these 
cells were in an activated state, found that the greater majority of the CD4 cells in the 
mammary secretions were activated cells. In other studies where T cells expressing 
the IL-2R have been examined, it was found that only 10% of lymphocytes were 
activated in bovine milk and this proportion did not change six weeks post-involution 
in the dry period (lnchaisri et al., 2000). No data have been reported for IL-2R 
expression on T cells in mammary secretions in late pregnancy. It is also of interest 
that there was a greater percentage of activated CD4 cells in the mammary gland 
prior to the 151 IMM immunisation, compared with three weeks after the 2nd IMM 
immunisation. These animals had been immunised the two preceding years, with the 
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same antigen. The finding of a high percentage of activated CD4 cells in the 
mammary gland prior to the 1st IMM immunisation may suggest that the priming IP/IM 
immunisation administered four weeks previously was already inducing an effect in 
the mammary gland. 
The finding that there was no significant difference between the percentage of 
activated cells (CD4 or CD8) for the High and Low groups suggests that the T cells 
were part of an overall general immune response to the IMM immunisations. There 
was a significant increase seen in the percentage of activated CD4- and CD8-
positive cells following the 2nd IMM immunisation. This may suggest that the memory 
T cells, upon re-exposure to antigen, proliferated with a second clonal expansion 
phase which was greater than the primary response, in a manner similar to that 
reported by others (Rogers et al., 2000; Schluns and Lefrancois, 2003). 
Analysis of the proportion of total lymphocytes in the entire population of cells 
isolated from the mammary secretion samples determined that the percentage of 
lymphocytes decreased after each IMM immunisation. There are several 
explanations for this reduction. This change may have been due to an influx of 
neutrophils, characteristic of an infected bovine mammary gland, leading to a relative 
decrease in the lymphocyte population. Rivas et al (2001) reported that prior to 
infection of the mammary gland, bovine milk contained approximately 7% neutrophils 
which then increased to 30 - 70% after acute infection. Another study found 3 - 22% 
neutrophils in uninfected bovine milk and 55 - 96% in chronically infected bovine milk 
(Riollet et al., 2001 ). The numbers for uninfected cows are similar to those observed 
in this study in the mammary secretions prior to IMM immunisation (7%), although the 
percentage of neutrophils (30%) observed following IMM immunisation is at the lower 
end of the range found in infected animals (Riollet et al., 2001; Rivas et al., 2001 ). 
Other cells, including macrophages and dendritic cells, may also have increased in 
numbers after IMM immunisation, as has been reported to occur in the infected 
bovine mammary gland (Concha, 1986; Rivas et al., 2001 ), and thereby decreased 
the proportion of lymphocytes in mammary secretions. Another explanation for the 
observed decreases in the proportion lymphocytes in this current study, may be that 
following IMM immunisation the mammary gland retained more lymphocytes in the 
tissues rather than releasing them into the gland cistern. In this study, secretion 
samples were collected to represent the cellular environment of the mammary gland 
tissues, but this may only be indicative. Future studies are required where 
corresponding tissue samples are collected to accurately validate the results. 
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It should be noted that the percentages of cells were not converted to numbers of 
cells, in this study. Although total cell counts were performed, these were counts of 
the cells isolated from the secretion sample. This did not always equate to the total 
number of cells in the sample. Samples that were collected two - five days after 
each IMM immunisation contained a gelatinous precipitate that made it difficult to 
extract all the cells from the samples. Therefore, although it would have been 
interesting to compare numbers of cells rather than percentages of the total cell 
population, this was not possible. 
The level of antibody found in mammary secretions collected over the time course of 
the experiment also suggest that an immune response had already been activated in 
the mammary gland prior to the 1st IMM immunisation. The titres of specific anti-C. 
albicans lgA were elevated in Day O mammary secretions: the values of 509.6 ± 
135.5 and 73.4 ± 33.5 kTU (adjusted for protein concentration) for the High and Low 
group, respectively were high compared with the value of 1.10 ± 0.45 kTU measured 
in secretions samples that were have obtained from untreated animals (n = 5) at a 
similar stage of pregnancy (unpublished data). The total lgA also appeared to be 
elevated in the secretion samples collected prior to IMM immunisation compared with 
that in later samples. However, the overall average of 20.29 ± 3.21 mg/ml was 
comparable to the total lgA in mammary secretions (24.31 ± 3.40 mg/ml) collected 
from untreated pregnant animals (n = 5; unpublished data). Others have reported 
levels of 0.54 mg/ml total lgA in the mammary secretions of dry cows, although these 
animals were not pregnant (lnchaisri et al., 2000). It is interesting to consider the 
source of the antigen-specific antibody-producing cells. These cells may have been 
long-lived plasma cells recruited by the previous years' immunisation and resident in 
the mammary gland. Studies in mice have shown that plasma cells can live for at 
least a year (Slifka et al., 1998). 
There are several possible explanations for the finding that both antigen-specific and 
total lgA antibody levels in the secretions decreased after the 1st IMM immunisation 
and then increased again. Whether or not saline was used during the sample 
collection procedure could account for the observed decrease, however, antibody 
levels were adjusted for the protein concentration in the samples. Another possibility 
is that the observed fall in the antibody levels may have been due to the introduction 
of antigen to the mammary gland in the IMM immunisation. This antigen could have 
bound to antigen-specific antibody already present in the mammary gland and thus 
interfered with the measurement of this antibody by the antigen-specific ELISA 
method, resulting in lower levels of antibody being reported. But examination of the 
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data show that the decrease of antibody titre from Day O to Day 2 in individual 
animals ranged from approximately 3 - 1000 kTU, yet all the animals received the 
same antigen dose. If the introduced antigen was interfering in the ELISA then the 
level of decrease should have been constant. On the other hand, the possibility that 
different animals processed the antigen differently cannot be ruled out. A fall in total 
lgA was also observed which could not have been due to introduced antigen 
interfering in the ELISA method, and this may indicate that antigen binding to 
antibody was not the cause for the observation of a decrease in antibody levels. 
However, if the antigen-specific antibody was binding antigen then being removed by 
macrophages, this could account for the fall in the antibody levels observed. Another 
explanation could be that the IMM immunisations induced a change in the antibody 
production by the plasma cells, either by reducing the numbers of antibody-producing 
cells or inducing a change in the rate of protein synthesis by the plasma cells. 
As described earlier, there was a significant difference (p < 0.01) between the High 
and Low groups in the titres of specific anti-C. albicans lgA in mammary secretions. 
However, there was a trend for the titres of antigen-specific lgA of the Low group to 
be higher than in previous years. This was also the case for the total lgA 
concentrations. Although the average concentration for total lgA for the two groups 
was still significantly different, the significance level had changed from less than 0.01 
to less than 0.05, with a higher concentration of total lgA in the Low group compared 
with that in earlier years. The positive correlation between the antigen-specific lgA 
and total lgA in the samples for the High group and not the Low group would suggest 
that only the High group produced sufficient quantity of specific anti-C. albicans lgA 
to appreciably increase the concentration of total lgA. 
The lack of significant difference between the titres of specific anti-C. albicans lgA in 
the colostrum samples collected from the left and right glands of the animals 
indicated that removing secretions samples and their cells from the mammary gland 
over the time course of the study had no effect on the final antibody response. This 
would indicate that the immunogen is dispersed rapidly and in support of this was the 
observation that there was no sign of the oil adjuvant in samples collected two days 
after the IMM immunisations. It is interesting that removal of cells contained in the 
secretions sample did not influence the final antibody response. This may suggest 
that the cells being released into the cistern of the gland are only a small proportion 
of the total number in the tissues of the mammary gland. 
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In summary, there were significant differences in the cellular responses to the IMM 
immunisations observed for the High and Low groups. The High group responded 
more rapidly to the 2nd IMM immunisation and sustained the response for longer 
when compared with the Low group. Overall the High group had an increased 
percentage of lgA-positive cells and this correlated with a greater antibody response. 
Therefore, this would imply that for animals to produce higher levels of antibody they 
require higher numbers of lgA-producing cells. 
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Chapter 6 
Expression of key immunomodulatory genes 
in the bovine mammary gland 
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6.1 Introduction 
The work in Chapter Six characterises the expression of various key 
immunomodulatory genes in the bovine mammary gland. Knowledge of gene 
expression profiles in the mammary gland may help elucidate the immune 
mechanisms involved in the recruitment of B cells to the bovine mammary gland, 
their differentiation and production of lgA for secretion into milk. Profiles of the 
expression of cytokine genes may provide insight into the type of immune response 
that is induced by our lgA immunisation procedure. 
Many of the studies investigating the immune mechanisms in the healthy and 
infected mammary gland of the dairy cow have focused on the identification of the 
cells in milk, classifying the cell types by markers expressed on their cell surface. 
More recently, studies have investigated the mammary gland cells in more detail by 
characterising the immunoregulatory genes that are being expressed by these cells 
(Alluwaimi and Culler, 2002; Riollet et al., 2000b; Riollet et al., 2001; Taylor et al., 
1997). Cytokine genes are of key interest because of their known functions. Of 
particular interest are those genes for the cytokines linked to the inflammatory 
process (TNF-a and IL-1) and the cytokines associated with the type Th1 (IL-2, IL-12, 
IFN-y and TNF-~) and Th2 (IL-4, IL-5, IL-6, IL-10 and IL-13) immune responses 
(Kelso, 1995). 
Cytokines act as intercellular messengers and have a crucial role in the signalling for 
inflammatory and immune processes. Central to the adaptive immune response is 
the production of IL-2. This cytokine stimulates T cells to express cytokines and 
drives clonal expansion and differentiation of activated T and B cells. Activated T 
cells are a major producer of IL-2 (Smith, 1988). In the cow, IL-2 mRNA has been 
detected in cells from normal and mastitic mammary glands (Alluwaimi and Culler, 
2002; Sordillo et al., 1991 b) although others have been unable to measure mRNA 
transcripts of this gene in milk cells (Riollet et al., 2000b; Riollet et al., 2001; Taylor et 
al., 1997). Usage of IL-2 as adjuvant in the bovine mammary gland has been shown 
to increase specific immune response to keyhole limpet haemocyanin compared with 
Freund's incomplete adjuvant (Pighetti and Sordillo, 1995). In addition, infusion of IL-
2 has been shown to induce recruitment of plasma cells into the involuting bovine 
mammary gland (Nickerson et al., 1992). 
IL-4 has a key role in the induction of activated B cells to proliferate and secrete lgG1 
(Kuhn et al., 1991; Turaga et al., 1993). IL-4 is produced mainly by T lymphocytes, 
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both CD4 and CD8 cells (Paul, 1991 ). In bovine cell culture studies, IL-4 has been 
shown to increase lgG1 and lgE in preference to lgG2 (Estes et al., 1995). Studies 
that have investigated the transcription levels of IL-4 in the bovine mammary gland 
have failed to detect any levels of mRNA for this cytokine in cells isolated from milk 
collected from healthy or infected glands (Riollet et al., 2000b; Riollet et al., 2001; 
Taylor et al., 1997). 
IL-6 was first described as a cytokine that enhances immunoglobulin secretion by B 
cells (Kishimoto, 1989). It is secreted by many different cell types, including T and B 
cells and macrophages (Hirano et al., 1989). The expression of IL-6 has been 
determined in the healthy bovine mammary gland at different physiological stages. 
IL-6 protein levels were higher in early colostrum compared with milk (Hagiwara et 
al., 2000) but no significant IL-6 mRNA was detected in milk cells from the middle 
and late stages of lactation (Alluwaimi and Cullor, 2002). Other studies have found 
IL-6 mRNA expression in milk cells from mastitic animals to be greater than those in 
healthy animals, implicating IL-6 in the pathogenesis of mastitis (Taylor et al., 1997). 
Studies have shown that glands infected with E. coli have increased transcription 
levels of IL-6 by 14 h (Shuster et al., 1997) and earlier in endotoxin-infused 
mammary glands (Shuster et al., 1993). However, in S. aureus infections 
transcription of IL-6 was less evident (Alluwaimi et al., 2003). 
IL-8, originally termed a cytokine, has been re-classified as the chemokine CXCL8 
(Graves and Jiang, 1995). It is a well-known neutrophil-chemoattractant produced by 
stimulated T cells, macrophages and endothelial cells (Bickel, 1993). Using in vitro 
studies, it has also been demonstrated to be chemotactic to both human T and B 
cells (Bacon et al., 1989; Schratzberger et al., 1997). In the bovine mammary gland 
the primary role for IL-8 is to attract neutrophils into the infected gland. Bacterial 
endotoxin lipopolysaccharide (LPS) has been shown to induce the production of 
large quantities of IL-8 in bovine mammary epithelial cell lines (Boudjellab et al., 
1998). In studies investigating the effects of mastitis inducing pathogens in the 
bovine mammary gland, E. coli was shown to induce increased protein levels of IL-8 
in milk, peaking at 16 hours (Bannerman et al., 2004; Riollet et al., 2000a). However, 
S. aureus challenge did not show an effect. Transcriptional levels of IL-8 mRNA are 
detectable in the healthy gland with no differences observed between mid- and late-
lactational stages (Alluwaimi and Culler, 2002). 
I L-1 O is described as an anti-inflammatory cytokine involved in the process of 
suppressing cell-mediated immunity while promoting humeral responses (Burdin et 
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al., 1997; Spits and de Waal Malefyt, 1992). It is produced by T cells and 
macrophages, and by B cells that are activated by CD40 ligand. In conjunction with 
IL-6, IL-10 acts to increase antibody production in B cells (Burdin et al., 1997). In the 
bovine mammary gland, levels of IL-10 mRNA were low or negligible when 
determined in milk cells from healthy or mastitic cows (Riollet et al., 2000b; Taylor et 
al., 1997). In studies where the IL-10 protein was measured, a significant transient 
increase in the cytokine was observed in mammary gland quarters infected with E. 
coli but not with S. aureus (Bannerman et al., 2004). 
IL-12 is an important regulatory molecule that enhances the differentiation of Th 1 
type cells (Trinchieri, 1997). Produced by macrophages, IL-12 induces T cells to 
produce IFN-y (Trinchieri, 1995). In the healthy bovine mammary gland, IL-12 mRNA 
has been shown to be elevated in late-lactation compared with mid-lactation 
(Alluwaimi and Cullor, 2002). A comparison of milk from healthy and mastitic cows 
showed transcriptional expression of IL-12 only in the infected cows (Taylor et al., 
1997), and an increase in mRNA and protein levels following S. aureus (Bannerman 
et al., 2004; Riollet et al., 2000b) and E. coli challenge (Bannerman et al., 2004). 
IFN-y, which is produced predominantly by CD4 (Th1) and CD8 cells, is a major 
positive regulator of cell-mediated immunity (Farrar and Schreiber, 1993). In the 
bovine mammary gland, IFN-y is an important mediator in the activation of recruited 
neutrophils and enhancement of their phagocytic activity (Wedlock et al., 2000). In 
cell culture studies using bovine cells, IFN-y has been shown to induce lgG2a 
production by B cells rather than lgG1 (Estes et al., 1994). Similar to IL-6, IFN-y 
protein was elevated in colostrum compared with early, mid- and late-lactation milk 
(Hagiwara et al., 2000), although IFN-y mRNA was present in cells from mature milk 
at all stages of lactation (Alluwaimi and Cullor, 2002; Hagiwara et al., 2000). During 
infection with mastitis-inducing pathogens, IFN-y protein production increased to high 
levels and remained elevated over an extended time (Bannerman et al., 2004). 
TNF-u is a potent pro-inflammatory cytokine produced by many different cells 
including epithelial cells, macrophages, monocytes and T cells. In conjunction with 
IL-1 p, TNF-u mediates the inflammatory response at both the local and systemic 
levels (Vassalli, 1992). TNF-u initiates the migration of neutrophils to the site of 
infection by inducing VCAM-1 expression on endothelial cells (Van Kampen and 
Mallard, 2001 ). Infusion of recombinant TNF-u into a healthy bovine mammary gland 
results in an increase in the influx of neutrophils (Watanabe et al., 2000). In addition, 
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TNF-a stimulation of phagocytic killing by bovine neutrophils has been demonstrated 
using in vitro studies (Rainard et al., 2000). The protein concentration of TNF-a is 
higher in colostrum compared with that of later milk (Hagiwara et al., 2000) and 
transcriptional levels of TNF-a are significantly elevated at middle and late lactation 
compared with levels for the cytokines IFN-y, GM-CSF, IL-6 and IL-2 (Alluwaimi and 
Cullar, 2002). Conflicting results have been reported regarding expression of TNF-a 
mRNA in mastitic glands. Taylor et al. (1997) was not able to detect TNF-a mRNA 
expression in cells isolated from the milk of normal or mastitic cows. Alluwaimi et al. 
(2003) found elevated transcription levels of TNF-a in the S. aureus infected bovine 
mammary gland whereas Bannerman et al. (2004) detected TNF-a mRNA 
expression after E. coli intra-mammary infection and not S. aureus infection. 
B-lymphocyte stimulator (BLyS), also termed B-cell activating factor, belonging to the 
TNF family (BAFF) and TNF- and Apol-related leukocyte-expressed ligand (TALL-1), 
is a recently discovered member of the TNF super-family (Moore et al., 1999; 
Schneider et al., 1999). Three receptors for BLyS expressed by B cells have been 
identified: B-cell maturation antigen (BCMA) (Thompson et al., 2000); BAFF-receptor 
(BAFF-R) (Thompson et al., 2001) and transmembrane-activator and cyclophilin 
ligand interactor (TACI) (Xia et al., 2000; Yu et al., 2000). BLyS has been shown to 
be required for the prolonged survival of mature B cells and plasma cells (Avery et 
al., 2003; MacKay and Browning, 2002; Schneider et al., 2001 ). Expression of this 
cytokine has been detected in the spleen, lymph nodes, peripheral blood 
mononuclear cells, macrophages and dendritic cells (Moore et al., 1999; Schneider 
et al., 1999) and more recently it has been reported to be expressed by neutrophils 
(Scapini et al., 2003). Macrophages and dendritic cells have been shown to directly 
regulate T-cell independent B-cell proliferation and the effect is mediated by BLyS 
(Craxton et al., 2003). Expression of BLyS by macrophages and dendritic cells has 
been reported to be stimulated by IFN-y and IL-10 (Nardelli et al., 2001 ). There are 
no reports in the literature about the role of BLyS in the ruminant. 
With regard to the production of lgA by B cells, cytokines act at multiple stages of B-
cell development, differentiation and secretion of antibody. TGF-13 plays a major role 
in the differentiation of B cells and has been shown to be essential in the class-
switching process to lgA (Kim and Kagnoff, 1990; Lebman and Edmiston, 1999). 
The T-cell derived cytokines, IL-2, IL-4, IL-5 and IL-10 (either alone or in 
combination) have all been demonstrated to be involved in the increased production 
of lgA in mouse studies (Husband et al., 1999). Transport of lgA into mammary 
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secretions is mediated by the polyimmunoglobulin receptor (plgR). Following 
sequencing of the bovine plgR gene (Kulseth et al., 1995; Verbeet et al., 1995), plgR 
has been shown to be expressed in the mammary gland of the lactating cow 
(Verbeet et al., 1995). Recently, expression of plgR mRNA has been reported in the 
ovine mammary gland, with the highest expression during established lactation 
(Rincheval-Arnold et al., 2002). 
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6.2 Aim and approach 
The aim of the work in this chapter was to characterise the expression of various key 
immunomodulatory genes in the bovine mammary gland. To achieve this, mammary 
tissues that had been characterised for immune cell distribution and adhesion 
molecule expression in earlier chapters of this thesis were investigated. The tissues 
included: 
• alveolar samples from the udders of healthy untreated cows at four different 
physiological stages of the mammary gland (Chapter Three) - late 
pregnancy, colostral phase, lactation phase and involution phase 
• alveolar samples from the immunised and non-immunised (control) 
mammary glands of cows at two time points following the multi-site 
immunisation regimen (Chapter Four) - seven days following the 2nd IMM 
immunisation and five weeks post-partum, in established lactation 
In addition, cells isolated from the mammary secretions and characterised for 
lymphocyte populations (Chapter Five), were also investigated. These samples were 
collected from immunised animals before, and at multiple times after, the IMM 
immunisations. These animals had been immunised in two previous years using our 
multi-site immunisation regimen and had been characterised as high- or low-
responding animals based on their titre of antigen-specific antibody measured in 
milks collected seven days post-partum. 
The objective was to determine transcription levels of genes for various cytokines in 
mRNA extracted from tissue and cell samples described above, using real-time PCR. 
The cytokines chosen were: IL-2; IL-6; IL-8; IL-10; IFN-y; TNF-a; TGF-~; and BLyS. 
These cytokines were selected because they may be key immunomodulatory 
molecules in the immune response elicited by our lgA immunisation protocol, as 
determined by a literature search. 
To measure the level of induction of lgA in tissues and cells of the immunised 
mammary gland, the transcription levels of lgA were also determined. Additionally, 
the gene expression of the receptor involved in the transcytosis of lgA across the 
mammary gland epithelium, plgR, was quantified in the mammary tissue samples to 





Oligonucleotide primers, used in PCR for detection of mRNA from the expression of 
genes in mammary tissues, are listed in Table 6.1 below. Primer sets were designed 
using Vector NTI bioinformatics software (lnformax, lnvitrogen) or obtained from a 
published bovine gene database (Coussens and Nobis, 2002). 
Table 6.1 Oligonucleotide primers used for PCR 
Target Primer sequence (5' - 3') Product 
size (bp) 
IL-2* F:GTGAAGTCA TTGCTGCTGGA 202 
R:GGTTCAGGTTTTTGCTTGGA 
IL-6 F:GACACCACCCCAGGCAGACTACTT 551 
R:GGAA TGCCCAGGAACTACCACAA T 
IL-8 F:TGCTCTCTGCAGCTCTGTGTGAA 259 
R:TCTTGCTTCTCAGCTCTCTTCACAA 
IL-10 F:GATGCGAGCACCCTGTCT 538 
R:CCGTTT ACGTCATGGAGTCTA 
IFN-y F:AGCCAAA TTGTCTCCTTCTACTTC 261 
R:CTGACTTCTCTTCCGCTTTCTG 
TNF-a F:CCCCAGGGCTCCAGAAGTT 579 
R:GGCGATGATCCCAAAGTAGACC 
TGF-P F:GGGTGGCCGGGGAAAGTG 496 
R:CCGTGAA TGGTGGCGAGGTC 
BLyS F:CTCGAGCAGAAGCTTCAGGGCTCCGAA 458 
R:CATATGGCCCTGCAGGAGGCAGAA 
plgR F :CAT A TGGTGTCCATCAAGTGCT ACT A 307 
R:CTCGAGAAGGGGTTTGTTCTGGAT 
lgA** F:GCGTGACTCCTGTGGCTGCTA 471 
R:AGGCGGTCGATGGTCTTCTGG 
p-actin* F:CAGAAGGACTCGTACGTGGG 200 
R:TTGGCCTT AGGGTTCAGGG 
* Primer set obtained from a published bovine gene database (Coussens and Nobis, 2002) 
** Heavy chain region 
F - Forward primer 
















6.4.1 Sample collection and preparation 
Three sets of samples were analysed for gene expression. These were mammary 
gland tissues and mammary gland cells (isolated from mammary secretion samples) 
that had been previously studied in Chapters Three, Four and Five. 
The first set of samples was collected from the alveolar areas of the udders of four 
untreated cows at each of four different physiological stages of the mammary gland -
late pregnancy, colostral phase, lactation phase and involution (see Section 3.4.1 ). 
The second set of samples was collected from eight cows that had been immunised 
using our multi-site immunisation protocol. Only one side of each cow's udder 
received the IMM immunisation while the other side was not immunised and acted as 
a control. Alveolar tissue was collected from immunised and control mammary 
glands, at two time points following the immunisation schedule (see Section 4.4.2). 
Four pregnant cows were sampled seven days following the 2nd intra-mammary 
immunisation and four cows were sampled five weeks post-partum, in established 
lactation. 
The third set of samples consisted of cells isolated from mammary secretions. Cows 
that had been previously immunised with our multi-site immunisation protocol were 
classified as high- and low-responding animals, based on their antibody response, as 
described in Section 5.4.1. These cows were re-immunised and mammary 
secretions collected over the time course of the two IMM immunisations (see Section 
5.4.2). Based on the cellular data described in Chapter Five, only selected days 
were chosen for mRNA analysis: Days 2, 12, 14, 15, 19, and 35 following the 151 IMM 
immunisation. Due to technical difficulties, no samples were available for Day 0. 
Samples from four high-responding cows and four low-responding cows were 
analysed for each selected day. 
Tissues samples were processed and frozen as per the protocol outlined in Section 
2.2.2.1. Mammary secretions were processed to extract the cells according to the 
protocol outlined in Section 2.2.2.3 and an aliquot of cells (107) was frozen at-80°C. 
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6.4.2 Quantitative real-time PCR analysis 
Extraction and purification of mRNA from the tissue and cell samples was performed 
using the protocol outlined in Section 2.2.4.1. First-strand synthesis of cDNA from 
the purified mRNA was performed using the protocol outlined in Section 2.2.4.2. In 
order to determine the efficiency of the real-time PCR reaction, PCR products of 
cDNA were prepared for each gene by amplifying a mammary gland cDNA sample 
by PCR as described in Section 2.2.4.3. Annealing temperatures for PCR had been 
previously customised for each gene and are listed in Table 6.2. The products were 
isolated on agarose gel as described in Section 2.2.4.4, purified as described in 
Section 2.2.4.5 and five 10-fold serial dilutions prepared. 
To determine the mRNA levels of target genes in unknown samples, real-time PCR 
was performed using the protocol outlined in Section 2.2.4.6 with the primers listed in 
Table 6.1 and annealing temperatures, customised for each gene, listed in Table 6.2. 
Five ten-fold serial dilutions of the PCR products for each gene were also analysed 
by real-time PCR to determine the efficiency of the real-time PCR reaction and to 
calculate the relative quantity of mRNA in unknown samples, as described in Section 
2.2.4.6. The mRNA levels of the target genes were reported relative to the mRNA 
levels of p-actin. This adjusted for any variation in the quantity of total mRNA used 
for each reaction. 
Table 6.2 The annealing temperature for the PCR and real-time PCR reaction, 
customised for target genes 
Gene Annealing temperature Annealing temperature 
for PCR (°C) for real-time PCR (°C) 
IL-2 62 65 
IL-6 60 64 
IL-8 55 59 
IL-10 60 64 
IFN-y 51 64 
TNF-a 64 64 
TGF-13 60 64 
BLyS 60 64 
plgR 62 65 
lgA* 65 64 
!3-actin 60 60 
* Heavy chain region 
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6.5 Results 
The efficiencies of the real-time PCR reaction for the target genes, calculated by the 
Lightcycler software (Roche) as described in Section 2.2.4.6, are listed in Table 6.3. 
Table 6.3 The efficiencies of the real-time PCR reaction for target genes 
Efficiencies were calculated by the Lightcycler software (Roche) using the slope of 
the line found by plotting the log concentration of PCR products against their cycle 
number at the crossing point, for each of the five 10-fold serial dilutions of PCR 
product. 
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6.5.1 Gene expression profiles in the untreated mammary gland 
The levels of gene expression (relative to j3-actin) in mammary alveolar tissue 
samples collected from untreated animals at each of four different physiological 
stages of the mammary gland (pregnant, colostral, lactation and involution) are listed 
in Table 6.4 for various key immunomodulatory genes. For many of the genes, there 
was a wide range in mRNA expression for animals within the groups. This variation 
is reflected in the large SEM values relative to the average value for the group. Many 
of the genes had low or undetectable levels of mRNA in the mammary alveolar 
tissues of the untreated animals. 
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Table 6.4 Expression level of genes (relative to j3-actin) in the untreated 
mammary gland 
Mammary alveolar tissues were collected from four untreated animals at each of 
four different physiological stages of the mammary gland - pregnant, colostral, 
lactation and involution. (Group average± SEM, n = 4). 
Pregnant Colostrum Lactation Involution 
Cytokine 
IL-2 0.20 ± 0.20 1.03 ± 0.75 0.62 ± 0.39 0.55 ± 0.55 
IL-6 0.22 ± 0.08 0.23 ± 0.21 0.82 ± 0.38 0.40 ± 0.20 
IL-8 5.20 ± 1.72 19.8 ± 16.3 2.85 ± 2.12 9.08 ± 3.18 
IL-10 0.01 ± 0.00 0.01 ± 0.01 0.02 ± 0.01 1.65 ± 1.63 
IFN-y 19.5 ± 7.47 0.01 ± 0.01 6.53 ± 3.76 9.79 ± 2.61 
TNF-a 0.05 ± 0.04 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
TGF-13 0.90 ± 0.20 0.81 ± 0.50 1.60 ± 0.26 0.49 ± 0.35 
BLyS 0.13 ± 0.12 1.04 ± 0.90 0.02 ± 0.01 0.32 ± 0.30 
Other 
plgR 0.03 ± 0.02 0.00 ± 0.00 0.43 ± 0.34 0.04 ± 0.03 
lgA* 4940 ± 1220 1660 ± 1040 8070 ± 3690 6440 ± 2340 
* Heavy chain region 
All samples of alveolar mammary tissue analysed had low or undetectable levels of 
IL-2 mRNA. The average expression of IL-2 was lowest in pregnancy compared with 
other physiological stages and highest in colostral phase tissues, however, there was 
no significant difference between the physiological stages. 
Similarly, alveolar mammary tissues had low or undetectable levels of IL-6 mRNA. 
The average expression of IL-6 was lowest in the pregnant and colostral phase, 
compared with four-fold higher levels in the lactation phase and two-fold higher levels 
in the involution phase. However, there was no significant difference between the 
physiological stages. 
The levels of expression of IL-8 in alveolar mammary tissues were variable amongst 
animals at each stage, ranging from undetectable to 68.56. The colostral group 
average of IL-8 mRNA was highest compared with two-fold, four-fold and seven-fold 
lower levels in the involution, pregnant and lactation groups, respectively. However, 
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these differences were not statistically significant due to the large variation amongst 
individual animals within each physiological stage 
Levels of IL-10 mRNA were very low in all mammary tissues sampled except for one 
animal in the involution group. This animal had a level of 6.55 compared with an 
average of 0.01 ± 0.003 for the remainder of the animals. 
The average level of mRNA for IFN-y was highest in the pregnant stage and lowest in 
the colostral stage. The expression level for the colostrum group was significantly 
different from both the pregnant (p < 0.05) and involution groups (p < 0.01 ). 
TNF-a. gene expression was undetectable in the mammary alveolar tissues of all the 
animals tested except one and the level for this animal was very low (0.18). 
Levels of TGF-13 mRNA were similar for all physiological stages of the mammary 
gland. All but two of the animals had detectable levels of mRNA. Compared with 
pregnant and colostral stages, the TGF-13 mRNA levels for the lactation phase were 
two-fold higher and for the involution phase two-fold lower, however, there was no 
significant difference between any of the physiological stages. 
There were low levels of expression for BLyS in alveolar mammary tissues for all 
physiological stages of the mammary gland with only one or two animals per group 
having detectable levels. There was no significant difference in level of BLyS 
expression between any of the physiological stages. 
The average level of plgR mRNA was higher in the lactation stage compared with the 
other physiological stages of the mammary gland but only two of the four animals 
had detectable levels. Overall the plgR mRNA levels were very low and there was 
no significant difference between any of the groups. 
The level of lgA mRNA in the alveolar mammary tissue samples in the pregnant, 
lactation and involution groups were similar. In the colostral group the average lgA 
mRNA level was approximately 2.5 - 4.0 times lower compared with the other groups, 
although this difference was not significant. Of all the various genes, lgA had the 
highest expression level relative to j3-actin expression. 
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6.5.2 Gene expression profiles in the immunised mammary gland 
The levels of gene expression (relative to p-actin) in mammary alveolar tissues 
collected from the immunised and control (non-immunised) sides of the udder of 
cows treated with our multi-site immunisation regimen are shown in Figure 6.1 for IL-
2, IL-6, IL-8, and IL-10 and Figure 6.2 for IFN-y, TNF-a, TGF-P and BLyS. The level 
of gene expression was determined in tissues collected at two time points following 
immunisation: seven days after the 2nd intra-mammary immunisation in pregnant 
cows and five weeks post-partum in lactating cows. 
IL-2 mRNA levels were low in both the immunised and control mammary alveolar 
tissue samples collected from the pregnant (0.03 ± 0.01) and lactating animals (0.07 
± 0.06). There was no significant difference in IL-2 expression between the 
immunised and control mammary glands sampled at the two different times points. 
There was also no significant difference for the level of IL-2 expression between the 
two time points in either immunised or control glands. The pattern of expression of 
IL-6 was very similar to that of IL-2. 
For IL-8, in the mammary alveolar tissues collected from the pregnant cows seven 
days after the 2nd IMM immunisation, there was a 15-fold increased level of mRNA in 
the immunised glands (2.31 ± 0.66) compared with the control glands (0.16 ± 0.08), 
and this difference was statistically significant (p < 0.05). A similar difference was not 
observed in mammary alveolar tissues collected from the lactation group five weeks 
post-partum. In the lactation group, the average IL-8 mRNA levels in the alveolar 
tissues of the immunised and control mammary glands were similar to the levels in 
the control mammary glands of the pregnant group. 
The level of expression for IL-10 mRNA was low, ranging from undetectable to 0.58. 
In the pregnant group, although the average level of IL-10 expression was seven-fold 
higher in the mammary alveolar tissues of the immunised glands compared with the 
control glands, there was no significant difference between the two sets of samples 
(p = 0.06). In the lactation group, there was no detectable expression of IL-10 in the 
immunised mammary glands compared with an average level of 0.16 ± 0.09 in the 
control mammary glands, but this difference was not significant. 
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Figure 6.1 Comparison of the expression levels of the immunised mammary gland 
versus control gland for the cytokines IL-2, IL-6, IL-8 and IL-10 
Alveolar tissue samples were collected from the immunised and control (non-
immunised) sides of the udder. Graphs show the expression levels of target genes 
(relative to ~-actin) in: A, samples from pregnant animals seven days after the 2nd 
intra-mammary immunisation; B, samples from lactating animals five weeks post-
partum. (Group average± SEM, n = 4). Significant differences between the groups 
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Figure 6.2 Comparison of the expression levels of the immunised mammary gland 
versus control gland for cytokines IFN-y, TNF-a, TGF-P and BLyS 
Alveolar tissue samples were collected from the immunised and control (non-
immunised) sides of the udder. Graphs show the expression levels of target genes 
(relative to ~-actin) in: A, samples from pregnant animals seven days after the 2"d 
intra-mammary immunisation; B, samples from lactating animals five weeks post-
partum. (Group average± SEM, n = 4). Significant differences between the groups 
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In the pregnant group, the average level of expression for IFN-y was increased two-
fold in the alveolar tissues of the immunised mammary glands (1.79 ± 0.34) 
compared with the control mammary glands (0.74 ± 0.15), and this difference was 
statistically significant (p < 0.05). In the lactation group, the average IFN-y mRNA 
levels in the alveolar tissues of the immunised and control mammary gland were 
similar to the levels in the control mammary gland of the pregnant group. 
Although the expression for TNF-u was low, there was a significant difference 
between the alveolar mammary tissues from the immunised and control glands when 
the samples for the pregnant group were compared (p < 0.01 ). The level of TNF-u 
mRNA in the lactating group, both the immunised and control mammary glands, was 
similar to the value for the control tissue samples of the pregnant group. 
There was no significant difference between the TGF-P mRNA for the immunised 
and control alveolar mammary gland tissue samples for both the pregnant and 
lactation groups. The level of TGF-P mRNA was similar at the two time points. 
In the pregnant group, there was a three-fold increased level of BLyS mRNA in the 
alveolar tissue samples of the immunised mammary glands (0.40 ± 0.07) compared 
with the controls (0.13 ± 0.02) and this difference was statistically significant (p < 
0.01 ). The average level of BLyS expression in the alveolar tissue of both 
immunised and control samples of the lactation group was similar to the control 
samples of the pregnant group. 
Overall the levels of plgR mRNA were low in the alveolar mammary tissues of the 
pregnant group and while the expression was three-fold higher in immunised tissues 
(0.11 ± 0.04) compared with the control tissues (0.04 ± 0.01 }, this difference was not 
significant (p = 0.1 ). Levels of plgR mRNA in the immunised and control tissues for 
the lactation group were very similar (0.43 ± 0.12 and 0.51 ± 0.13, respectively) and 
significantly higher compared with those levels in the pregnant group (p < 0.05). 
The level of lgA mRNA in the alveolar mammary tissues of the pregnant immunised 
mammary glands was three-fold higher compared with the control mammary glands 
(771.1 ± 108.4 and 262.2 ± 85.6; p < 0.01 ). In the lactation group the level of lgA 
mRNA in the immunised (998. 7 ± 108.4) and control tissues (958.4 ± 85.6) was 
similar to the immunised tissues in the pregnant group. The transcription levels of 
lgA and plgR correlated poorly (r2 = 0.39). 
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6.5.3 Gene expression profiles in cells isolated from mammary 
secretions following intra-mammary immunisation 
The levels of gene expression (relative to p-actin) for cells isolated from bovine 
mammary secretions on Days 2, 12, 14, 15, 19 and 35 following the 151 IMM 
immunisation are shown in Figure 6.3 for IL-8, IL-10 and IFN-y and in Figure 6.4 for 
TNF-a, TGF-P and lgA. The level of gene expression in samples was determined for 
both high- and low-responding animals, however, no significant difference was found 
between the two groups for their level of expression. Therefore, data for the same 
day are pooled for the two groups. 
When interpreting the data for the mammary secretion cells, it needs to be 
remembered that the proportions of the different cell populations within the mammary 
secretion samples were not constant. Lymphocyte percentages fell following each of 
the IMM immunisations and in addition the percentages of neutrophils also changed 
over the time course, in relation to other cell types (see Figure 5.1 ). In the approach 
taken here, the source of mRNA from day-to-day may be from a varied population of 
cells. Cytokine mRNA levels may have been a contribution from one type of cell or 
from several types of cells. In addition, due to technical difficulties, no sample of 
cells was retained for mRNA analysis for Day O and therefore, there was no baseline 
value obtained for comparison with post-lMM immunisation values. 
There were very low levels of mRNA expression for IL-2 and IL-6, in cells isolated 
from mammary secretions, for all days analysed (data not shown), with approximately 
half of the samples having levels being below the level of detection. 
The expression of IL-8 in cells isolated from mammary secretions appeared to be 
higher in the days shortly after IMM immunisation (Day 2, 14 and 15) compared with 
the other days analysed. Levels of IL-8 mRNA were 14-fold higher on Day 14 (two 
days after the 2nd IMM immunisation) compared with Day 12 (the day of the 2nd IMM 
immunisation) and this difference was highly significant (p < 0.001 ). 
IL-10 levels of mRNA in cells isolated from mammary secretions were generally low 
over the time course. On Day 15 and 19 (three and seven days after the 2nd IMM 
immunisation, respectively) some individual animals had increased levels of IL-1 O 
mRNA. However, the average values for all animals at these time points were not 
significantly different from other days analysed. 
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Figure 6.3 Relative gene expression of the cytokines IL-8, IL10 and IFN-y in 
the mammary secretion cells 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Graphs show the level of 
gene expression (relative to (3-actin) in the cells. (Combined average of the high-
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Figure 6.4 Relative gene expression of the cytokines TNF-a, TGF-P and IgA in 
the mammary secretion cells 
Cells were isolated from mammary secretions collected at intervals following intra-
mammary immunisation (at times marked with arrows). Graphs show the level of 
gene expression (relative to p-actin) in the cells. (Combined average of the high-
and low-responding animals ± SEM, n = 8) 
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All days analysed had low levels of IFN-y in cells isolated from mammary secretions 
except Day 19 (seven days after the 2nd IMM immunisation). On this day, levels of 
IFN-y mRNA were four-fold higher compared with others days and this difference was 
statistically significant (p < 0.01 ). 
The level of TNF-a. mRNA in the cells isolated from mammary secretions for days 
analysed over the time course did not vary until Day 35 (three weeks after the 2nd 
IMM immunisation). On this day, TNF-a. mRNA levels were three-fold higher 
compared with other days analysed and this difference was statistically significant (p 
< 0.01). 
Although the levels of TGF-13 mRNA were readily detected in cells isolated from 
mammary secretions the values did not appear to change with IMM immunisation 
although there was a trend for levels to increase over the time course of the 
experiment. 
Levels of BLyS mRNA in the cells isolated from mammary secretions were very low 
(data not shown). 
Cells isolated from mammary secretions were not analysed for plgR mRNA because 
the proportion of total cells in mammary secretions that express plgR i.e. epithelial 
cells, were considered to be low based on the literature (Jensen and Eberhart, 1981; 
Lee et al., 1980). However, identification of epithelial cells in cells isolated from 
mammary secretions was not undertaken in this study. 
The lgA mRNA level in the cells isolated from mammary secretions was at a constant 
level until Day 19 (seven days after the 2nd IMM immunisation). At this time point, the 
levels increased 2.0 - 4.0 times compared with the previous days analysed (p < 
0.01 ). By Day 35 the average level of lgA mRNA was higher than on Day 19 but 
there was considerable animal variation for this time point. A comparison of the 
percentages of lgA-positive cells as measured by flow cytometry (Chapter Five, 
Section 5.5.1.3) and lgA mRNA levels showed no correlation (data not shown). 
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6.6 Discussion 
The regulation of humoral immune responses is complex, involving the interaction 
between different cell types and soluble stimulatory/inhibitory factors such as 
cytokines and chemokines. Data from mouse studies using cloned cells have shown 
specific cytokines to be associated with either a Type 1 or Type 2 immune response 
(Mosmann et al., 1986). However, there is some debate about the delineation of 
cells into strict subsets in vivo (Kelso, 1995). In addition, work undertaken in cattle 
has found that the classical roles of many cytokines in the laboratory mouse may not 
be extrapolated to the bovine species (Estes and Brown, 2002). The objective of this 
chapter was to establish cytokine expression profiles in mammary gland samples that 
may give a better understanding of the immune response being elicited by our 
immunisation procedure. 
In the healthy untreated animals, analysis of the cytokine profiles of the mammary 
gland alveolar tissues showed that there was a wide range of mRNA expression for 
individual animals. For many of the cytokines, the variation amongst individual cows 
within each of the four physiological stages of the mammary gland was as large as 
the variation between the four different stages. 
In accordance with other studies (Alluwaimi and Cullor, 2002; Leutenegger et al., 
2000), levels of IL-2 mRNA were generally low. Similarly the cytokines associated 
with the Th2 response, IL-6 and IL-10, were also found to be low in this study. This 
was also in agreement with other studies where these cytokines were reported to be 
low in healthy cows (Alluwaimi and Cullor, 2002; Riollet et al., 2000b; Taylor et al., 
1997). Conversely, mRNA levels of IFNy were significantly different between 
physiological stages with levels higher in pregnant, lactation and involution phases of 
the mammary gland compared with the colostrum phase. This observation was 
different to reports in the literature where IFN-y measured as protein in milk was 
observed to be elevated in colostrum compared with early, middle and late lactation 
(Hagiwara et al., 2000). However, this disparity in results may reflect that IFN-y 
measured as protein in milk in the Hagiwara et al. study (2000) is not equivalent to 
IFN-y mRNA levels in tissues, as measured in this study. Aside from the fact that 
there may be differences in comparing mRNA and protein, there may also be a 
different repertoire of cells contributing to the protein levels of this cytokine in milk 
versus cells contributing to the mRNA levels in the mammary tissues. 
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Mammary gland levels of IL-8 mRNA in the untreated animals appeared to be 
elevated in the colostrum phase. However, because of very large variations amongst 
individual animals there was no significant difference in values between the 
physiological stages of the mammary gland. IL-8 is a chemoattractant for neutrophils 
and elevated levels of this cytokine may reflect a response to bacterial infection, 
although all animals in this study were supposedly free of mastitis infection. In 
contrast, levels of TNF-a mRNA were undetectable at all physiological stages of the 
mammary gland suggesting that they were indeed healthy uninfected mammary 
glands. The undetectable levels of TNF-a mRNA in this study were different to the 
observations described by Alluwaimi and Cullar (2000) where the levels of TNF-a 
mRNA in milk cells were significantly elevated in mid- and late-lactation milk 
compared with other cytokines measured. 
In the mammary gland tissues of untreated animals, the mRNA levels of lgA relative 
to p-actin mRNA were the highest of all of the genes tested. Interestingly, the mRNA 
levels of lgA were lowest in colostral mammary tissues and highest in lactation 
mammary tissues. This is the opposite of that observed for protein levels of lgA, 
which are highest in colostrum mammary secretions compared with other 
physiological stages of the mammary gland. However, this may simply reflect the 
fact that lgA is concentrated in colostrum over many weeks pre-partum. Why 
expression of the gene should be elevated in lactation when levels of the lgA protein 
are low in milk (0.08 g/1 in milk compared with 0.37 g/1 in colostrum) (Butler, 1983), 
could not be ascertained from the data in this study but may possibly indicate that 
lgA mRNA is not being translated into protein or the translated protein is not being 
transported into secretions. This finding warrants further investigation. 
The transport of lgA into mammary secretions is controlled by plgR (Brandtzaeg, 
1985; Kaetzel et al., 1991 ). Overall the levels of plgR mRNA detected in the 
untreated bovine mammary gland was in accordance with that found in studies using 
sheep (Rincheval-Arnold et al., 2002) and mice (Van der Feltz et al., 2001 ). An 
interesting finding was that mRNA levels of plgR did not correlate with lgA mRNA 
levels. This may suggest that plgR is a limiting factor for the secretion of lgA into 
bovine mammary secretions, similar to that suggested by others for ovine mammary 
secretions (Scicchitano et al., 1986; Sheldrake et al., 1984 ). 
Overall, the data suggest that in the healthy untreated animals, cytokine expression 
in the mammary gland is generally low, consistent with a non-inflammatory, non-
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infected physiological state although a wide variation for individual animal expression 
levels within groups at the four different physiological stages of the mammary gland 
was observed. 
Cytokine profile analysis of immunised and control (non-immunised) mammary 
tissue, collected at two different time points after the 2nd IMM immunisation, also 
found low expression levels for many of the cytokines tested, similar to the untreated 
animals. This was the case for both IL-2 and IL-6, and the low levels were similar 
when immunised and control alveolar tissues were compared. There was a trend 
towards increased mRNA expression of IL 10 mRNA in the immunised mammary 
tissues seven days after the 2nd IMM immunisation, in comparison to the control 
tissues and this was also the pattern for IFN-y expression. All of these cytokines are 
expressed by subpopulations of activated T cells, for example in a Th1 type immune 
response CD4 cells express IL-2 and IFN-y, whereas in a Th2 type response, CD4 
cells express IL-6 and IL-10. However, overall data for these cytokines did not yield 
any conclusive information about the relative activity of these cells types except to 
suggest that they were not actively expressing cytokines at the time points sampled 
or the levels of cytokines required for biological activity are below the level of 
detection by this method of analysis. 
Transcription levels of the pro-inflammatory cytokine TNF-a were increased in the 
immunised mammary tissues compared with the control tissues, sampled seven days 
after the 2nd IMM immunisation. Immunised animals sampled during lactation had 
reduced mRNA levels of this cytokine compared with the immunised samples 
collected from the pregnant animals. Taken together, this would suggest that the 
IMM immunisation had induced an inflammatory response in the mammary gland. 
However, the generally low levels of TNF-a would suggest that a prolonged 
inflammatory response was not invoked. 
The observation that immunised mammary tissues, sampled seven days after the 2nd 
IMM immunisation, showed markedly increased levels of expression of IL-8 (15-fold) 
in comparison to control tissues suggests that IMM immunisation may induce an 
influx of cells via stimulation of this cytokine in mammary tissues. This is based on 
the knowledge that IL-8 has been shown to be a potent inducer of neutrophil 
infiltration into tissues (Bickel, 1993), and in vitro studies have shown that it may also 
be chemotactic for T and B cells (Bacon et al., 1989; Schratzberger et al., 1997). 
Transcriptional levels of IL-8 from tissues collected five weeks post-partum from the 
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immunised and control mammary glands of the lactating group were similar and 
reduced compared with pregnant immunised tissues, suggesting that the IMM 
immunisation stimulation of IL-8 production was not sustained over weeks. 
The cytokine shown to be involved in lgA class-switching in mice, TGF-~. (Kim and 
Kagnoff, 1990; Lebman and Edmiston, 1999), showed no discernible difference in 
mRNA levels between the immunised and control mammary tissues of both time 
points following IMM immunisation. However, transcriptional levels for this cytokine 
were readily detectable in most tissue samples analysed. Of course, it must be 
remembered that TGF-~ has a myriad of functions. One of the most pronounced 
properties of TGF-~ is that it is anti-proliferative for immune cells, including B cells 
(Lebman and Edmiston, 1999). Given its suppressive nature, it may be important for 
this cytokine to be highly regulated and changes in expression of TGF-~ may not 
have been observed in this study due to the timing of sampling. 
The TNF family member, BLyS has been attributed with the function of maintaining 
the survival of both mature B cells and plasma cells (Avery et al., 2003; MacKay and 
Browning, 2002). Expression levels of BLyS were three-fold higher in the immunised 
mammary tissues than control tissues, suggesting that the higher numbers of plasma 
cells detected in immunised tissues (as described in Chapter Four) may be, at least 
in part, attributable to the action of this cytokine. 
On the whole, levels of lgA mRNA were found to be increased when immunised 
mammary tissues were compared with control tissues, collected seven days after the 
2nd IMM immunisation, suggesting that the immunisation had induced increased 
levels of lgA mRNA. In contrast, levels of plgR mRNA in the immunised animal were 
low, with levels higher in mammary tissues collected five weeks post-partum 
compared with tissue collected seven days after the 2nd IMM immunisation, similar to 
the finding in the untreated animals and in accordance with the findings of other 
studies on sheep (Rincheval-Arnold et al., 2002) and mice (Van der Feltz et al., 
2001 ). Taken together these results would indicate that the up-regulation of lgA 
production does not induce a corresponding increase in plgR transcriptional levels 
and may suggest that plgR is limiting lgA secretion in the ruminant mammary gland. 
Cells that were isolated from mammary secretions over the IMM immunisation time 
course had low IL-2 mRNA levels, similar to the other two sample sets analysed. T 
cells are a major producer of IL-2 (Smith, 1988). Therefore, a more significant level 
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of IL-2 might have been expected in the mammary secretion cells because T cells 
comprised approximately 1 O - 25% of the total cells in these samples and greater 
than 90% of these were activated cells (see section 5.5.1.2). However, IL-2 acts in a 
paracrine/autocrine fashion (Janeway et al., 2001 b) and thus, in vivo, a low level may 
be all that is required for effective biological activity. Cell culture studies have 
demonstrated that IL-2 can be a potent immunomodulator of bovine immune cells 
(Shafer-Weaver and Sordillo, 1996; Sordillo et al., 1991 a; Wedlock et al., 2000). 
The finding that cells isolated from mammary secretions showed an increase in IFN-y 
at the same time point corresponding to that when IFN-y mRNA levels in immunised 
mammary tissues were also elevated suggests that IFN-y expression is elevated by 
IMM immunisation. IFN-y is produced by T cells and the observation that there was 
no increase in IFN-y mRNA levels from Day 2 until Day 19 (seven days after the 2nd 
IMM immunisation) may reflect the reduction in the percentage of total lymphocytes 
observed in mammary secretions following IMM immunisation. The expression 
profile for IL-10 over the time course was less well-defined. Although there appeared 
to be a trend for levels of IL-10 mRNA to increase following the 2nd IMM 
immunisation, there was a variation in response between individual animals. In 
another bovine study, measurement of the IL-10 protein by ELISA showed the levels 
increased for a short time after E. coli mammary gland infection (Bannerman et al., 
2004). Human recombinant IL-10 has been shown to be suppressive on bovine T-
cell proliferation and IFN-y production (Brown et al., 1994). This did not appear to be 
the case in this study; levels of IFN-y mRNA were at their peak on Day 19 when IL-
10 levels were also at their peak. This may indicate that the level of IL-10 was not 
sufficient to suppress the T-cell production of IFN-y or that the cells producing IL-10 
were not in the proximity of the T cells producing IFN-y 
In the cells isolated from the mammary secretions over the time course, mRNA levels 
of the pro-inflammatory cytokine TNF-u were generally low, similar to those levels 
found in immunised mammary tissues, although these levels were increased by Day 
35, (three weeks after the 2nd IMM immunisation). However, in general the TNF-u 
mRNA levels in immunised animals were detectable, in contrast to the undetectable 
levels in the untreated animals. In other studies, transcriptional levels of TNF-u in 
milk cells from mastitic animals have found a variety of results, ranging from no 
detection to elevated levels, compared with healthy animals (Alluwaimi et al., 2003; 
Taylor et al., 1997). In cows with naturally occurring mastitis, TNF-u mRNA levels 
were undetectable in milk cells (Taylor et al., 1997) in contrast to cows experimentally 
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infected where levels of TNF-a in milk cells were increased at 24 h and then 
decreased by 36 h post-infection (Alluwaimi et al., 2003). This would suggest that 
either cells expressing TNF-a mRNA levels occur transiently in milk or cells express 
TNF-a only in the acute stages of the infection. This could also explain why an 
increase in TNF-a was not observed in mammary secretions because in this study 
the first samples were collected 48 h post IMM immunisation. The reason for an 
increase in TNF-a mRNA in Day 35 samples cannot be explained with the data to 
hand. 
In the cells isolated from mammary secretions, the marked increase in IL-8 mRNA 
levels following the 2nd IMM immunisation were mirrored by the infiltration of 
neutrophils as measured by flow cytometry (Chapter Five). In addition these data 
were in agreement with IL-8 mRNA levels observed in immunised mammary tissues, 
where levels were elevated in samples collected seven days after the 2nd IMM 
immunisation compared with control samples. Taken together, this would indicate 
that the IMM immunisation induced an innate immune response in the mammary 
gland with increased levels of IL-8 inducing an influx on neutrophils to the gland. 
However, an innate response is generally characterised as a rapid response yet IL-8 
expression levels were still elevated in mammary secretion cells at Day 35, three 
weeks post-lMM immunisation. This may suggest that IL-8 is playing a different role 
at this time point that cannot be ascertained from the data in these studies. 
In mammary secretion cells the general observation was that TGF-P mRNA levels 
tended to be lower in the early stages of the time course following IMM immunisation 
compared with the later stages. This late stage increase in TGF-P may explain why 
no difference was observed in TGFP mRNA levels between the immunised and 
control tissues samples collected from animals seven days after the IMM 
immunisation. In addition, expression levels of this cytokine were similar for 
immunised animals both seven days after IMM immunisation and five weeks post-
partum suggesting that this is the normal level for mRNA TGF-P and that immediately 
following IMM immunisation the expression of this cytokine in cells isolated from 
mammary secretions was reduced. Down-regulation of this cytokine during the early 
immune response would help promote cell proliferation as TGF-P has been 
demonstrated to be anti-proliferative for both T and B cells (Lebman and Edmiston, 
1999; Stoeck et al., 1989). In this manner TGF-P plays a important role in the 
mediation of immune regulation (Wahl et al., 2004). 
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Interestingly, levels of BLyS mRNA were lower in samples of mammary secretion 
cells compared with samples of mammary tissues. This may reflect the differences in 
cell types that were in the different samples, although neutrophils (present in the 
secretion cell population) have been shown to express BLyS (Scapini et al., 2004). 
The lgA mRNA levels in cells isolated from the mammary secretions, which 
increased over the time period sampled, did not correlate with the percentages of 
lgA-positive cells as measured by flow cytometry. This may have been due to the 
fact that flow cytometry did not measure plasma cells but only plasmablasts. 
Contribution to lgA mRNA levels would have been from both populations of these 
cells. 
Overall data for the immunised animals suggest that IMM immunisations induce a 
complex immune response. Low levels of TNF-a would suggest that a prolonged 
inflammatory response is not invoked although a transient inflammatory response 
cannot be ruled out. A mammary secretion sample was not collected until two days 
after each IMM immunisation, by which time a spike in TNF-a may have occurred 
undetected. The observed increases in IL-8, along with rises in IFN-y, may indicate 
that the IMM immunisations induced innate and cell-mediated types of immune 
responses, in addition to a humoral response. This was supported by the data that 
there were fluctuations in both neutrophils and lymphocyte cell populations in the 
total cells isolated from mammary secretions after the IMM immunisations. No 
conclusion could be drawn regarding the relative activity of Th1 and Th2 type CD4 
cells from the cytokine gene expression profiles. Many of the cytokine genes were 
expressed at low levels and changes occurred within a relatively short time following 
the IMM immunisations, and this was reflected in the comparison of the data for the 
immunised tissue trial and the time course trial. 
Surprisingly, there was no difference in the mRNA cytokine expression profile in the 
cells isolated from mammary secretions when high- and low-responding animals 
were compared. There are several potential explanations for this observation. The 
results may suggest that the cells released into the cistern and collected in mammary 
secretions did not truly reflect the mammary gland cellular environment. 
Alternatively, these results may indicate that mRNA transcription levels in cells do not 
translate into protein bioactivity in the mammary gland. Another possibility is that the 
cytokine profile reflected not only the lgA induction but also a more generalised 
inflammatory response to the immunisation challenge which one would expect to be 
similar in both the high- and low-responding animals. However, the observation that 
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there was no difference in cytokine expression levels in the mammary gland of these 
animals may simply mean that the factors that determine a high- and low-responding 
animal occur prior to IMM immunisation and are induced by the priming of the animal 





7.1 General discussion 
The overall aim of this thesis was to investigate the molecular and cellular 
mechanisms that are involved in the local induction of lgA secretion in the bovine 
mammary gland. In our earlier studies, it has been shown that each of the intra-
peritoneal (IP), intra-muscular (IM) and intra-mammary (IMM) routes for immunisation 
are required for maximal lgA responses (Hodgkinson and Hodgkinson, 2003). All the 
combinations of IP, IM, and IMM routes were trialled but the highest titre of lgA 
antibody in colostrum and milk in the greatest number of animals was found when a 
combination of all three routes was used. In particular, earlier studies have shown 
that IMM immunisation is critical for lgA production in mammary secretions signifying 
that this immunisation is essential for inducing pathways involved in the process. If 
one side of the udder is immunised and not the other, then lgA is produced only in 
the milk from the side that has been treated. This suggests that lgA produced by our 
regimen is localised to the mammary gland and that the IMM immunisation activates 
molecular and cellular processes in the treated gland to induce this response. For 
local lgA secretion, it is essential to have immune cells in the mammary gland. At the 
start of the work for this thesis, the key questions were: what cells are required in 
situ; where do they come from; how do they get into the mammary gland; and how do 
they interact to induce the lgA production in mammary secretions? It was these key 
'knowledge gaps' pertaining to the cow, identified from the proposed mechanism of 
action of our multi-site immunisation regimen (section 1.5.3.3), that provided the 
focus for the investigations detailed in this thesis. 
The concept of a common mucosal immune response suggests that antigenic 
challenge at one mucosal surface can be reflected in immune effector responses at 
distant mucosal sites (McDermott and Bienenstock, 1979; McDermott et al., 1980). 
Our multi-site immunisation regimen is based on this principle. In the proposed 
mechanism of lgA production (Section 1.5.3.3), the cells that are generated by the 
administration of antigen at the IP and IM sites migrate into the blood and circulate 
the body. These cells home to the mammary gland after the gland has been 
exposed to the same antigenic challenge via the IMM immunisation. Homing of 
effector cells has been shown in mice to be coordinated by the interaction of 
adhesion molecules and chemokines expressed on the vascular endothelium of the 
local tissues and their receptors displayed on the cell surface of immune cells 
(Butcher et al., 1999; Picker, 1994; Radi et al., 2001 ). 
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From the work in this thesis, it can be seen that following the IMM immunisations 
there was an increase in the numbers of T and differentiated B cells in the alveolar 
tissue of the mammary gland. In this study, the characterisation of adhesion 
molecules expressed by the bovine mammary gland found differences when the 
results were compared with studies on mice. MAdCAM-1 and VCAM-1 did not 
appear to be involved in the recruitment of lymphocytes to the mammary gland in the 
cow, unlike in the mouse. A study on mice observed a correlation between T cell 
immigration to the mammary gland and MAdCAM-1 levels on mammary vascular 
endothelium (Tanneau et al., 1999). In another study on mice, there was evidence of 
a link between VCAM-1 and lgA plasmablast recruitment to the mammary gland 
(Finke and Acha-Orbea, 2001 ). 
The observed differences in adhesion molecule expression between the mouse and 
cow may account for the variation in the immunoglobulin repertoire secreted in the 
milk of the two species. In the cow, the predominant immunoglobulin class is lgG, in 
contrast to the mouse, where the major immunoglobulin class is lgA (Brambell, 
1970). However, in the work in this thesis, when lgA production was induced in the 
bovine mammary gland there was no evidence of changes to MAdCAM-1 or VCAM-1 
expression in immunised mammary tissues compared with non-immunised (control) 
mammary tissues. In support of the non-detection of MAdCAM-1 in immunised 
mammary alveolar tissues by immunohistochemical methods, very low levels of 
MAdCAM-1 mRNA were found in these same tissues compared with bovine Peyer's 
patch tissues. 
Overall the results of the investigations suggest that the adhesion molecules involved 
in lymphocyte homing to the bovine mammary gland differ from those described in 
the literature for the mouse. Contrary to the situation in the mouse, MAdCAM-1 and 
VCAM-1 may not be involved in the recruitment of lymphocytes to the bovine 
mammary gland. In the cow, other factors such as chemokines may be responsible 
for this process. 
Recently it has been proposed that CCL28 is a key regulator of lgA plasma-cell 
accumulation in the mammary gland and this chemokine has been shown to be up-
regulated in the mouse mammary gland during lactation (Wilson and Butcher, 2004). 
In the Wilson and Butcher (2004) study, lgA plasma cells isolated from mammary 
tissues expressed CCR10, the receptor for CCL28, while in vivo treatment with anti-
CCL28 blocked lgA plasma-cell accumulation. In future studies, it would be of 
interest to measure mRNA levels of this chemokine and its receptor in mammary 
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tissues and cells (isolated from mammary secretions) collected from cows immunised 
using our multi-site immunisation regimen. 
Although a clear mechanism for recruitment of lymphocytes to the bovine mammary 
gland has not resulted from these studies, a marked increase in the numbers of 
lymphocytes in tissues following IMM immunisation was observed. This suggests 
that there is a mechanism in operation to recruit cells to the mammary gland in 
response to IMM immunisation. Whether all of the lymphocytes were recruited to the 
mammary gland or just a small percentage of the cells which then proliferated in situ 
could not be elucidated from these studies. In other studies, it has been shown that 
memory T cells (both Th1 and Th2 type CD4 cells) respond rapidly to re-exposure to 
antigen that originally induced them, by proliferating and secreting cytokines (Rogers 
et al., 2000). Therefore, it is possible that memory T cells recruited to the mammary 
gland, proliferated when re-exposed to antigen. Following IMM immunisation, an 
increase was observed in the proportion of CD4 cells compared with COB cells, 
however, cytokine gene expression analysis was not able to differentiate whether 
these CD4 cells were Th1 or Th2 type cells. Overall, it can be seen that IMM 
immunisation had a marked stimulatory effect on the alveolar tissues of immunised 
mammary glands compared with the non-immunised (control) glands, as shown by a 
significant accumulation of lymphocytes. 
In response to foreign antigen exposure, the first line of defence is usually an innate 
immune response. This is typified by an influx of neutrophils into tissues in response 
to pro-inflammatory cytokines and the expression of the chemokine IL-8 by 
endothelial cells (Bickel, 1993). In the studies in this thesis, the same pattern of 
response, an increase in neutrophils and a rise in IL-8 mRNA expression, was 
observed following the IMM immunisations. A key component of the host innate 
immune response is the up-regulation of pro-inflammatory cytokines. Measurement 
of mRNA expression for the pro-inflammatory cytokine TNF-a determined that levels 
were not highly elevated following IMM immunisation. However, as samples were 
not collected until two days after the immunisation, a rise and subsequent fall in TN F-
a prior to the first sampling cannot be discounted. In other studies where the bovine 
mammary gland was experimentally infused with mastitis-inducing organisms, TNF-a 
protein levels in milk were reported to be elevated 1 - 5 h later, with levels reduced to 
normal by 24h (Paape et al., 2002b) and levels of TNF-a mRNA in milk cells were 
reported to be increased at 24 h and decreased by 36 h (Alluwaimi et al., 2003). In 
the studies in this thesis, there were physical signs of inflammation, including 
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oedema in the mammary gland and generalised non-specific changes in the 
consistency of mammary secretions, for several days following the IMM 
immunisations, suggesting that levels of the pro-inflammatory cytokine TNF-a may 
have been transiently elevated following IMM immunisation. 
A significant increase in both T cells and differentiated B cells was found in the 
alveolar tissues that were collected seven days after IMM immunisation. In another 
study in this thesis, analysis of mammary secretion cells before and after IMM 
immunisation illustrated the rate of lymphocytes infiltrating into and/or proliferating in 
the mammary gland in response to the immunisations. The increased levels of 
mRNA for the cytokines, IL-10 and IFN-y following the IMM immunisation, suggest 
that these cells were activated and interacting with one another. For example, the 
cytokine IL-10 has been shown to induce B cells to increase antibody production 
(Burdin et al., 1997) and may be inducing this effect here in the immunised mammary 
gland. On the other hand and in contrast to IL-10, transcriptional levels of IL-6 were 
very low in mammary secretion cells following IMM immunisation, although IL-6 has 
been demonstrated in other studies to be essential for lgA production (Morse et al., 
1997). IL-6 knockout mice have greatly reduced numbers of intestinal plasma cells 
and poorly developed lgA responses to mucosal immunisation (Ramsay et al., 
1994a). 
Some of the 'classical' cytokines of the adaptive immune response were found to be 
raised following IMM immunisation, e.g. IFN-y, and IL-10. Activation of this cytokine 
repertoire suggests that both cell-mediated and humeral responses may be induced 
by the IMM immunisation. The concept that expression patterns of cytokines may be 
linked to a particular immune response is based on in vitro cell culture studies using 
cloned mouse cells (Mosmann et al., 1986; Mosmann et al., 1997; Mosmann and 
Sad, 1996). However, the paradigm may not extrapolate to in vivo conditions or to 
other species and in particular cows (Estes and Brown, 2002). Also, it should be 
noted that in the studies in this thesis, the cytokine mRNA levels were measured in 
samples that contained a mixture of cells; therefore, it is difficult to distinguish which 
cells are responsible for individual changes in cytokine transcription. Many of the 
cytokines are produced by several different cell types. For example IL-10 is 
produced by T cells, macrophages and activated B cells (Burdin et al., 1997; Spits 
and de Waal Malefyt, 1992). The other factor that must be considered is that the 
same cytokine produced by different cells can have different actions. For example, 
TGF-P produced by T cells plays a major role in the class-switching process to lgA 
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(Kim and Kagnoff, 1990; Lebman and Edmiston, 1999) while TGF-P produced by 
epithelial cells has been shown to have an inhibitory effect on lymphocyte 
proliferation (Ebert, 1999). Overall a cautious approach is needed when interpreting 
cytokine gene expression profiles. 
Of primary interest in these studies were the 8 cells. This cell type is essential for the 
production of lgA antibody in mammary secretions. The main questions are: where 
do the 8 cells come from, and at what stage in the development of a response do 
they enter the gland? The IMM immunisation is administered four weeks after the 
primary immunisations at the IP/IM sites, in conjunction with a booster dose at the 
IP/IM sites. Therefore, memory T and 8 cells generated in response to the primary 
immunisation will respond to the subsequent antigen booster. From the 
characterisation studies of cells isolated from mammary secretions, it was shown that 
there were increased percentages of plasmablasts in the mammary gland as early as 
two days after IMM immunisation (Chapter Five). Many of these 8 cells consisted of 
the lgA isotype and this, in conjunction with priming at mucosal sites and the concept 
of the common mucosal immune system, would suggest that these cells were of 
mucosal origin. 
There were low numbers of 882 cells observed in mammary secretions with no 
apparent difference between the High and Low group for this cell type. In addition, 
from the immunohistochemical studies it can be said categorically that seven days 
after IMM immunisation there are increased numbers of plasma cells in the tissues of 
the immunised mammary gland (Chapter Four). Taken together, these data would 
suggest that the 8 cells enter the gland as plasmablasts that then differentiate into 
antibody-secreting plasma cells presumably under the influence of Th2 type CD4 
cells, antigen-presenting cells and associated secretory cytokines. Proliferation of 
plasmablasts would, therefore, probably occur in situ. It is thought that differentiation 
of plasmablasts into plasma cells is preceded by a burst of proliferation, with 
cessation of cell division being a prerequisite of differentiation (Calame et al., 2003a; 
Chen-Kiang, 2003). The finding, in the studies in this thesis, of antibody-containing 
cells with double nuclei in mammary gland tissues may be suggestive that these cells 
do proliferate in the mammary gland. On the other hand, the cells had the 
histological appearance of antibody-secreting cells (plasma cells) rather than 
immature plasmablasts, having their cytoplasm heavily stained by antibody specific 
for lgA or lgM. This raises the debate about whether or not plasma cells are able to 
proliferate. In the literature, plasma cells are definitively described as terminally 
differentiated cells (Chen-Kiang, 2003; Cyster, 2003; O'Connor et al., 2003). 
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The final step in the process of producing lgA in mammary secretions, as described 
in Section 1.5.3.3, is the transfer of lgA antibody across the alveoli epithelial cells and 
into the lumen. The transport of lgA into secretions is controlled by the poly-
immunoglobulin receptor (plgR) with one plgR molecule transporting one molecule of 
lgA (Brandtzaeg, 1985; Kaetzel et al., 1991). The plgR molecule is not recycled. In 
the studies in this thesis, transcriptional levels of plgR were found to be generally low 
in mammary tissues from untreated animals, although there was higher expression 
during the lactation stage. This pattern of expression of plgR mRNA is in accordance 
with the findings of others in sheep (Rincheval-Arnold et al., 2002) and mice (Van der 
Feltz et al., 2001 ). Therefore, this may suggest that the low levels of lgA 
characteristic of bovine mammary secretions are due to a deficiency in the transport 
of this immunoglobulin by plgR, as suggested by others for sheep (Scicchitano et al., 
1986; Sheldrake et al., 1984 ). There was no significant difference in the expression 
of this gene between immunised and control alveolar tissues, from both pregnant and 
lactating animals, although levels of mRNA plgR were higher in the lactation 
samples, similar to the untreated animals. In tissues samples, transcriptional levels 
of plgR correlated poorly with transcriptional levels of lgA, again suggesting a 
deficiency in the lgA transport system. 
The use of animals that had been previously immunised with our multi-site regimen 
allowed for a valuable comparison between animals that responded well to the 
immunisation and animals that responded poorly. From the work in Chapter Five, the 
main finding was a significant difference between the high- and low-responding 
animals in the pattern of cellular response following IMM immunisation. Interestingly, 
a difference between the groups for their cytokine expression levels in mammary 
secretion cells could not be detected. This could be explained by the fact that there 
was no significant difference between the T-cells populations for these two groups, if 
this cell type contributed a significant proportion of the mRNA detected in cell 
samples. This again highlights the difficulty in interpreting mRNA cytokine data for 
samples that have a mixture of cell types. 
Another valuable outcome from using high- and low-responding animals is that it 
reinforced the finding that animals respond in a consistent manner to the multi-site 
immunisation regimen each year they are immunised. This was the third consecutive 
year that these animals had been immunised. The results for lgA levels in milk 
confirmed that a high-responding cow appears to always produce a high titre 
antibody response and conversely a low-responding cow appears to always produce 
a low titre antibody response. These data imply that there are different genetic 
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characteristics in these animals that are influencing the outcome of their immune 
response. This has widespread ramifications and may lead to the discovery of 
genetic factors that control or regulate immune responses to vaccination. 
There are several other factors that need to be considered when drawing conclusions 
from the data produced in this thesis. Relatively small numbers of animals were 
used for experimentation. Since the experimental animal was a dairy cow, there 
were significant cost implications for trial design. Small experimental groups mean 
that individual animal variation has a large influence on results. For example, the 
levels of cytokine mRNA in the mammary gland tissues of untreated animals at four 
different physiological stages of the mammary gland often had larger variation within 
the group than compared with the different stages. This meant that the only 
conclusion that could be drawn is that the cytokine expression is highly variable. 
Small numbers of animals were also an issue in the experiment in Chapter Four 
where na"ive animals were immunised. At least one of the animals did not respond 
with significant levels of lgA as determined by the level of antigen-specific lgA in 
mammary secretions. On the other hand, animals in this experiment were 
immunised on one side of the udder only, therefore, the other side acted as an 
individual control for each animal. Clearly with the dairy cow being such an 
expensive animal, this places constraints on experimental design but it is contended 
that within the boundaries of the resources available, the experimental design was 
appropriate for addressing the key questions in this thesis. 
The timing of collection was another issue when data were being interpreted. For 
example, in Chapter Four, tissues samples were collected from the mammary gland 
seven days after the 2nd IMM immunisation. The timing meant that although the 
expression of MAdCAM-1 was not detected in these tissues samples, it cannot be 
discounted that expression of the adhesion molecule may have occurred earlier. If 
cell migration occurred within a short time period of the IMM treatment, it is possible 
that expression of the adhesion molecules on the vascular endothelium may have 
occurred undetected in the interval prior to tissue samples being collected. However, 
data from the experiment where cells in mammary secretion were analysed showed 
that increased levels of T and B cells were sustained for more than seven days after 
the IMM immunisation. This would suggest that the infiltration of lymphocytes to the 
mammary gland was still occurring when the tissues samples were collected from the 
immunised mammary glands. On the other hand, it is possible that the observed 
increased level of cells may have been due to proliferation in situ of a small number 
of cells that had been recruited immediately following IMM immunisation. 
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Another example of timing influencing the interpretation of results was in the 
experiment where mammary secretions were collected from the mammary gland 
after the IMM immunisations. In this case it was decided that it would be prudent not 
to sample the gland until two days after the IMM immunisation in order to reduce the 
chance of removing immunogen along with the secretions. The timing meant that 
early events in the immune response, for example a transient inflammatory response, 
would not be detected using this approach, Secretion samples taken within the first 
24 h following IMM immunisation would provide valuable information. 
Another issue relates to the use of mammary secretion cells to reflect the cellular 
environment of the mammary gland. Many studies investigating the health of the 
dairy cow udder have used cells isolated from the milk. While colostrum and milk 
samples from healthy animals have low numbers of cells (Concha, 1986), mastitis is 
characterised by a high somatic cell count in milk (Jensen and Eberhart, 1981 ). One 
study suggested that at the pre-partum stage of mammary development (the dry 
period) the gland is more susceptible to infection, therefore, there are increased 
numbers of immune cells in pre-partum mammary secretions to counteract bacterial 
infection (Jensen and Eberhart, 1981 ). The mechanism of transport of cells into the 
lumen of the healthy cow is not completely understood although several modes of 
transport in the infected mammary gland have been suggested (Nickerson and 
Pankey, 1985). In the experiment in Chapter Five, cells from mammary secretion 
were utilised to monitor the immune response of the mammary gland to the IMM 
immunisation. In the pre-lMM immunisation secretion samples, which were collected 
during the dry-period from pre-partum animals, there were high numbers of 
lymphocytes. The percentages of lymphocytes decreased following each of the two 
IMM immunisations then recovered to their previous levels. The reason for this was 
not determined from the data but may be due to a greater number of neutrophils 
being transported into mammary secretions using the same pathways. Another 
explanation may be that the mammary gland retained lymphocytes in the tissues 
following IMM immunisation in a manner similar to that process in infected lymph 
nodes (Janeway et al., 2001 a). Using mammary secretion cells allowed for multiple 
non-invasive sampling over an extended time period. However, the validity of the 
results from these studies needs to be verified using tissue sampling. 
In summary, the data presented in this thesis have increased the understanding of 
the molecular and cellular mechanisms underlying our multi-site immunisation 
procedure. The main focus of this work was investigating the effects of the IMM 
immunisations in the mammary gland. Many of the key elements of the response 
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identified in the proposed mechanism in Section 1.5.3.3 have now been 
characterised for the cow. 
The work in this thesis has shown that the immune response invoked by the IMM 
immunisations is not a simple response but is complex, and in many ways follows the 
'classical' immune response to foreign pathogenic invasion. After each of the IMM 
immunisations there is firstly an inflammatory response as characterised by the 
physical changes to the mammary gland and its secretions. This is quickly followed 
by a rise in IL-8 and an influx of neutrophils, distinctive of an innate immune 
response. The actual mechanism for recruiting the circulating lymphocytes into the 
bovine mammary gland is not as yet determined. In mammary secretions prior to the 
IMM immunisation, the T-cell population is a combination of helper T cells (CD4) and 
cytotoxic T cells (CD8), in a ratio of approximately 1.5:1 respectively. As the cellular 
response progresses, there is a change in this ratio to 3:1 indicating a greater 
proportion of CD4-positive cells compared with CD8-positive cells in mammary 
secretions. These changes may indicate that CD4 (MHC class II) type cells are 
recruited in preference to CD8 (MHC class I) type cells and/or the CD4 cells are 
preferentially proliferating in response to antigen exposure. Whether the CD4 cells 
are Th1 or Th2 type could not be determined from the data to hand. The known fact 
that the multi-site immunisation regimen activates a humeral response may indicate 
that a proportion of the CD4 cells are of the Th2 type. 
As the cellular response of the mammary gland progresses, the percentage of B 
lymphocytes increases from 30 to 50% of the total lymphocyte population. These B 
cells consist of a combination of lgA-, lgM- and lgG-positive cells. Following the IMM 
immunisations, the lgA-positive cells increase in a biphasic pattern with the response 
being greater after the 2nd IMM immunisation. In contrast, the magnitude of response 
for the lgM-positive cells is similar for both IMM immunisations. High-responding 
animals react more rapidly to the 2nd IMM immunisation and sustain the response for 
longer when compared with the Low-responding animals. The High-responding 
animals also produce a greater percentage of lgA-positive cells and this correlates 
with a greater antibody response. Overall the data indicate that the B cells enter the 
gland as plasmablasts that then differentiate into antibody-secreting plasma cells, 
presumably under the influence of the Th2 CD4 cells and antigen-presenting cells 
and their secreted cytokines. By seven days after the 2nd IMM immunisation, there 
are significantly increased numbers of lgA, lgM and lgG plasma cells in immunised 
mammary gland alveolar tissues in comparison with non-immunised tissues. By Day 
35, antigen-specific and total lgA antibody levels in mammary secretions are 
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significantly higher in High-responding animals compared with the Low-responding 
animals. 
Many of the underlying molecular and cellular mechanisms for the induction of lgA 
secretion in the bovine mammary gland have been established by the work 
undertaken in this thesis. Our multi-site immunisation regimen induces a complex 
immune response and there is still considerable work required to fully elucidate the 
underlying mechanisms. Future avenues for investigation are outlined in Section 7.3 
below. 
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7 .2 Future work 
There are several areas of investigation that could be explored to further increase the 
understanding of the immune response induced by our multi-site immunisation 
regimen. As with many scientific investigations, further questions are raised by the 
research. This work is no exception. 
The mechanism by which circulating lymphocytes are recruited into the mammary 
gland from the blood was not established, although the role of several adhesion 
molecules was investigated and found to be unlikely candidates. A further study 
would be to investigate the function of chemokines in lymphocyte homing to the 
bovine mammary gland, in particular the chemokine CCL28 and its receptor CCR10. 
A recently published paper has identified these two molecules as key components in 
the recruitment of lgA antibody-producing cells to the mouse mammary gland (Wilson 
and Butcher, 2004). Mammary gland tissue samples and the mammary secretion 
cells that were collected from immunised animals could be used to measure 
transcription levels of the CCL28 and CCR10 genes. Likewise, mammary secretion 
samples that were already collected and stored could be used for measurement of 
the CCL28 protein levels and for migration studies, using purified bovine lymphocytes 
and transmembrane wells. 
Data about the timing of the immune response in the mammary gland following IMM 
immunisation has been generated from the study characterising cells in mammary 
secretions. A follow-up study collecting tissue samples from immunised mammary 
glands and control glands at key time points is required to verify the molecular and 
cellular data. The key time points to sample may be two and seven days following 
each the two IMM immunisations. These tissues would be used for 
immunohistochemical studies and mRNA analysis, using both real-time PCR and 
microarrays. This study would use high- and low-responding animals. A third subset 
of animals would also be of interest to include, a group of animals that do not 
respond at all to our immunisation, i.e. have undetectable lgA antibody levels in milk 
following the multi-site immunisation regimen. 
Studies in this thesis used one tissue sample per animal. RT-PCR studies of genes 
that control milk production in the mammary gland have highlighted the variation in 
gene expression in alveolar tissue collected from different regions of the gland 
(Molenaar et al., 1992). It would be valuable to collect several tissues samples, at 
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one time point, from one or two animals for comparative studies of tissue sampling. 
This could be incorporated into the study described above. 
Another beneficial study would involve a cell culture study. The correlation between 
the number of lgA-positive cells and specific antibody titre indicates that numbers of 
plasma cells are important for high-titre antibody levels in mammary secretions. In 
addition the data from this work would suggest that the plasmablasts migrate to the 
mammary gland and then proliferate prior to undergoing terminal differentiation. The 
study would involve extracting lgA plasmablasts from blood, after the IP/IM 
immunisation, and investigate in vitro factors that induce their proliferation. Some 
potential candidates may include IL-6 and IL-10. Potentially these factors could be 
incorporated into the intra-mammary immunogen in slow-release formulations to 
discharge at the appropriate time to induce cell proliferation. 
Other cell culture studies that may be interesting would be to characterise by real-
time PCR the cytokines being expressed in single cell preparations, isolated from 
mammary secretions following IMM immunisation. This would provide more definitive 
information about the cytokine dynamics of the induced immune response in the 
mammary gland. 
Identification of genetic markers that differentiate the animals that respond to the 
multi-site immunisation regimen with high-titre antibodies levels in milk and animals 
that respond with low-titre antibody levels is another study that would yield very 
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